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ABSTRACT 
 
STRUCTURAL REMODELING OF ALPHA-SYNUCLEIN BY SMALL MOLECULES: 
A NOVEL PATH TO NEUROPROTECTIVE THERAPEUTICS  
Malcolm James Daniels 
Harry Ischiropoulos 
Neurodegenerative diseases share the unifying features of insoluble protein aggregates and 
irreversible neuron loss. Parkinson’s disease (PD) is defined by proteinaceous Lewy bodies—
which contain α-synuclein—and loss of dopamine neurons leading to motor dysfunction. Growing 
evidence implicates α-synuclein aggregation as a causal driver of neurodegeneration in certain 
forms of PD. However, the precise mechanism(s) by which the process or products of α-synuclein 
aggregation drive neuron death remains unknown. Better understanding of this key question 
might further development of neuroprotective therapies for PD and related disorders. To address 
this gap, we reviewed how the native conformation of α-synuclein relates to its physiological 
function and roles in pathology. We also examined how the mouse brain proteome and 
phosphoproteome change in response to α-synuclein aggregation using quantitative proteomics. 
This revealed that proteomic changes were not widespread, but instead were enriched within 
certain functional areas. For the first time, we found that the immunoproteasome is induced 
during aggregation, providing a new tunable target for studying α-synuclein aggregation and its 
connection to toxicity. We also employed nordihydroguaiaretic acid (NDGA) and analogs to study 
the chemistry and products of phenolic inhibitors of α-synuclein aggregation. We discovered that 
oxidation-dependent cyclization is required for NDGA analogs to inhibit α-synuclein aggregation 
and that this inhibition is caused by modification of α-synuclein monomers that retain their 
conformational dynamics and lipid interactions. Further, we found that these NDGA analog-
modified monomers exert a dominant negative effect on aggregation of untreated α-synuclein, 
vii 
 
exposing a novel mechanism for inhibiting α-synuclein aggregation. Using transgenic 
Caenorhabditis elegans, we showed that cyclized NDGA can prevent neurodegeneration driven 
by α-synuclein. These findings outline a novel paradigm for small molecule inhibition of α-
synuclein aggregation wherein they act by stabilizing dynamic α-synuclein monomers, preventing 
aggregation. This in turn prevents aggregation of untreated α-synuclein and reduces 
neurodegeneration. Together this work underscores the importance of α-synuclein’s native 
structural dynamics and provides several novel tools for future use in untangling the relationship 
between α-synuclein aggregation and neuron loss in PD and related disorders. 
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CHAPTER 1: INTRODUCTION  
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1.1 Neurodegenerative diseases and protein aggregation 
The most common neurodegenerative diseases are Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), and Amyotrophic Lateral Sclerosis (ALS). 
Each disease is characterized by degeneration in distinct regions of the brain, producing 
neurologically correlated clinical symptoms. However, these diseases share remarkable 
similarities: the progressive accumulation of proteinaceous inclusions, the progressive loss of 
neurons, and a lack of curative therapies. 
AD is characterized by accumulation of extracellular plaques containing the Aβ peptide 
fragment (Glenner and Wong, 1984) and intracellular neurofibrillary tangles containing hyper-
phosphorylated tau (Lee et al., 1991). PD displays intracellular accumulation of α-synuclein-
containing Lewy bodies (Spillantini et al., 1997). In HD, the protein huntingtin forms neuronal 
intranuclear inclusions (DiFiglia et al., 1997). Most ALS patients develop motor neuron inclusions 
containing ubiquitin and TDP-43 (Neumann et al., 2006). Increasing evidence suggests a causal 
link between protein aggregation and neurodegeneration, but the mechanism of neurotoxicity has 
not been identified. In this study, we examine how the physiological role and pathological 
aggregation of α-synuclein are influenced by its dynamic structure, and how α-synuclein 
aggregation changes the brain proteome. We also seek to better understand inhibitors of α-
synuclein aggregation in hopes of providing a tool to address this deficit. 
1.2 Parkinson’s disease 
Parkinson’s disease (PD) is the most common age-related movement disorder, affecting 
1.5-3% of people over the age of 75 (Van Den Eeden et al., 2003; Pringsheim et al., 2014). 
Incidence is expected to rise as the age of the global population increases (Wirdefeldt et al., 
2011). The motor phenotype was first characterized in western medical literature by James 
Parkinson in An Essay on the Shaking Palsy and is defined by resting tremor, rigidity, and 
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bradykinesia (Parkinson, 1817). More than a century later, a loss of neuromelanin pigmentation of 
the substantia nigra pars compacta (SNpc) was described in PD (Trétiakoff, 1919). Ultimately, 
parkinsonian motor symptoms can be attributed to a loss of dopamine in the SNpc (Ehringer and 
Hornykiewicz, 1960). While dopamine neuron loss in the SNpc is normal in aging, the pattern of 
degeneration in PD is distinct, involving greater loss in the ventrolateral and caudal portions 
(Fearnley and Lees, 1991). 
Many PD patients develop symptoms beyond the central motor phenotype. Nearly all PD 
patients experience some form of sleep disturbance and many experience sensory dysfunction, 
particularly olfactory (Koller, 1984; Lees et al., 1988). Older and more advanced PD patients often 
experience dementia (Emre, 2003; Levy et al., 2002).  
1.2.1 Genetics 
Up to 10% of PD cases are familial, driven by both dominant and recessive genetic 
inheritance (Hernandez et al., 2016). Autosomal dominant forms of familial PD are driven by 
mutations in many genes (e.g. SNCA, LRRK2, VPS35, UCHL1) (Maraganore et al., 2004; 
Paisán-Ruíz et al., 2004; Vilariño-Güell et al., 2011; Zimprich et al., 2004, 2011). LRRK2 
mutations are the most common cause of familial PD cases, found in ~10% of patients (Paisán-
Ruíz et al., 2008). Autosomal recessive forms of PD are caused by mutations in other genes, 
such as PARK2, PINK1, and PARK7 (encoding Parkin, Pten-induced putative kinase 1, and DJ-1, 
respectively) (Bonifati et al., 2003; Kitada et al., 1998; Valente et al., 2001, 2004). Many of the 
autosomal recessive forms of PD caused by mutations in these three genes are juvenile onset.  
While most PD cases are sporadic, with age as the greatest risk factor, genetic risk 
factors can still contribute to disease. Genome-wide association studies have found PD risk 
alleles across many genes previously identified in familial PD (SNCA, LRRK2, PARK16) as well 
as others encoding proteins involved in pathology (MAPT, encoding microtubule-associated 
protein tau) (Satake et al., 2009; Simón-Sánchez et al., 2009). More recent meta-analysis has 
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further expanded these findings both in terms of primary and conditional risk alleles (Nalls et al., 
2014).  
1.2.2 Histopathology 
The pathological hallmark of PD is the presence of Lewy bodies. These cellular 
inclusions were first described by Friedrich Lewy in 1912 and later named Lewy bodies, after their 
discoverer (Lewy, 1912; Trétiakoff, 1919). Lewy bodies are proteinaceous and were found in the 
1980’s to contain both neurofilamin and ubiquitin (Goldman et al., 1983; Lennox et al., 1989). 
Later examination revealed that aggregated α-synuclein is also a major component (Spillantini et 
al., 1997). In addition to Lewy bodies, pathological neuronal projections termed Lewy neurites are 
present in PD, and also contain aggregated α-synuclein (Braak et al., 1994; Spillantini et al., 
1998). 
Sporadic PD cases can be scored based on a stereotypical pattern of the spread of Lewy 
pathology which progresses to new regions while worsening in those previously affected (Braak 
et al., 2003). As these stages progress, a rough correlation can be drawn between the 
neurological functions of the regions affected and the additional symptoms experienced by 
patients as PD worsens. This could be taken as evidence that Lewy bodies cause 
neurodegeneration in PD. However, Lewy bodies have been found in tissue from normal patients 
who lacked both PD symptoms and striatal neurodegeneration (Ding et al., 2006; Markesbery and 
Jicha, 2009). Conversely, parkinsonian neurodegeneration can occur in the absence of Lewy 
bodies. In fact, the most common LRRK2 mutation causes early onset PD that lacks any Lewy 
pathology (Gaig et al., 2007).   
1.3 α-Synuclein  
Synuclein proteins were first discovered in cholinergic vesicles and nuclei purified from 
the electric organ of Torpedo (Maroteaux et al., 1988). Syn1, later renamed α-synuclein, was first 
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characterized in rat brains probed with sera against electric organ samples (Maroteaux and 
Scheller, 1991). A component of the α-synuclein sequence was detected as the non-amyloid 
component of amyloid plaques in Alzheimer’s disease, but was not attributed to α-synuclein until 
its discovery in humans (Jakes et al., 1994; Uéda et al., 1993). Interest in α-synuclein increased 
greatly following its identification in Lewy bodies and the discovery of an α-synuclein point 
mutation in a several kindreds with early-onset familial PD (Polymeropoulos et al., 1997; 
Spillantini et al., 1997). 
1.3.1 Sequence and structure  
α-Synuclein is 140 amino acids in length with a calculated molecular mass of 14,460.16 
kDa. Its primary sequence is divided into three functionally defined domains. The N-terminal 
domain (composed of amino acids 1-60) is characterized primarily by lysine-rich imperfect 
repeats projected to form amphipathic α-helices upon lipid interaction (George et al., 1995; 
Maroteaux et al., 1988). These elements repeat seven times and contain amino acids 10-86. This 
region has a greater affinity for acidic phospholipid membranes (Davidson et al., 1998). When 
bound to lipid membranes, this region can form an extended conformation of two α-helices, or 
double back to form a hairpin, depending on the curvature of the surface (Trexler and Rhoades, 
2009; Ulmer and Bax, 2005). All α-synuclein point mutations (A30P, E46K, H50Q, G51D, A53E, 
A53T) that cause autosomal dominant forms of PD occur in the N-terminal domain (Appel-
Cresswell et al., 2013; Krüger et al., 1998; Lesage et al., 2013; Pasanen et al., 2014; 
Polymeropoulos et al., 1997; Proukakis et al., 2013; Zarranz et al., 2004). 
 Amino acids 61-95 compose the NAC or non-amyloid component domain which was 
named based on its fragmentary identification in amyloid plaques (Uéda et al., 1993). This 
domain contains an amino acid sequence (71-82) that is both necessary and sufficient for α-
synuclein aggregation into fibril aggregates with β-sheet secondary structure (Giasson et al., 
2001). The role of the NAC domain in α-synuclein aggregation has been reinforced by repeated 
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studies (Du et al., 2003). Recent crystallography has highlighted two regions, PreNAC (47-56) 
and NACore (68-78), both of which can independently aggregate into fibrils, but may also directly 
interface within the hydrophobic core of full length α-synuclein fibrils (Rodriguez et al., 2015).  
 The C-terminal domain (composed of amino acids 96-140) is hydrophobic and remains 
unstructured both when α-synuclein is bound to lipids and aggregated into fibrils (Chen et al., 
2007; Ulmer and Bax, 2005). Although the C-terminal domain does not assume β-sheet 
confirmation during aggregation, C-terminal truncation increases the rate of α-synuclein 
aggregation (Hoyer et al., 2004; Li et al., 2005). This effect may be explained in part by transient, 
temperature sensitive, long range interactions between the C-terminal domain and the N-terminal 
domain (Dedmon et al., 2005). These interactions have been implicated in stabilizing monomeric 
confirmation of α-synuclein, reducing its propensity to aggregate (Bertoncini et al., 2005a).  
 The C-terminal domain is the site of many post-translation modifications of α-synuclein, 
particularly phosphorylation. This includes phosphorylation at serine 129, which was first detected 
in Lewy body extracts and is used as a marker of pathologically aggregated α-synuclein (Fujiwara 
et al., 2002). A more exhaustive discussion of α-synuclein post-translational modification can be 
found in Section 2.4.  
 Many intramolecular interactions occur with the α-synuclein C-terminal domain. 
Interactors include neurotransmitters, most notably dopamine, and other small molecules, which 
are addressed at length in Section 1.4.3 (Conway et al., 2001). α-Synuclein has been shown to 
interact with several metal ions, some of which are implicated in toxicity. Various metals have 
been shown to alter α-synuclein conformation and aggregation kinetics (Uversky et al., 2001a). 
The C-terminal domain is the site of interaction with a wide variety of divalent metal ions including 
Fe(II), Mn(II), Co(II), and Ni(II) (Binolfi et al., 2006). Uniquely, interaction with Cu(II) is mediated 
not only by the C-terminal, but also by H50 (Rasia et al., 2005). This interaction induces α-
synuclein oligomerization (Paik et al., 1999). Subsequent experiments have shown that similar 
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conformation changes are caused by interaction with Cu(II) and dopamine at the C-terminal (Ha 
et al., 2014; Tavassoly et al., 2014).  
 The interaction between iron, α-synuclein, and PD has been an area of particular interest. 
α-Synuclein has been found to bind with Fe(II) and Fe(III), the latter inducing α-synuclein 
oligomerization (Binolfi et al., 2006; Hillmer et al., 2010; Tabner et al., 2002; Uversky et al., 
2001a). Environmental exposure to iron and other heavy metals (Gorell et al., 1999), as well as 
their accumulation in the brain (Hirsch et al., 1991), have been linked to PD. The connection 
between iron and α-synuclein in PD likely lies in oxidative stress and damage. Oxidative stress is 
linked to both parkinsonianism and α-synuclein modification (Giasson et al., 2000; Javitch et al., 
1985; Krueger et al., 1990; Przedborski et al., 2001; Souza et al., 2000a). Interaction between α-
synuclein and Fe(II) can be caused by redox cycling (Hillmer et al., 2010). The ratio of 
Fe(II)/Fe(III) ions shifts toward Fe(III), while levels of glutathione, a key redox regulator, are 
depleted in PD brains (Riederer et al., 1989). Recent evidence suggests that α-synuclein acts as 
a ferrireductase (Davies et al., 2011). It is possible that aggregation of α-synuclein may prevent 
its reductase activity causing a toxic loss of function during the progression of PD. While α-
synuclein may act as a ferrireductase, there is abundant evidence suggesting its chief function is 
to mediate vesicle fusion/fission in the synapse, further discussed in Section 1.3.2. 
 The native conformation of α-synuclein has been the subject of several studies and 
intense debate, especially given the potential of native structural dynamics to alter its propensity 
to aggregate. This topic is addressed at length in Section 2.4. Following the compilation of that 
summary, further examination of the native state of α-synuclein has continued to reinforce the 
importance of the N-terminal KTKEGV consensus repeats in α-synuclein multimer formation and 
appropriate lipid interaction. KTKEGV repeat mutations designed to perturb multimerization also 
induce inappropriate lipid interaction and may contribute to both increased α-synuclein 
aggregation and defects in vesicular trafficking (Dettmer et al., 2017). The protein 
glucocerebrosidase 1 (GBA1) is involved in lysosomal lipid quality control and loss of function 
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mutations are strong risk factors for PD (Sidransky et al., 2009). Deficiency in GBA1 has been 
shown to inhibit α-synuclein multimerization and enhance pathology during α-synuclein 
aggregation (Kim et al., 2018). Taken together, the growing body of work around the native state 
of α-synuclein suggests that complex structural dynamics influence both its physiological function 
and its propensity to aggregate. Therefore, any disturbances of native state—through mutations, 
changes in lipid interaction, alteration of cellular redox state, etc.—may contribute to α-synuclein 
dysfunction.  
1.3.2 Physiological function 
When identified, synucleins were found in the nucleus and presynapse of neurons 
(Maroteaux et al., 1988). Subsequent studies have failed to reproduce detection of synucleins in 
the nucleus, but have reinforced their presence in presynaptic terminals (George et al., 1995; Iwai 
et al., 1995; Maroteaux and Scheller, 1991; Murphy et al., 2000; Withers et al., 1997). Synelfin, 
later to be renamed α-synuclein, expression was found to increase during Zebra finch song 
learning, suggesting a role in neurotransmission or long-term potentiation (George et al., 1995).   
The identification of α-synuclein in the presynapse, and its implication in neuronal 
plasticity, led to examination of neuronal function in α-synuclein knockout mice. These mice were 
found to lack a gross developmental or functional phenotype (Abeliovich et al., 2000). Striatal 
brain slices from knockout mice displayed higher levels of dopamine release in response to 
repeated stimuli than those from wildtype mice, suggesting α-synuclein may play a role in 
regulating neurotransmitter release. Subsequent studies on synuclein double (α and β) and triple 
(α, β, and γ) knockout mice revealed a high degree of redundancy among the family (Burré et al., 
2010; Chandra et al., 2004). Only the triple knockout showed a profound phenotype, which 
included age-related neurological deficits, premature mortality, and motor symptoms consistent 
with models of dopamine neuron loss (Burré et al., 2010).  
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α-Synuclein modulates vesicular trafficking during neurotransmission. While α-synuclein 
knockout leads to increased vesicular reserve pool in presynaptic terminals (Murphy et al., 2000), 
α-synuclein overexpression leads to deficits in vesicle fusion and increased vesicular pools in 
some models (Larsen et al., 2006). α-Synuclein has been shown to regulate the function of 
SNARE proteins involved in vesicular fission and fusion (Chandra et al., 2005). This work has 
been further supported by direct evidence of physical interaction between α-synuclein and the v-
SNARE synaptobrevin 2 (Burré et al., 2010). α-Synuclein’s particular role may lie in facilitating 
vesicle endocytosis following neurotransmitter release into the synapse (Vargas et al., 2014).  
1.3.3 Aggregation and pathogenesis 
The Lewy bodies found in sporadic and familial forms of PD contain aggregated α-
synuclein (Baba et al., 1998; Spillantini et al., 1997). Rather than amorphous aggregates, the α-
synuclein within Lewy bodies exists as unbranched fibrils roughly 10 nm in diameter and ranging 
from 50 to 700 nm in length (Spillantini et al., 1998). Subsequently, these fibrils were shown to 
contain α-synuclein with β-sheet secondary structure (Serpell et al., 2000). As such, α-synuclein 
aggregates show strong structural similarity with Aβ amyloids in Alzheimer’s disease and many 
other proteins that form amyloid-like fibril aggregates (Nelson et al., 2005; Sawaya et al., 2007). 
Partially resolved structure based on a combination of nuclear magnetic resonance and electron 
cryomicroscopy revealed an in-register, antiparallel conformation composed of five β-sheet 
regions (Heise et al., 2005; Tuttle et al., 2016; Vilar et al., 2008). The rate limiting step in fibril 
formation is the generation of a nucleus, while elongation of existing fibrils is much more rapid 
(Uversky et al., 2001b; Wood et al., 1999). 
All α-synuclein mutations associated with familial forms of the disease alter aggregation 
kinetics, though not all enhance fibril formation (Appel-Cresswell et al., 2013; Giasson et al., 
1999; Krüger et al., 1998; Lesage et al., 2013; Li et al., 2001; Narhi et al., 1999; Pasanen et al., 
2014; Proukakis et al., 2013; Zarranz et al., 2004). Additionally, duplication and triplication of the 
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SNCA gene encoding α-synuclein leads to α-synuclein aggregation and early onset, with age of 
onset accelerated by greater gene dose (Chartier-Harlin et al., 2004; Singleton et al., 2003). This 
suggests a causal link between α-synuclein aggregation and neurodegeneration.  
Numerous animal models expressing excess α-synuclein or mutant α-synuclein prone to 
aggregation exhibit neurodegeneration, though none perfectly recapitulates PD. Transgenic mice 
expressing human wildtype and mutant α-synuclein exhibit inclusion formation and 
neurodegeneration, though not within the SNpc (Emmer et al., 2011; Giasson et al., 2002; 
Gomez-Isla et al., 2003; Lee et al., 2002; van der Putten et al., 2000). Lentiviral expression of 
either wildtype or mutant α-synuclein leads to aggregation and progressive loss of dopaminergic 
neurons in the SNpc (Lo Bianco et al., 2002; Kirik et al., 2002). Invertebrate models have also 
been employed to examine α-synuclein toxicity. Caenorhabditis elegans and Drosophila 
melanogaster models have been used extensively, showing particular utility for modeling 
dopaminergic neurodegeneration and motor phenotypes, respectively (Cao et al., 2010; Feany 
and Bender, 2000; Lakso et al., 2003).  
A recent model of neurodegeneration driven by α-synuclein aggregation avoids the use 
of transgenic models. Instead, a small amount of pre-formed α-synuclein fibrils (PFFs) is injected 
into the brain of wildtype mice. This induces aggregation of endogenous α-synuclein that spreads 
from the site of injection along the connectome as well as concomitant progressive 
neurodegeneration and motor phenotype (Luk et al., 2012b, 2012a). These effects are not 
observed in transgenic mice lacking the Snca gene encoding α-synuclein, demonstrating the role 
of endogenous α-synuclein (Luk et al., 2012a). These results have been reproduced with 
intramuscular injection in mice, enteric injection in rats and primates, and intracerebral injection in 
mice, rats, and primates (Manfredsson et al., 2018; Paumier et al., 2015; Sacino et al., 2014a, 
2014b; Shimozawa et al., 2017). Likewise, intracerebral and enteric injection of Lewy body 
extracts results in spreading, progressive aggregation of endogenous α-synuclein and 
neurodegeneration (Holmqvist et al., 2014; Recasens et al., 2014). These models provide 
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compelling evidence that otherwise non-toxic α-synuclein leads to neurodegeneration when 
undergoing aggregation.  
Independent lines of evidence suggest that the propagation of α-synuclein aggregation 
throughout the brain is caused by cell-to-cell transmission of aggregated α-synuclein seeds. This 
connectome-based propagation is suggested by the progressive staging of Lewy body pathology 
in sporadic PD (Braak et al., 2003), the accumulation of aggregates in fetal tissue grafted into the 
striatum of PD patients (Kordower et al., 2008; Li et al., 2008), and the spread of aggregation 
away from the site of injection in PFF animal models (Holmqvist et al., 2014; Luk et al., 2012a; 
Manfredsson et al., 2018; Sacino et al., 2014b). How α-synuclein aggregates escape neurons is 
unknown, but aggregates have been detected in exosomes and may escape during 
neurotransmission due to the presynaptic localization of α-synuclein (Danzer et al., 2012). Uptake 
of α-synuclein aggregates from the synapse may be neuronal endocytosis (Lee et al., 2008). 
While mechanistic questions remain regarding the specifics of cell-to-cell transfer of α-synuclein 
aggregates (Tyson et al., 2016), evidence still suggests that propagation is caused by aggregated 
α-synuclein. In a model of propagation between primary neurons, treatment with antibodies 
against pathologically aggregated α-synuclein reduces the spread of pathology (Tran et al., 
2014). Exogenous PFFs are taken up by neurons and localize to the lysosome. Transient 
inhibition of lysosomal activity results in greater recruitment of endogenous α-synuclein into 
aggregates (Karpowicz et al., 2017). 
The mechanism by which α-synuclein aggregation leads to neurotoxicity remains an 
important question in the field. Toxicity is most commonly attributed to a toxic gain of function, 
rather than a toxic loss of α-synuclein function. This is supported by the fact that α-synuclein 
knockout does not result in profound dysfunction (Abeliovich et al., 2000). Instead, the most 
commonly accepted theory is that α-synuclein oligomers present during aggregation drive toxicity. 
Enhanced oligomer—rather than fibril—formation can drive neurotoxicity caused by α-synuclein 
mutants associated with familial PD (Conway et al., 2000). Toxicity may be a product of α-
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synuclein oligomers causing membrane permeabilization, perhaps leading to metabolic stress as 
neurons attempt to maintain physiological ion gradients. Certain types of α-synuclein oligomers 
induce calcium influx through neuronal membranes and display pore-like structure when viewed 
by atomic force microscopy (Danzer et al., 2007). In fact, many proteins that form amyloid-like 
species aggregates can exist as oligomers that increase membrane ion-conductance (Kayed et 
al., 2004). This permeabilization may also affect organellar membranes. α-Synuclein oligomers 
can disturb mitochondrial ion gradients through this mechanism (Luth et al., 2014). Other 
potential mechanisms of α-synuclein oligomer toxicity have been proposed including 
perturbations of microtubule-kinesin transport (Prots et al., 2013) and alterations of vesicular 
trafficking (Choi et al., 2013). Distinct populations of α-Synuclein oligomers are induced by 
expression of A53T α-synuclein in mice. Oligomers extracted from regions with α-synuclein 
inclusions cause in vitro neurotoxicity and act as seeds, while those from other regions do not. 
Further, levels of inclusion formation and neurodegeneration within brain regions do not correlate 
with the relative abundance of oligomers (Tsika et al., 2010). This suggests that α-synuclein 
oligomers are not a single entity, but that multiple distinct populations may exist with markedly 
different attributes and implications for disease. Whether or not oligomers are the sole cause of α-
synuclein neurotoxicity, it is increasingly clear that the process of α-synuclein aggregation gives 
rise to species or events that lead to neurodegeneration and eventual neuron death. 
1.4 Therapies targeting α-synuclein 
 The body of evidence implicating α-synuclein in PD and related disorders has caused 
substantial interest in PD therapies targeting α-synuclein. Many different methods have been 
employed and an even greater number proposed.  
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1.4.1 Expression and clearance  
Altering the steady-state level of α-synuclein has long been an area of interest. The 
promise of these attempts is underscored by the gene-dose dependent onset of familial PD 
caused by SNCA gene duplication and triplication (Chartier-Harlin et al., 2004; Singleton et al., 
2003) as well as the resistance of α-synuclein knockout mice to MPTP, a toxin that leads to 
parkinsonian neurodegeneration (Dauer et al., 2002; Thomas et al., 2011). 
In vivo suppression of α-synuclein expression has been achieved in rodents through 
delivery of AAV encoding shRNA and by both unprotected and exosome-protected siRNA. 
(Alarcón-Arís et al., 2018; Benskey et al., 2018; Cooper et al., 2014; Lewis et al., 2008; Zharikov 
et al., 2015a). These approaches reduce inclusion formation (Cooper et al., 2014). Knockdown 
also preserves neurons and dopamine biosynthesis, as well as providing resistance to rotenone 
toxicity (Zharikov et al., 2015a). Promisingly, one group found that α-synuclein expression in the 
SNpc of mice can be reduced by intranasal delivery of siRNA, opening the door to non-surgical 
intervention in adults (Alarcón-Arís et al., 2018).  
Increasing α-synuclein clearance has shown promise in reducing pathology. 
Overexpression of transcription factor EB, which regulates the autophagy-lysosomal degradation 
pathway, reduces α-synuclein aggregation and cytosolic levels while protecting against 
neurodegeneration. Conversely, inhibition of transcription factor EB expression exacerbates 
aggregation and neuron loss (Decressac et al., 2013). Glucocerebrosidase (GCase), a lysosomal 
glycoside hydrolase involved in Gaucher disease pathogenesis, has also been implicated in α-
synuclein degradation. Loss of GCase leads to α-synuclein accumulation, while α-synuclein 
inhibits lysosomal function, potentially creating a pathological feedback loop (Mazzulli et al., 
2011). AAV gene therapy increasing GCase expression reduces α-synuclein levels, aggregation, 
and neurodegeneration in mouse models expressing A53T α-synuclein (Morabito et al., 2017; 
Rocha et al., 2015; Sardi et al., 2013). Small molecule modulators of GCase activity have also 
been identified and reduce α-synuclein levels in neurons induced from stem cells derived from 
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Gaucher disease and parkinsonian patients (Aflaki et al., 2016). Several other lines of evidence 
also suggest that enhancing autophagy could be therapeutic in PD (Moors et al., 2017). 
1.4.2 Immunization and immunotherapy 
Modulating immune responses to α-synuclein and α-synuclein aggregates has shown 
promise in ameliorating pathology. Active immunization—induction of a host immune response 
through antigen challenge—has been explored in mice. In the first such study, mice were actively 
immunized with exposure to recombinant human α-synuclein. Mice in which immunization 
produced a high antibody titer showed reduced levels of both total α-synuclein and inclusions, as 
well as improved synaptic markers, while those with lower titers did not see a benefit (Masliah et 
al., 2005). Subsequently, active immunization against α-synuclein has been shown to reduce 
inclusion levels, neurodegeneration, and motor phenotype in mice, while inducing microglial 
activation (Mandler et al., 2015).   
Passive immunization with various antibodies against total α-synuclein and pathological 
α-synuclein has also been examined. Transgenic mice expressing human wildtype or mutant 
(A30P) α-synuclein showed reductions in inclusions and neurodegeneration following treatment 
with antibodies against native and pathological α-synuclein (Bae et al., 2012; Games et al., 2014; 
Lindström et al., 2014; Masliah et al., 2011). Passive immunization with Syn303, an antibody 
against pathological α-synuclein aggregates, reduced α-synuclein inclusions, neurodegeneration, 
and motor phenotype in wildtype mice treated with α-synuclein PFFs (Tran et al., 2014). The 
considerable promise of immunotherapy against PD has led to several clinical trials, the most 
advanced of which is recruiting for a phase 2 trial (NCT03100149, estimated primary completion 
in 2020) examining the efficacy of the 9E4 antibody (Games et al., 2014; Masliah et al., 2011) to 
delay motor phenotype in PD patients (Schenk et al., 2017). 
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1.4.3 Altering aggregation 
The strong evidence that α-synuclein aggregation plays a causal role in PD has led to 
extensive examination of many approaches to modulating that aggregation pathway. Dopamine, 
and related molecules containing catechol moieties (vicinal hydroxyls on an aromatic ring), were 
the first small molecules shown to modulate α-synuclein aggregation. They inhibit α-synuclein 
fibril formation, instead leading to formation of soluble oligomers (Conway et al., 2001). This 
interaction has been shown to require oxidation of dopamine and can be inhibited by electron 
donors (Mazzulli et al., 2006; Norris et al., 2005). Dopamine interacts with the α-synuclein C-
terminal at residues Y125EMPS129 (Herrera et al., 2008; Mazzulli et al., 2007; Norris et al., 2005). 
This interaction is stabilized by electrostatic interaction with E83 and can be impaired by E83A 
mutation (Herrera et al., 2008). 
The identification of dopamine as an aggregation inhibitor is notable given the selective 
loss of dopaminergic neurons in PD. As discussed in Section 1.3.3, α-synuclein oligomers have 
been shown to destabilize neuron membranes and may be responsible for α-synuclein 
neurotoxicity. Recently, elevation of α-synuclein in mice expressing A53T α-synuclein was shown 
to enhance neurodegeneration and oligomer formation. The same study found, in C. elegans, that 
increased dopamine levels enhanced neurodegeneration in animals expressing A53T α-
synuclein, but not in animals expressing A53T α-synuclein mutated in the Y125EMPS129 to abolish 
dopamine interaction (Mor et al., 2017). These findings represent the most direct evidence to date 
that direct interaction between dopamine and α-synuclein enhances α-synuclein neurotoxicity.  
While dopamine may enhance α-synuclein toxicity through modulating aggregation, 
studies have also identified potentially neuroprotective modulators. Many of these inhibitors 
interact directly with α-synuclein and induce formation of oligomeric species. Some share little of 
their structure or putative chemistry with dopamine, such as Anle138b (Deeg et al., 2015; Wagner 
et al., 2013) and rifampicin (Li et al., 2004). However, the preponderance of oligomer-inducing 
aggregation inhibitors are polyphenols, flavonoids, catechols, or lignans that bear vicinal hydroxyl 
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substitutions on aromatic rings (Ehrnhoefer et al., 2008; Di Giovanni et al., 2010; Masuda et al., 
2009; Meng et al., 2010). An ongoing clinical trial is evaluating one such polyphenol, 
epigallocatechin gallate (EGCG), in multiple system atrophy, a synucleinopathy characterized by 
inclusion formation in glia (Levin et al., 2016; Wakabayashi et al., 1998). Previous studies 
characterizing the effects EGCG on α-synuclein aggregation and neurodegeneration are further 
discussed in Section 4.2. 
Other attempts to alter α-synuclein aggregation have endeavored to alter protein-protein 
interactions. Chaperone proteins such as heat shock proteins (Hsp) 70 and 104 have been 
shown to reduce α-synuclein aggregation and toxicity. Hsp70 and Hsp40 are present in Lewy 
bodies and expression of Hsp70 reduced α-synuclein aggregation and neurodegeneration in D. 
melanogaster expressing A30P and A53T α-synuclein (Auluck et al., 2002). Hsp70 reduced α-
synuclein aggregation in mice expressing A30P α-synuclein (Klucken et al., 2004). Hsp104 was 
shown to reduce both α-synuclein aggregation and neurodegeneration in rats expressing A30P α-
synuclein (Lo Bianco et al., 2008). Hsp expression can be altered pharmacologically and may 
represent a druggable target in PD (Kilpatrick et al., 2013; McLean et al., 2004).  
Altering α-synuclein-lipid interactions has also been explored as a method to alter 
aggregation, though rationales and results have varied. The small molecules NPT100-18A and 
squalamine displace α-synuclein from membranes, reducing α-synuclein oligomers and 
neurodegeneration (Perni et al., 2017; Wrasidlo et al., 2016). Conversely, phtalocyanine 
tetrasulfonate has been shown to stabilize lipid-bound α-synuclein and reduce aggregate 
formation (Fonseca-Ornelas et al., 2014). Markedly altering the dynamics of α-synuclein-lipid 
interactions may result in side-effects given their role in physiological function and 
neurotransmission (covered in Section 1.3.2). 
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1.5 Current study 
Strong evidence implies that α-synuclein aggregation plays a causal role in PD 
pathogenesis. As such, altering α-synuclein aggregation in PD represents a promising target for 
therapeutics. While the interaction between α-synuclein and dopamine has been well 
characterized, less is known about interactions between α-synuclein and putatively 
neuroprotective molecules that alter aggregation. Additionally, many of these small molecules 
may perturb the native interactions between α-synuclein membranes, either directly, or by 
inducing membrane destabilizing oligomers. 
Chapter 2 reviews α-synuclein’s remarkable structural flexibility, considering its role in 
physiological function and pathological aggregation. We propose a model of the α-synuclein 
aggregation energy landscape based on the existing literature.  
Chapter 3 presents our examination of changes in the mouse brain proteome and 
phosphoproteome during α-synuclein aggregation. We found that the proteome does not undergo 
widespread changes. Instead, we identified specific changes in dopamine biosynthesis directly 
related PD pathophysiology and the model’s motor phenotype. Importantly, we quantified 
changes in levels of proteins not previously implicated in α-synuclein aggregation. We thoroughly 
explored Lmp7, a subunit of the immunoproteasome, demonstrating that it also changes in PD 
patient brains and that the immunoproteasome can degrade α-synuclein fibrils. The implication of 
Lmp7 in PD, as well as the larger brain proteome we generated, provide novel insight into the 
process of neurodegeneration driven by α-synuclein aggregation and open the door to new 
therapies. 
Chapter 4 contains our exploration the mechanism of action by which 
nordihydroguaiaretic acid (NDGA), and novel related analogs (Asiamah et al., 2015), inhibit α-
synuclein aggregation. We also analyzed the α-synuclein species formed, particularly considering 
structural dynamics. We found that NDGA must undergo oxidation and cyclization before 
interacting with α-synuclein in a manner distinct from EGCG and dopamine. We also found that 
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NDGA renders monomeric α-synuclein resistant to aggregation without altering native lipid 
interactions. Further, we observed that the presence of NDGA-modified monomers prevents 
aggregation of untreated α-synuclein. Finally, we found that cyclized NDGA, but not NDGA, 
reduces α-synuclein-driven dopamine neuron degeneration in Caenorhabditis elegans.  
Chapter 5 includes a summary of our findings, seeks to contextualize them within the 
field, and explores their implications for future research and therapeutic development.  
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2.1 Abstract 
α-Synuclein is a conserved, abundantly expressed protein that is partially localized in pre-
synaptic terminals in the central nervous system.  The precise biological function(s) and structure 
of α-synuclein are under investigation.  Recently, the native conformation and the presence of 
naturally occurring multimeric assemblies have come under debate.  These are important 
deliberations because α-synuclein assembles into highly organized amyloid-like fibrils and non-
amyloid amorphous aggregates that constitute the neuronal inclusions in Parkinson’s disease and 
related disorders.  Therefore understanding the nature of the native and pathological 
conformations is pivotal from the standpoint of therapeutic interventions that could maintain α-
synuclein in its physiological state.  In this review, we will discuss the existing evidence that 
define the physiological states of α-synuclein and highlight how the inherent structural flexibility of 
this protein may be important in health and disease. 
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2.2 Introduction 
α-Synuclein is a soluble protein that is highly conserved in vertebrates and abundantly 
expressed in nervous tissue (Jakes et al., 1994).  It was first discovered in 1988 in association 
with purified synaptic vesicles from the Torpedo electric ray (Maroteaux et al., 1988).  Soon 
afterward α-synuclein was found to be widely distributed across the mammalian brain and 
localized to presynaptic nerve terminals, suggesting functions related to neurotransmission (Iwai 
et al., 1995).  Independent of these reports, α-synuclein was identified as the precursor to a 
hydrophobic peptide found in Alzheimer’s disease senile plaques, termed the non-Aβ component 
of Alzheimer’s disease amyloid (NAC) (Uéda et al., 1993).  The α-synuclein gene was also 
dynamically regulated during song learning in zebra finch, supporting a role in synaptic plasticity 
(George et al., 1995).   
The discovery of a mutation in the α-synuclein gene that was associated with autosomal 
dominant inheritance of Parkinson’s disease (PD) provided the impetus for a major shift in α-
synuclein research (Polymeropoulos et al., 1997).  PD is a neurodegenerative disorder primarily 
characterized by the loss of dopamine-producing neurons in the substantia nigra pars compacta 
resulting in motor impairment.  Since the original publication of the A53T mutation, several 
mutations, as well as multiplications of the α-synuclein gene have been linked to PD (Chartier-
Harlin et al., 2004; Ferese et al., 2015; Krüger et al., 1998; Lesage et al., 2013; Pasanen et al., 
2014; Proukakis et al., 2013; Singleton et al., 2003; Zarranz et al., 2004). Furthermore, several 
antibodies against α-synuclein robustly detect the well-known pathoanatomical features of PD, 
Lewy bodies and Lewy neurites, in postmortem brain tissue from patients with sporadic PD as 
well as other related neurodegenerative disorders (Baba et al., 1998; Spillantini et al., 1997; 
Takeda et al., 1998).  The finding that wildtype α-synuclein was detected in Lewy bodies and 
Lewy neurites prompted the publication of numerous studies that investigated the biochemistry 
and biology of α-synuclein.  Despite the rather impressive body of work several fundamental 
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questions remain: What is the physiological function of α-synuclein?  What is the structure of 
native α-synuclein?  What factors contribute to the induction of aggregation-competent 
conformational states of α-synuclein?  In this review, we will briefly review the evidence for the 
different biological functions and discuss ongoing efforts to precisely define physiological 
structures of α-synuclein.  
2.3 The physiological function(s) of α-synuclein 
The initial studies indicated that α-synuclein is not required for neuronal development or 
synapse formation, but instead may modulate synaptic activity.  In rodents, α-synuclein is 
detected close to the time of birth and continues to increase until one month of age, when it 
reaches a steady-state level that is maintained throughout adulthood (Shibayama-Imazu et al., 
1993).  Similarly, in cultured rat neurons the development of synapses precedes α-synuclein 
expression and translocation to axonal terminals (Murphy et al., 2000; Withers et al., 1997).  The 
hypothesis that α-synuclein regulates synaptic activity was directly tested in mice lacking α-
synuclein.  α-Synuclein null mice develop normal brain architecture and synaptic contacts, and do 
not exhibit gross behavioral phenotypes (Abeliovich et al., 2000).  However, subtle abnormalities 
in activity-dependent neurotransmitter release have been observed.  Upon repeated stimulation, 
dopaminergic synapses from α-synuclein null mice sustain highly elevated dopamine release 
(Abeliovich et al., 2000; Yavich, 2004).  Functional redundancy among α-synuclein and the other 
synuclein family members, β- and γ-synuclein, may account for the mild phenotypes observed in 
the single knockout.  In α/β-synuclein double knockout mice, synaptic plasticity appears unaltered 
relative to α-synuclein single knockouts, although dopamine levels in the striatum are reduced 
(Chandra et al., 2004).  The importance of synucleins is particularly highlighted by α/β/γ-synuclein 
triple knockouts, which have decreased life span and late-onset synaptic dysfunction compared 
with wildtype mice (Burré et al., 2010; Greten-Harrison et al., 2010).  Triple knockouts in another 
study had motor deficits and decreased striatal dopamine, along with abnormal dopamine 
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neurotransmission (Anwar et al., 2011).  Collectively, these reports emphasize the important role 
of the synucleins in long-term synaptic maintenance and plasticity. 
Synaptic vesicle trafficking.  Examination of the role of α-synuclein in the synaptic vesicle 
cycle has yielded conflicting results.  Depletion of α-synuclein from rodent hippocampal neurons 
both in vivo and in vitro induces a significant loss of undocked synaptic vesicles, suggesting that 
α-synuclein acts to replenish or maintain the resting and/or reserve vesicle pools (Cabin et al., 
2002; Murphy et al., 2000).  In contrast, another study found that increasing α-synuclein in rodent 
hippocampal neurons reduces the recycling pool of vesicles (Nemani et al., 2010).  The effect of 
α-synuclein on vesicles docked at the plasma membrane prior to exocytosis is similarly unclear.  
Knockout or knockdown of α-synuclein in rodent hippocampal neurons results in either a 
decrease or no change in the number of docked vesicles (Cabin et al., 2002; Murphy et al., 
2000).  Conversely α-synuclein expression in PC12 cells causes an accumulation of vesicles at 
the plasma membrane and impairment of exocytosis (Larsen et al., 2006).  However, in mice 
modestly overexpressing α-synuclein (levels are not associated with neurotoxicity), hippocampal 
synapses display a redistribution of vesicles away from the active zone.  The density of vesicles 
in synaptic boutons is also reduced, consistent with α-synuclein-mediated inhibition of vesicle 
clustering.  This is supported by α-synuclein-induced defects in vesicle re-clustering following 
endocytosis in rat hippocampal neurons (Nemani et al., 2010).  Still, opposing results have been 
obtained from yeast, in which α-synuclein expression results in massive accumulations of 
vesicles that co-localize with Rab GTPases (Gitler et al., 2008; Soper et al., 2008).  Likewise, α-
synuclein has been shown to restrict vesicle diffusion away from synapses in mouse hippocampal 
neurons (Wang et al., 2014).  Several lines of evidence, therefore, support the participation of α-
synuclein in synaptic vesicle trafficking, though the specific steps for which it may be most 
important, i.e. vesicle docking, recycling and/or re-clustering, remain unclear.  
Chaperone-like activity and neurotransmitter release.  α-Synuclein and the other 
synuclein family members may act as molecular chaperones, facilitating neurotransmitter release.  
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Cysteine-string protein α (CSPα) is a chaperone that is essential for synaptic health; its deletion 
in mice leads to a decrease in SNARE protein complexes, nerve terminal degeneration, motor 
impairment and death.  When expressed in CSPα-deficient mice, α-synuclein is able to rescue 
this degenerative phenotype and restore levels of SNARE complexes in synaptic terminals.  
Moreover, mice lacking both α-synuclein and CSPα exhibit an exacerbated phenotypic decline 
(Chandra et al., 2005).  These findings suggest that α-synuclein is able to complement the activity 
of CSPα in promoting synapse integrity.  Direct evidence for the interaction of α-synuclein with 
SNARE complexes was documented by co-immunoprecipitation of α-synuclein with SNARE 
proteins and specific binding to the vesicle-associated SNARE protein synaptobrevin-2.  In 
mammalian cells and purified in vitro systems, α-synuclein dose-dependently facilitates SNARE 
complex assembly (Burré et al., 2010).  Additional support for chaperone-like activity includes 
sequence homology between α-synuclein and 14-3-3 protein chaperones as well as the 
association of α-synuclein with 14-3-3 and its binding partners in rat brain (Ostrerova et al., 
1999).  α-, β-, and γ-synucleins are also able to prevent the aggregation of denatured proteins in 
vitro (Souza et al., 2000b), further supporting a conserved chaperone-like function of synucleins 
and the existence of several protein-protein interactions that facilitate synaptic function. 
Putative role in neurotransmitter synthesis and reuptake.  Published evidence indicates 
that α-synuclein-mediated protein-protein interactions may modulate dopamine synthesis and 
recycling.  α-Synuclein may inhibit the activity of tyrosine hydroxylase (TH), the rate-limiting 
enzyme in dopamine synthesis.  α-Synuclein and TH co-immunoprecipitate from rat striatal tissue 
and MN9D dopaminergic cells and α-synuclein was shown to inhibit TH activity in MN9D and 
PC12 cells, potentially through PP2A phosphatase-mediated reduction of serine 40 
phosphorylation of TH (Peng, 2005; Perez et al., 2002).  α-Synuclein may also interact with and 
inhibit the activity of aromatic amino acid decarboxylase, which catalyzes the conversion of L-
DOPA to dopamine (Tehranian et al., 2006).  Thus, α-synuclein may serve as a negative 
regulator of dopamine synthesis, though further validation of these findings is necessary.  Several 
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reports have also implicated α-synuclein in the regulation of the dopamine transporter (DAT), 
though the evidence is conflicting with regards to the functional consequences.  Direct binding of 
α-synuclein to DAT has been demonstrated in multiple studies.  However, α-synuclein does not 
appear to alter DAT function, but rather in various cellular contexts can promote or inhibit DAT 
trafficking to the plasma membrane (Oaks and Sidhu, 2011).  Elucidating the relationship 
between α-synuclein and DAT requires further investigation. 
2.4 α-Synuclein structural flexibility 
Primary sequence.  The primary sequence of α-synuclein consists of 140 amino acids 
with a predicted molecular mass of 14,460.16 Da and an isoelectric point of 4.67 (Figure 2.1).  
The sequence of α-synuclein is composed of three functionally defined domains.  The N-terminal 
region (amino acids 1-60) is characterized by the presence of unique and highly conserved 
sequence of imperfect tandem repeats with a central consensus motif of K(A)-T(A,V)-K(V)-
E(Q,T)-G(Q)-V(A).  These motifs spanning residues 10-86 are projected to form two amphipathic 
α-helices and are characteristic of several proteins such as apolipoproteins that bind reversibly to 
membranes (George et al., 1995; Maroteaux et al., 1988).  Indeed the structure of membrane 
bound α-synuclein contains two α-helices (amino acids 3-37 and 45-92) in a roughly antiparallel 
arrangement with a short linking region (Ulmer and Bax, 2005).  These helices are stabilized by 
interaction with a variety of phospholipid bilayers, though α-synuclein interacts preferentially with 
membranes of high curvature and an abundance of acidic phospholipids, properties consistent 
with those of synaptic vesicles (Davidson et al., 1998; Zhu et al., 2003b).  Upon interaction with 
membranes of low curvature α-synuclein adopts a distinct secondary structure characterized by a 
single extended helix that includes both previously described helical domains and the linker 
region (amino acids 38-44) (Ferreon et al., 2009; Georgieva et al., 2010; Trexler and Rhoades, 
2009).  All known mutations associated with familial PD (A30P, E46K, H50Q, G51D, A53E, and 
A53T) are found in the N-terminal domain (Krüger et al., 2008; Lesage et al., 2013; Pasanen et 
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al., 2014; Polymeropoulos et al., 1997; Proukakis et al., 2013; Zarranz et al., 2004).  These 
mutations, with the exception of G51D, A53E, and A30P, increase the propensity of α-synuclein 
to form insoluble aggregates and produce morphologically distinct aggregate species (Ghosh et 
al., 2014; Giasson et al., 1999; Greenbaum et al., 2005; Lesage et al., 2013; Mahul-Mellier et al., 
2015; Narhi et al., 1999).  Though the precise mechanism by which these mutations promote 
aggregation has not been conclusively shown, evidence implicate an accelerated formation of 
oligomers (Conway et al., 2000) likely due to the destabilization of the native N-terminal 
conformation (Bertoncini et al., 2005b; Burré et al., 2015; Coskuner and Wise-Scira, 2013; 
Dettmer et al., 2015a).  
Amino acids 61-95 compose the hydrophobic NAC domain (Uéda et al., 1993).  This 
region contains a sequence of amino acids (71-82) necessary and sufficient for α-synuclein self-
assembly into amyloid fibrils (Giasson et al., 2001).  Recently the crystal structures of residues 
68-78 (termed NACore), and residues 47-56 (PreNAC) were resolved by the use of micro-
electron diffraction, revealing that strands in this region stack in-register into β-sheets that are 
typical of amyloid assemblies (Rodriguez et al., 2015). 
The C-terminal domain (96-140) is rich in negatively charged amino acids (contains 10 
glutamate and 5 aspartate residues) and was originally proposed to be essential for maintaining 
the solubility of the protein.  The presence of 5 proline residues, which are known to induce turns 
Figure 2.1: Primary sequence of human α-synuclein.  Green color indicates the imperfect 
tandem repeats.  Known mutations are indicated in red.  The hydrophobic NAC domain is 
underlined.  The major sites of posttranslational modifications identified in vivo are highlighted 
in blue (Ac, acetylation; Ub, ubiquitination; NO2, nitration; and PO3- phosphorylation).   
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and disrupt secondary protein structure, suggested that this region is devoid of secondary 
structure (George et al., 1995; Ulmer and Bax, 2005).  However, the C-terminus was shown to 
form transient, long-range interactions with the N-terminus resulting in the formation of multiple 
compact monomeric structures (Bertoncini et al., 2005b; Dedmon et al., 2005).  These compacted 
structures of α-synuclein are temperature sensitive and are resistant to aggregation.  The data 
also indicated that at elevated temperatures the C-terminus assumes an extended conformation 
that liberates N-terminal associations and enables aggregation (Bertoncini et al., 2005b; Dedmon 
et al., 2005).  Moreover, C-terminally truncated forms of α-synuclein aggregate faster than full 
length protein (Hoyer et al., 2004; Li et al., 2005).  Truncated α-synuclein has been detected in 
the brains of both control (non-disease) and PD patients.  Cleavage of full-length protein at 
residues D115, D119, N122, D125 and Y133 was documented in α-synuclein extracted from LBs 
(Anderson et al., 2006).  
The C-terminus appears to be important for the interaction of α-synuclein with other 
proteins and for the interaction with small molecules (Burré et al., 2010, 2012; Conway et al., 
2001; Mazzulli et al., 2006; Souza et al., 2000a; Woods et al., 2007).  Additionally, it contains the 
major sites of metal binding and post-translational modifications.  Binding of iron, copper, and 
other metals has been shown to influence α-synuclein function and aggregation (Uversky et al., 
2001a).  Addition of Fe(III), but not Fe(II) to preformed oligomers of α-synuclein accelerates 
aggregation, raising the question of metal binding at different points during the aggregation 
process (Kostka et al., 2008).  Cu(II) is unique among metals at accelerating aggregation of α-
synuclein at physiologically relevant concentrations.  The sole histidine residue H50 in α-
synuclein was found to be critical for Cu(II) binding (Rasia et al., 2005) whereas other divalent 
metal ions, including Mn(II), Co(II), Ni(II) and Fe(II), preferentially bind to the C-terminus of α-
synuclein at residues D121, N122, and E123 (Binolfi et al., 2006).   
Post-translational modifications.  α-Synuclein undergoes a number of post-translational 
modifications, including N-terminal acetylation, serine and tyrosine phosphorylation, lysine 
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ubiquitination and tyrosine nitration (Barrett and Greenamyre, 2015; Oueslati et al., 2010).  α-
Synuclein purified under mild conditions is acetylated in the N-terminus.  The N-terminal 
acetylation may account for the formation of an oligomeric form of the protein with partial α-helical 
structure (Trexler and Rhoades, 2012).  However, semisynthetic production of N-terminally 
acetylated α-synuclein demonstrated that modified and unmodified versions of the protein share 
similar secondary structure, aggregation propensities, and membrane binding (Fauvet et al., 
2012).  NMR studies indicated that the first 12 residues undergo a chemical shift due to N-
terminal acetylation.  This modification also appears to stabilize the helicity of the N-terminus 
within the context of the full-length protein, and increases the affinity of α-synuclein for lipids 
(Dikiy and Eliezer, 2014).  
Mass spectrometry-based methodologies revealed that α-synuclein extracted from 
human Lewy bodies was phosphorylated at S129 (Fujiwara et al., 2002).  An antibody raised 
against phosphorylated S129 was then used to show that α-synuclein was phosphorylated at this 
site only in subjects with disease and that S129 phosphorylated α-synuclein was present only in 
the Triton-X- and Sarkosyl-insoluble, urea soluble fraction.  These data indicated that some 
form(s) of aggregated α-synuclein and not the soluble protein is targeted for phosphorylation at 
S129.  Indeed in vitro data showed that purified fibrils of α-synuclein are substrates for casein 
kinase 1 or 2 (Waxman and Giasson, 2010).  Other data indicated that polo-like kinase (PLK) 2-
mediated phosphorylation of S129 increased autophagy-mediated degradation of α-synuclein, 
suggesting that phosphorylation may be a neuroprotective mechanism to accelerate clearance of 
aggregated protein (Oueslati et al., 2013).  In addition to the monomeric α-synuclein, S129 
phosphorylated bands with apparent molecular weight of 22 kDa and 29 kDa were observed in 
the detergent insoluble extract (Hasegawa et al., 2002).  These bands were also immunoreactive 
with anti-ubiquitin antibodies suggesting that S129 phosphorylated α-synuclein is also targeted 
for mono- and di-ubiquitination.  It has long been established that the core of Lewy bodies stains 
positive for both α-synuclein and ubiquitin whereas the surrounding halo is immunoreactive for α-
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synuclein (Hasegawa et al., 2002).  Of the 15 lysine residues in α-synuclein, the major sites of 
LB-derived α-synuclein undergoing ubiquitination were residues K12, K21, and K23 (Anderson et 
al., 2006; Hasegawa et al., 2002; Sampathu et al., 2003).  
A number of spectroscopic methodologies (CD and NMR) were employed to explore the 
effect of S129 phosphorylation on the structure of α-synuclein.  CD data revealed that 
phosphorylation of S129 did not affect secondary structure, such that both non-phosphorylated 
and phosphorylated S129 exhibited random coil structure (Paleologou et al., 2008).  NMR data 
revealed a number of chemical shifts that occur due to phosphorylation.  While the residues 
surrounding S129 exhibited the greatest perturbation, residues 1-90 also exhibited detectable 
chemical shifts (Paleologou et al., 2008)  This likely reflects the previously documented long-
range interactions of the C- and N-termini.  The potential effects of phosphorylation of S129 on 
the structure of the protein were not faithfully reproduced by mutation of S129 to either E or D, 
two common phosphomimics used to study the structural consequences of phosphorylation.  For 
example, phosphorylation at S129 increased the hydrodynamic radius of the protein, whereas 
S129 E/D mutants did not (Paleologou et al., 2008).   
Subsequent studies found additional sites of phosphorylation.  Elevated levels of 
phosphorylated α-synuclein at residue S87 were detected in human brains with Alzheimer’s 
disease, Lewy Body disorders, and multiple system atrophy (Paleologou et al., 2010).  S87 
phosphorylation alters the biophysical properties of α-synuclein, including inhibition of fibril 
formation and reduction in membrane binding (Paleologou et al., 2010).  Additionally, 
phosphorylated α-synuclein at residue Y125 was detected in Drosophila expressing human 
wildtype α-synuclein as well as in human brains, though levels were decreased in disease 
compared with aged-matched healthy controls (Chen et al., 2009). 
The proximity of the α-synuclein phosphorylation sites to the metal binding sites raised 
the question of how phosphorylation may affect metal ion interactions.  This was investigated by 
the use of C-terminal peptides containing residues 119-132 that were either unmodified, 
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phosphorylated at Y125 or at S129 (Liu and Franz, 2005).  By exploiting the luminescence 
properties of Tb3+, it was found that phosphorylated Y125 showed enhanced Tb3+ binding relative 
to wildtype or phosphorylated S129.  Additionally, phosphorylated Y125 preferentially bound to 
trivalent rather than divalent metal ions.  To investigate this further, longer C-terminal fragments 
comprised of residues 107-140 that were either unmodified of monophosphorylated at Y125 or 
S129 were tested for their affinity to various metal ions.  By using a fluorescence quenching 
assay, the dissociation constants of the metal ion complexes and the α-synuclein peptides were 
determined.  These data indicate that either phosphorylation at Y125 or S129 increases the 
binding affinity for Cu (II) and Fe(II), but not Fe(III).  Furthermore, phosphorylated Y125 has a 
greater affinity for Pb(II) than wildtype, but phosphorylated S129 has an even greater affinity than 
phosphorylated Y125.  Additionally, tandem MS indicated that phosphorylation causes the metal 
ion binding sites to shift towards the C-terminal end of α-synuclein (Lu et al., 2011). 
α-Synuclein within Lewy bodies is nitrated on all four tyrosine residues (Giasson et al., 
2000).  Chemical nitration of α-synuclein results in the formation of both tyrosine nitrated 
monomers and nitrated dimers (Souza et al. 2000b).  Immunoelectron microscopy confirmed that 
nitrated monomers and dimers are incorporated into amyloid fibrils.  Purified nitrated α-synuclein 
monomer by itself was unable to form fibrils, whereas the nitrated dimer accelerated aggregation 
of unmodified α-synuclein (Hodara et al., 2004).  Additionally, nitration at residue Y39 in the N-
terminus decreased binding to synthetic vesicles and prevented the protein from adopting α-
helical conformation (Hodara et al., 2004).  These observations were recently confirmed and 
elegantly expanded by the generation of site-specifically nitrated α-synuclein using protein 
semisynthetic chemistries (Burai et al. 2015).  Using the synthetic nitrated α-synuclein the data 
showed that nitration did not interfere with phosphorylation of S129 by PLK3 and reaffirmed that 
intermolecular interactions between the N- and C-terminal regions of α-synuclein are critical in 
directing nitration-induced oligomerization of α-synuclein (Burai et al. 2015).   
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Native conformation(s) of α-synuclein.  Figure 2.2 depicts the rapid growth in the number 
of publications identified in PubMed using the term synuclein and highlights key studies that 
explored the native structure and conformation of the protein.  Early biochemical studies of α-
synuclein isolated from bacterial expression systems or α-synuclein expressed in rodent tissues 
indicated that it is monomeric with limited secondary structure.  Electrophoretic separation of α-
synuclein purified without heating on 6, 10, or 14% acrylamide gels estimated an apparent 
molecular weight of 20±3 kDa.  However, the values of sedimentation coefficient (S20,w = 1.7S), 
stokes radius (34 Å), analysis on native gels and derivation of the frictional coefficient (f/fo=2.09) 
indicated an apparent molecular weight in the range 57-58 kDa (Weinreb et al., 1996).  To 
reconcile this apparently anomalous behavior it was proposed that monomeric α-synuclein 
achieves minimal structure in simple solutions and this rather extended unstructured 
conformation resembles a globular protein with a larger apparent molecular weight.  This 
assumption was further corroborated by examination of purified monomeric α-synuclein by CD, 
FTIR and small angle X-ray scattering, which failed to identify significant secondary structural 
features.  Furthermore, minimal shifts in the spectroscopic features of α-synuclein were observed 
when the protein was placed in solutions that would increase hydrophobicity and neutralize 
negative charges indicating that the protein is natively unstructured, joining a growing group of 
Figure 2.2. The graph depicts the number of publications retrieved from PubMed using 
the search term “alpha synuclein” from a single publication in 1998 to 862 in 2015.  Significant 
milestones that examined the native structure and conformations of α-synuclein are displayed.   
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proteins sharing similar biochemical and biophysical characteristics (Uversky et al., 2001b).  NMR 
and CD data, however, indicated that α-synuclein assumes increasingly folded secondary 
structure when exposed to conditions that promote aggregation (low pH and high temperature) or 
upon interaction with phospholipids.  Collectively these data indicated that native α-synuclein is 
primarily an unstructured monomer, which can assume different compact conformations that 
resist aggregation, adopts α-helical conformation upon binding to lipids and undergoes 
conformational changes prior to oligomerization and formation of amyloid fibrils (Uversky et al., 
2001b).  However, the methodologies employed to quantify the molecular weight of α-synuclein in 
these elegant studies were not based on first principles and therefore a lingering uncertainty 
remains regarding the native size of the protein.  Moreover, crosslinking experiments in both 
intact cells expressing α-synuclein and lipid-free lysates revealed the stabilization of high 
molecular weight α-synuclein multimers (consistent with dimers, trimers, and larger multimers).  
These multimers were not reduced by dilution of lysates before crosslinking, nor by reducing the 
concentration of crosslinker from 1 mM to 8 µM, suggesting that they represented endogenous 
protein complexes (Cole et al., 2002).   
Examination of the α-synuclein native state was reignited in 2011 with the publication of 
results indicating that α-synuclein exists natively as a tetramer, rather than a monomer.  
Methodologies that are based on first principles were employed to examine the molecular weight 
and size of α-synuclein extracted under non-denaturing conditions from human red blood cells.  
Analytical ultracentrifugation produced a sedimentation equilibrium value of 4.78 S, indicating a 
molecular weight of 57.8 kDa.  Analysis of particle geometry by scanning transmission electron 
microscopy revealed the presence of roughly spherical molecules with a diameter of 
approximately 3.0-3.5 nm.  Automated sampling of 1000 α-synuclein particles showed a 
distribution of molecular weights between 10 and 175 kDa with a peak distribution at 55 kDa.  
These findings constitute the most direct measurements of the native molecular weight of α-
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synuclein.  The tetrameric species were shown to have α-helical conformation and were resistant 
to aggregation (Bartels et al., 2011).   
Complimentary observations were made using recombinant GST-tagged α-synuclein 
purified from bacterial expression systems under non-denaturing conditions.  Single-particle 
electron microscopy of purified α-synuclein revealed complexes of sizes and internal geometries 
consistent with trimers and dimers, which were corroborated by measurements of the 
hydrodynamic radii and elution on native state PAGE.  As observed previously, these species 
were more resistant to aggregation than denatured monomer.  CD also showed that several α-
synuclein mutations associated with early onset PD (A30P, E46K, A53T) exist in less ordered 
conformations than wildtype α-synuclein.  These mutants were also more prone to aggregation 
(Wang et al., 2011).  However, using the same α-synuclein construct that contains a 10-residue 
N-terminal extension, which forms multimers when isolated from E. coli, NMR studies indicated 
that only a small fraction of α-synuclein assembles into α-helical trimers and tetramers and the 
majority remains as a disordered monomer (Gurry et al., 2013).  These data indicated that 
several potential conformers of α-synuclein may exist in equilibrium.  The observation that α-
helical trimers and tetramers constitute only a small fraction of the total α-synuclein may explain 
other studies in which in-cell NMR was used to probe for the structure of α-synuclein and 
reported primarily the presence of unstructured monomer.  NMR data of α-synuclein in intact cells 
failed to detect stable or highly populated α-synuclein multimers and confirmed the intrinsically 
disordered nature of the protein in E. coli regardless of its purification method (Binolfi et al., 
2012).  Collectively these studies generated an apparent controversy and stimulated several 
additional studies that explored the native size and structure of α-synuclein.   
A re-examination of the native state of α-synuclein reasserted that the behavior of α-
synuclein from various sources was consistent with a disordered monomer.  This behavior was 
observed with protein extracted and isolated under both denaturing and non-denaturing 
conditions.  CD spectra previously attributed to tetrameric assemblies were not reproduced using 
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isolated monomer, but were replicated with the addition of small unilamellar vesicles.  Natively 
isolated α-synuclein before or after boiling that disrupts secondary structure migrated as high 
molecular weight α-synuclein bands in native PAGE, which was attributed to the rather expanded 
size of the unstructured monomer in solution.  These findings reaffirmed that the majority of 
native α-synuclein is a monomer with minimal secondary structure (Fauvet et al., 2012).  Further 
support was provided by similar explorations in the mouse brain, which indicated that the 
predominant native form of α-synuclein is an unstructured monomer.  α-Synuclein exhibited 
random coil structure in solution, readily aggregated over time, and adopted α-helical structure 
only upon membrane binding (Burré et al., 2013).   
α-Synuclein multimers were detected in postmortem non-diseased human brain using 
mild protein extraction methods, but no further purification.  These α-synuclein multimers had 
Stokes radii ranging from 33.2-37.5 Å, sedimentation coefficients ranging from 1.4S to 3.8S and 
apparent molecular weights ranging from 53-70 kDa in native gradient gels.  The multimers were 
detected by anti-α-synuclein antibodies that recognize different epitopes and the multimer identity 
was confirmed by mass spectrometry.  Consistent with previous observations, melting point 
thermostability analysis showed progressive loss of the α-synuclein multimers and heating of the 
brain extracts above 55 oC collapsed the higher molecular weight α-synuclein conformers into the 
53 kDa species, which corresponds to the unstructured monomer.  These data indicated the 
presence of α-synuclein conformers, defined as conformationally diverse α-synuclein multimers, 
in the human brain.  Therefore it appears that both monomer and metastable multimers coexist 
and that interactions with lipids, other proteins, or small molecules may transiently stabilize these 
species (Gould et al., 2014).  This was further supported by controlled bimolecular fluorescence 
complementation methodologies in different cell types that found α-synuclein metastable 
conformers assembled in synapses.  It was suggested that the function of these multimeric α-
synuclein conformers is to restrict recycling of synaptic vesicles and thus reduce neurotransmitter 
release (Wang et al., 2014).   
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Additional support for native multimeric species comes from recent studies in which serial 
purification of α-synuclein from non-pathological human cortical tissue was performed.  Removal 
of lysate components other than protein followed by sequential removal of proteins though size 
exclusion, anion chromatography, and thiopropyl sepharose 6b separation, resulted in the 
isolation of >90% pure α-synuclein.  Each step of serial purification resulted in a progressive loss 
of α-synuclein immunoreactive high molecular weight bands observed after disuccinimidyl 
glutarate crosslinking and SDS-PAGE separation.  Analysis of α-synuclein secondary structure by 
CD found that the sequentially purified protein had greater α-helical content than the recombinant 
α-synuclein.  However, a high degree of variability in secondary structure was observed between 
purified samples raising questions about the stability of these helical conformations (Luth et al., 
2015).  Furthermore, crosslinking experiments conducted in brain tissue from mice expressing 
wildtype or A53T human α-synuclein in the absence of mouse α-synuclein showed that the A53T 
mutation reduced the presence of soluble multimeric α-synuclein (Dettmer et al., 2015a). 
2.5 Concluding remarks and perspectives  
Collectively the studies on the native structure indicate a remarkable conformational 
plasticity and structural flexibility of α-synuclein.  The ability of the protein to adopt N-terminal α-
helical conformation through its association with lipids has been well documented.  The 
association with lipids has been shown to prevent fibril formation (Martinez et al., 2007; Zhu and 
Fink, 2003) and may also stabilize physiological multimeric species that together with the 
monomer regulate SNARE complex assembly and recycling of synaptic vesicles (Burré et al., 
2014; Wang et al., 2014).  However, other groups have demonstrated a role for phospholipid 
membranes in promoting pathological α-synuclein aggregation, potentially by acting as a scaffold 
for amyloid nucleation.  This event may preferentially occur at low lipid to protein ratios, when 
monomeric α-synuclein is free in solution and can participate in nucleation (Galvagnion et al., 
2015; Ysselstein et al., 2015).  
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In figure 2.3 we propose a model which incorporates and summarizes the existing 
knowledge regarding α-synuclein biology and structure.  The steady state levels of α-synuclein 
are carefully regulated by protein synthesis and removal by several pathways such as the 
ubiquitin-proteasome pathways and autophagy (Webb et al., 2003).  Controlling the steady state 
levels of this protein by regulating synthesis and degradation may be the first critical defense in 
preventing aggregation.  Conformational change to α-helical rich structures, and stabilization of 
metastable multimers is achieved by specific interactions with vesicular phospholipids and 
proteins.  The sequestration of α-synuclein in association with membrane vesicles and with other 
proteins may be of critical importance for preventing aggregation.  Therefore these dynamic 
equilibria maintain functionality and promote assemblies that are resistant to aggregation.  
Catastrophic events that may include inappropriate post-translational modifications will 
disassemble the multimers as well as transform aggregation-incompetent monomers to 
Figure 2.3. Free energy landscape of possible α-synuclein conformers and multimeric 
assemblies.  The conversion of native α-synuclein to aggregation-competent monomers 
may depend on dissociation from stabilizing interactions with lipids and/or proteins as well as 
dissociation of the metastable tetrameric species.  α-Synuclein aggregation-competent 
monomers can then assemble into dimers and larger oligomeric conformers.  The generation 
of α-synuclein oligomers can rapidly lead to formation of stable amyloid fibrils, or ‘off-
pathway’ amorphous aggregates, both of which have been observed in postmortem brain 
tissue from patients with PD and related disorders.      
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aggregation-competent species.  The first step in the pathway to amyloid fibril formation is the 
generation of a dimer that is either held together by hydrophobic interactions induced by 
increased conformational transition to β-sheet structure or upon covalent cross-linking.  Following 
this nucleation event (Wood et al., 1999) the hydrophobic patch of amino acids between residues 
71-82 appears to be primarily responsible for allowing additional α-synuclein monomers to 
assemble to form oligomeric structures.  This transition is the committed rate limiting step for 
aggregation and must overcome a relatively large thermodynamic requirement that permits the 
conversion from an unstructured coil to organized β-sheet conformation.  Oligomers are soluble 
in aqueous buffers and can appear spherical or ring-like by atomic force and electron microscopy 
(Conway et al., 2000; Lashuel et al., 2002).  Soluble, high molecular weight oligomers have been 
extracted from human brain tissue and their levels appear to be increased in PD brain (Sharon et 
al., 2003) as well as mouse models of α-synuclein aggregation (Tsika et al., 2010).  As oligomers 
grow, they reach an undefined critical length and are able to assume additional quaternary 
structure.  At this stage, these structures may continue to grow in linear β-sheets, forming 
polarized protofibrils and eventually fibrils. Fibrils may further arrange into protein inclusions 
although it remains unclear if other proteins within these inclusions anchor these fibrils.  
Alternatively, oligomers may remain soluble by interacting with small molecules (Conway et al., 
2001) or by incorporating post-translationally modified α-synuclein molecules.  These structures 
remain “off the amyloid fibril pathway” and may constitute what has been described in human 
postmortem tissue as “dots” or “dust-like” amorphous aggregates (Braak et al., 2001; Duda et al., 
2002).  At this juncture, it remains unclear which of these assemblies are toxic to neurons.  
Recent data indicate that several conformationally distinct assemblies (possibly different strains) 
of α-synuclein generated in vitro will induce the aggregation of endogenous α-synuclein resulting 
in neurodegeneration (Guo et al., 2013; Luk et al., 2012a; Peelaerts et al., 2015; Sacino et al., 
2014b).  The appreciation of different α-synuclein conformers and assemblies as well as their 
roles in disease may guide potential therapeutic approaches.  For example, therapeutic strategies 
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can be centered on preserving and stabilizing the physiological multimeric conformers as well as 
preventing monomers from aggregating. Alternatively, sequestration and removal of aggregation-
competent monomers and oligomers can be considered.  
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3.1 Abstract 
Accumulation of aggregated α-synuclein into Lewy bodies is thought to contribute to the onset 
and progression of dopaminergic neuron degeneration in Parkinson’s disease (PD) and related 
disorders.  Although protein aggregation is associated with perturbation of proteostasis, how α-
synuclein aggregation affects the brain proteome and signaling remains uncertain.  In a mouse 
model of α-synuclein aggregation, 6% of 6,215 proteins and 1.6% of 8,183 phosphopeptides 
changed in abundance, indicating conservation of proteostasis and phosphorylation signaling.  
The proteomic analysis confirmed changes in abundance of proteins that regulate dopamine 
synthesis and transport, synaptic activity and integrity, and unearthed changes in mRNA binding, 
processing and protein translation.  Phosphorylation signaling changes centered on axonal and 
synaptic cytoskeletal organization and structural integrity.  Proteostatic responses included a 
significant increase in the levels of Lmp7, a component of the immunoproteasome.  Increased 
Lmp7 levels and activity were also quantified in postmortem human brains with PD and dementia 
with Lewy bodies.  Functionally, the immunoproteasome degrades α-synuclein aggregates and 
generates potentially antigenic peptides.  Expression and activity of the immunoproteasome may 
represent testable targets to induce adaptive responses that maintain proteome integrity and 
modulate immune responses in protein aggregation disorders.  
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3.2 Introduction 
Cells have developed protein homeostasis networks to maintain proper cellular function 
and combat potentially toxic protein aggregation.  Failure to sustain proteostasis upon protein 
aggregation may contribute to the pathogenesis of several neurodegenerative diseases of aging 
such as Parkinson’s disease, Alzheimer’s disease and Amyotrophic lateral sclerosis (Balch et al., 
2008; Douglas and Dillin, 2010; Powers et al., 2009).  These diseases are characterized by 
progressive misfolding and aggregation of proteins and ultimately neuron death.   
However, it remains unclear how intracellular aggregation of proteins leads to neuron 
dysfunction and death.  Studies in cellular model systems have shed some light on the 
pathological mechanisms of endogenous protein aggregation.  Dynamic changes in the proteome 
of cultured cells following intracellular aggregation of artificial synthetic proteins indicated that the 
formation of amyloid-like aggregates attracted several interacting proteins, which were 
functionally linked to protein synthesis and quality control (Olzscha et al., 2011).  These findings 
were recently expanded to show that not only artificial synthetic proteins enriched in β-sheet 
structure but also fragments of mutant huntingtin and TAR DNA-binding protein 43 (TDP-43) 
peptides, which aggregate in human diseases, cause disturbances in the proteome by interfering 
with nuclear-cytoplasmic protein and RNA transport (Woerner et al., 2016).  Collectively, these 
studies highlight the impact of protein aggregation on the proteome and proteostasis, and provide 
the intriguing hypothesis that the re-allocation of cellular resources to combat changes in the 
proteome upon endogenous protein aggregation leads to dysfunction and ultimately neuron 
death.   
To explore, for the first time, protein aggregation induced changes in the proteome and 
signaling through phosphorylation in vivo we capitalized on the development of a mouse model of 
α-synuclein aggregation and the use of quantitative mass spectrometry (MS)-based proteomic 
technologies.  α-Synuclein is a 140 amino acid protein that is predominantly localized to vesicles 
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in pre-synaptic terminals (Davidson et al., 1998; George et al., 1995; Maroteaux et al., 1988) 
participating in the regulation of neurotransmitter release and synaptic plasticity (Abeliovich et al., 
2000; Chandra et al., 2004; Nemani et al., 2010).  Several point mutations, as well as 
multiplications, of the α-synuclein gene are associated with familial Parkinson’s disease (PD) 
(Farrer et al., 2004; Polymeropoulos et al., 1997; Singleton et al., 2003).  Moreover, highly 
organized amyloid-like fibrils and non-amyloid amorphous aggregates of non-mutant α-synuclein 
are deposited into Lewy bodies, cytoplasmic inclusions that serve as histopathological hallmarks 
of sporadic PD and other related neurodegenerative disorders (Duda et al., 2002; Giasson et al., 
2000; Spillantini et al., 1997).  
To investigate the pathological mechanisms of α-synuclein aggregation, Luk et al. 
developed a mouse model of α-synuclein aggregation (Luk et al., 2012a).  In this model, 
unilateral injection of preformed fibrils (PFFs) of recombinant wild type mouse α-synuclein into the 
striatum of non-transgenic mice induces progressive aggregation of endogenous α-synuclein, first 
in regions proximal to the injection site 30 days post injection (dpi) with further involvement of 
distally interconnected regions by 90 and 180 dpi.  Injected mice developed significant 
dopaminergic neuron degeneration and impaired balance and motor coordination at 180 dpi (Luk 
et al., 2012a, 2016).  Importantly, degeneration and α-synuclein inclusions within the nigrostriatal 
dopaminergic system are confined to the injected side and absent in the non-injected 
contralateral side of the brain at 180 dpi.  Additionally, injection of PFFs into α-synuclein null 
(Snca-/-) mice fails to induce these effects, indicating that endogenous α-synuclein is required for 
aggregation and dopamine neuron degeneration (Luk et al., 2012a).  This PFF injection model 
has been reproduced in mice, rats and non-human primates (Osterberg et al., 2015; Paumier et 
al., 2015; Peelaerts et al., 2015; Sacino et al., 2014b; Shimozawa et al., 2017).  Therefore, this 
model (both wild type and Snca -/- injected mice) provides an opportunity for in vivo study of 
quantitative changes in the proteome upon aggregation of α-synuclein using MS-based 
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proteomics and phosphoproteomics when used in combination with Stable Isotope Labeling in 
Mammals (SILAM) (Wu et al., 2004).   
3.3 Methods 
Animals. Wild type female, 2-3 month old, C57BL6/C3H mice were obtained from the Jackson 
Laboratories (Bar Harbor, ME).  Snca-/- mice were maintained on a C57BL6 background.  13C-
Stable Isotope Labeling in Mammals (SILAM) mouse brain tissue (C57BL6 female, L-Lysine-13C6, 
97%) was purchased from Cambridge Isotope Laboratories, Inc.  All housing, breeding, and 
procedures were performed according to the NIH Guide for the Care and Use of Experimental 
Animals and approved by the University of Pennsylvania Institutional Animal Care and Use 
Committee (IACUC). 
Stereotaxic injection of PFFs. For stereotaxic injections, the PFFs were diluted in sterile PBS 
and fragmented using a Bioruptor bath sonicator (Diagenode, Denville, NJ).  Sonication was 
performed at high power for 10 cycles (30s on, 30s off, at 10°C).  Mice were anesthetized with 
ketamine hydrochloride (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.).  For each animal, PFFs 
were stereotaxically targeted into the ventral striatum (AP: +0.2 mm Bregma, lateral: 2.0 mm from 
midline, depth: 3.6 mm beneath the dura), dorsal striatum (AP: +0.2 mm, lateral: 2.0 mm, depth: 
2.6 mm), and overlaying cortex (AP: +0.2 mm, lateral: 2.0 mm, depth: 0.8 mm).  Injections were 
made through a single needle tract using 10 µL syringes (Hamilton, NV) at a rate of 0.1 µL per 
min (2.5 µL total per site) with the needle in place for ≥ 5 min at each target.  Animals were 
monitored regularly following recovery from surgery.  Mice were sacrificed at 90 days post 
injection by overdose with ketamine/xylazine.  For biochemical studies, dorsal striatum and 
ventral midbrain from ipsilateral and contralateral sides were dissected and stored at -80 °C until 
used.  For histological studies, the brain and spinal cord were removed after transcardial 
perfusion with PBS and underwent overnight post-fixation in either neutral buffered formalin 
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(Fisher Scientific) or 70% ethanol (in 150 mM NaCl, pH 7.4), before being processed and 
embedded in paraffin. 
Immunohistochemistry and neuron counting for mouse brain. Immunohistochemistry for α-
synuclein phosphorylated at Ser-129 and tyrosine hydroxylase (TH) were performed on 6 µm 
thick coronal sections as previously described (Luk et al., 2012a). Digitized images of stained 
sections were acquired using a Perkin Elmer Lamina scanner at 20x magnification.  Midbrain 
dopaminergic neurons belonging to the substantia nigra pars compacta and the ventral tegmental 
area were quantified from TH-immunostained coronal sections spanning the entire extent of the 
midbrain (every 9th section).  Only intact neurons with visible nuclei and TH positive staining were 
included in the counting based on established criteria (Fu et al., 2012). Statistical analysis 
between groups was compared using unpaired t-test.   
Sample preparation and LC-MS/MS analysis. For each mouse injected, the midbrain and 
striatum of the injected and non-injected sides were individual dissected and kept separate.  Two 
midbrain and striatum regions of the injected hemisphere were combined to generate one 
biological sample for the proteomic analysis.  The same approach was employed for the non-
injected side.  Four biological samples for wild type and three for Snca-/- for each injected and 
non-injected side were analyzed through the proteomic workflow.  Homogenates were prepared 
as described previously (Mertins et al., 2013).  Briefly, brains were homogenized with a tissue 
grinder in cold urea buffer: 8 M urea, 75 mM NaCl, 50 mM Tris HCl pH 8.0, 1 mM EDTA, 2 µg/mL 
aprotinin (Sigma, A6103), 10 µg/mL leupeptin (Roche, 11017101001), 1 mM PMSF (Sigma, 
78830), 10 mM NaF, 5 mM sodium butyrate, 5 mM iodoacetamide (Sigma, A3221), Phosphatase 
Inhibitor Cocktail 2 (1:100, Sigma, P5726), and Phosphatase Inhibitor Cocktail 3 (1:100, Sigma, 
P0044).  Following 10 min centrifugation at 20,000g, protein concentration was determined by a 
BCA assay (Thermo, 23235).  The supernatant was then combined with 13C-labeled brain lysates 
in a 1:1 ratio (5µg).  Samples were reduced for 45 min with 5 mM dithiothreitol followed by 
alkylation with 20 mM iodoacetamide for 45 min. Samples were then diluted 1:4 with 50 mM Tris 
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HCl pH 8.0 (to reduce urea concentration to 2 M), then digested overnight with trypsin (Promega, 
V5111) at 37°C overnight.  1% formic acid was added to the digests to remove urea by pelleting.  
The tryptic peptides were desalted by ultraMicro-Spin Vydac C18 column (Nestgroup, Inc, 
SUMSS18V).  After peptide separation by high-pH reverse phase chromatography, 95% of 
peptides were combined in a concatenated pattern into 12 fractions for phosphoproteomic 
analysis.  Lyophilized phosphopeptides fractions were re-suspended in 50% acetonitrile/0.1% 
trifluoroacetic acid (TFA) and then diluted 1:1 with 100% acetonitrile/0.1% TFA.  These samples 
were then enriched for phosphorylation by incubation with 10 µL immobilized metal affinity 
chromatography (IMAC) for 30 min.  Enriched IMAC beads were the loaded onto C18 silica-
packed stage tips washed twice with 50 µL of 80% acetonitrile/0.1% TFA and 100 µL of 1% 
formic acid.  Phosphopeptides were then eluted from IMAC beads with three washes of 70 µL 
500 mM dibasic sodium phosphate, pH 7.0, (Sigma, S9763) and 2 washes of 100 µL of 1% 
formic acid. Elution from stage tips was then performed with 60µL of 50% acetonitrile/0.1% formic 
acid. Washes were performed on a tabletop centrifuge at a maximum speed of 3,500 g.  The 
peptides were analyzed by mass spectrometry (MS) and the data was analyzed with MaxQuant 
(described below).  The SILAM ratio of light/heavy generated from the MaxQuant was converted 
to log2 scale and the median of the SILAM ratios therefore was calculated.  If the SILAM ratio was 
close to 1:1, a larger scale sample prep was performed similarly as described above.  Protein (2 
mg heavy: 2 mg light) was digested with trypsin/Lys-C mix (Promega, V5073) at 1:25 enzyme: 
protein ratio.  This protease mix has been reported to enhance mass spectrometry-based 
proteomics analysis by reducing the missed cleavages at lysine residue of a given peptide 
(Mertins et al., 2013).  The peptide fragments were desalted on tC18 SepPak cartridge (Waters, 
WAT036815) and the peptides were lyophilized and stored in -80 °C.  For reverse phase-HPLC, 
the peptides were reconstituted in 20 mM ammonium formate, pH 10.0.  Peptide concentration 
was determined by UV280 before they were separated by high-pH reverse phage 
chromatography (Acquity UPLC H-Class instrument, Waters) to 72 fractions.  Solvent A (2% 
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acetonitrile, 5mM ammonium formate, pH10) and solvent B (90% acetonitrile, 5mM ammonium 
formate, pH 10) were used to separate peptides with a ZPRBAX 300Extend-C18 column 
(4.6mmx250mm, 5 Micron, Agilent).  The gradient for separation was 1 mL/min flow rate as at 9 
min, 100% A; 13 min, 94% A; 63 min, 71.5%; 68.5 min, 66% A; 81.5 min, 40% A; 83 min; 0% A; 
at 88-120 min with 1.2 mL/min with 100%A.  Five percent of the samples were removed and 
recombined in a concatenated pattern into 24 fractions for proteomics analysis.  
Peptide digests were analyzed on a hybrid LTQ Orbitrap Elite mass spectrometer (Thermofisher 
Scientific, San Jose, CA) coupled with a NanoLC Ultra (Eksigent Technologies). Mobile phase A 
consisted of 1% methanol/0.1% formic acid and mobile phase B consisted of 1% methanol/0.1% 
formic acid/79% acetonitrile.  Peptides were eluted into the MS at 200 nl/min with each RP-LC 
run comprising a 15 min sample load at 3% B and a 90 min linear gradient from 5 to 45% B.  The 
mass spectrometer repetitively scanned m/z from 300 to 1800 (R = 240,000 for LTQ-Orbitrap).  
FTMS full scan maximum fill time was set to 500 ms, while ion trap MSn fill time was 50 ms; 
microscans were set at one.  FT preview mode, charge state screening, and monoisotopic 
precursor selection were all enabled with rejection of unassigned and 1+ charge states. 
Database searching, construction of the mouse brain reference proteome and proteomic 
data analysis. Protein identification was performed with MaxQuant (1.5.1.2) using a mouse 
UniProt database.  Carbamidomethyl was defined as a fixed modification.  The False Discovery 
Rate for peptides was set at 1%.  Fragment ion tolerance was set to 0.5 Da.  The MS/MS 
tolerance was set at 20 ppm.  The minimum peptide length was set at 7 amino acids.  The re-
quantification option was left unchecked and the match-between-runs was turned on.  For a 
protein to be quantified, the peptide must be identified at least once in light and once in heavy.  
To construct a unified set of literature and experimental proteins, UniProt accessions were cross-
referenced by gene or protein name.  For literature proteins, we selected several studies that 
used MS-based proteomics to identify proteins in the unperturbed mouse brain (Price et al., 2010; 
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Walther and Mann, 2011; Wang et al., 2006). A reference proteome was generated combining 
the literature proteome with proteins identified in our experimental runs (Data file S4).   
The Light-to-Heavy (L/H) ratio in the non-injected side was divided by the L/H ratio in the injected 
side to compute the injected/non-injected ratio of ratios.  Resulting lists of proteins were analyzed 
using the Perseus software (http://www.coxdocs.org/doku.php) (Tyanova et al., 2016).  The H/L 
ratios reported by MaxQuant were inverted and log2 transformed.  The mean, standard deviation, 
coefficient of variation, and principle component analysis (PCA) were calculated to examine the 
precision and repeatability of experiments.  We used Z-score to scale the data by subtracting the 
mean of each column from the values and dividing by the standard deviation of the column.   
Student’s t-test and group averages were calculated and visualized in volcano plots within 
Perseus.  Lists of statistically significant proteins with p-value < 0.05 were selected and DAVID 
Bioinformatics Resources V6.8 was employed for Gene Ontology (GO) analysis.  GO data was 
visualized using GO plot package in R (Walter et al., 2015).  The gene network analysis was 
performed using GeneMANIA (http://genemania.org/) prediction server (Montojo et al., 2014). 
Motif-x software tool was used for motif analysis of phosphoproteome using IPI Mouse Proteome 
as background.   
The mass spectrometry proteomics data have been deposited to the ProteomeXchance 
Consortium via the PRIDE partner repository with the dataset identifier PXD0009647. 
Western blot analysis of mouse tissue. Mouse brain samples were extracted using the same 
method described above for the MS analysis.  For each analysis, 5-20 μg of sample was added 
per lane, separated on 12% Bis-Tris Pre-Cast gels (ThermoFisher) and transferred to PVDF 
membranes using 7.5% BSA in TBS for blocking.  All primary antibodies were used overnight at 
1:1000.  Antibodies were used against TH (tyrosine hydroxylase; EMD Millipore, 657012 
RRID:AB_696697), DAT (dopamine transporter; EMD Millipore, MAB369 RRID:AB_2190413), 
Ddc (aromatic-L-amino-acid decarboxylase; Abcam, ab3905 RRID:AB_304145), NSE (neuron 
specific enolase; Abcam, ab53025 RRID:AB_881756), PKC-β2 (protein kinase C beta-2; Abcam, 
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ab32026 RRID:AB_779042), Akt (protein kinase B; Cell Signaling, 9272 RRID:AB_329827), 
Lmp7 (proteasome subunit beta type-8; Abcam, ab3329 RRID:AB_303708), and α-synuclein 
clone D37A6 (Cell Signaling Technology, #4179 RRID:AB_1904156) or clone Syn211 (Sigma-
Aldrich Cat# S5566, RRID:AB_261518).  Antigen-antibody complexes were detected using an 
Odyssey LC scanner (LiCor) after incubation with appropriate secondary antibodies.  
Densitometry was used to quantify intensity of protein bands. 
Western blot analysis and proteasome activity of human tissue. Brain samples (amygdala, 
cortex) from dementia with Lewy bodies and non-disease brains that have been described 
previously (Rutherford et al., 2013; Waxman et al., 2008) were extracted using high salt buffer 
containing 1% Triton-X100 (150 mM NaCl, 50 mM Tris, pH 7.6).  Protease inhibitors were added 
to buffer prior to use.  To collect triton-soluble fractions, samples were homogenized, sonicated 
and centrifuged at 15,000 rpm for 30 min.  500 μL of buffer was added to each sample.  Protein 
concentrations were determined by BCA assay (Thermo Fisher).  Samples were separated in a 
12% Bis-Tris Pre-Cast gel (ThermoFisher) and transferred to a PVDF membrane and blocked 
using 7.5% BSA in TBS.  For each analysis 40 μg of sample was added per lane.  All primary 
antibodies were used overnight at 1:1000.  Antibodies were used against Lmp7 (proteasome 
subunit beta type-8; Abcam, ab3329 RRID:AB_303708), β5 (proteasome subunit beta type-5; 
Invitrogen, PA1-977 RRID:AB_2172052) and NSE (neuron specific enolase; Abcam, ab53025 
RRID:AB_881756).  Antigen-antibody complexes were detected using an Odyssey LC scanner 
(LiCor) after incubation with appropriate secondary antibodies.  Densitometry was used to 
quantify intensity of protein bands.  For proteasome activity, the brain samples were 
homogenized as described above in the absence of protease inhibitors and freshly prepared 
samples were analyzed using the proteasome activity fluorometric assay (BioVision K245).  
Assays were performed in a 96-well plate at 37°C using 5 μg of brain lysate per experimental 
condition.  Each condition was analyzed with or without the proteasome inhibitor lactacystin 
(Enzo Life Science PI104).  After 60 min, the fluorescence with inhibitor was subtracted from the 
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fluorescence without inhibitor in each sample.  Three biological replicates were quantified for 
each experimental condition.  Statistical analysis between groups was compared using unpaired 
t-test. 
Immunohistochemistry for human brain. Human brain sections were obtained from the Brain 
Bank of the Honolulu Asian Aging Study (White and al, 1996).  The study is approved by the 
Kuakini Medical Center Institutional Review Board and participants signed informed consents.  
Five cases of PD and five healthy controls were examined.  DAB and fluorescent 
Immunohistochemistry for Lmp7, IBA1, and GFAP was performed on 10 µm thick tissue sections.  
For colorimetric DAB staining, formalin fixed paraffin embedded sections were rehydrated in 
ethanol and diH2O and submerged in H2O2 for 30 minutes to quench endogenous peroxidase 
activity.  Antigen retrieval was accomplished by microwaving the slides in a pressure cooker with 
R Buffer U (Electron Microscopy Sciences, 62706-13).  The tissue sections were then blocked at 
room temperature in 2% normal horse serum and incubated with Lmp7 antibody (Abcam, 
Ab3329, 1:5000) at 4° C for 18 hours.  Slides were rinsed in 0.1M Tris and incubated with a 
biotinylated secondary antibody, ABC, and DAB solution according to Vectastain instructions 
(Vector Labs, PK-6200 and SK-4100).  Images were acquired using a Nikon Eclipse E800 
microscope.  For fluorescent triple labeling, tissue sections were also rehydrated in ethanol and 
diH2O and subjected to the same antigen retrieval and blocking steps as described previously.  
Slides were then incubated with the same Lmp7 antibody at 1:2500 concentration, along with 
antibodies against IBA1 (ionized calcium binding adaptor molecule 1; Abcam, ab5076 
RRID:AB_2224402, 1:1000) and GFAP (glial fibrillary acidic protein; Millipore, NE1015 
RRID:AB_2043416, 1:2000) antibodies at 4° C for 18 hours.  Slides were then rinsed in 0.1M Tris 
and incubated with corresponding Alexa Fluor-conjugated secondary antibodies (Invitrogen, 
A10042 RRID:AB_2534017; A21202 RRID:AB_141607; A21447 RRID:AB_2535864) for 1 hour 
at room temperature.  Slides were rinsed again in 0.1M Tris and incubated with Hoechst 33342 
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(Life Technologies, H3570), mounted with Fluormount G (Southern Biotech, 0100-01) and cover-
slipped. I mages were acquired using a Nikon A1RSI laser scanning confocal microscope. 
In Vitro Degradation Assay.  Purified human WT α-synuclein was aggregated at 5 mg/mL for 7 
days at 1,400 rpm at 37°C.  The fibrils generated from the aggregation of α-synuclein were used 
as substrate for the in vitro degradation assays.  Myelin Basic Protein (Sigma M1891) was used 
at 25 μM and α-synuclein was used at 1 mg/mL.  Human Immunoproteasome 20S (Enzo BML-
PW8720) and Human Proteasome 20S (Enzo BML-PW9645) were used at a ratio of 0.11:1 
proteasome:α-synuclein.  Human Proteasome Activator 11S complex (BML-PW9420) was added 
at a final concentration of 500 nM.  Reactions were incubated at 37°C agitating at 600 rpm, and 
samples were removed at indicated time points.  Samples were separated in a 12% Bis-Tris Pre-
Cast gel (ThermoFisher) and stained with colloidal blue. Densitometry was used to quantify 
protein degradation of monomer bands of α-synuclein. Initial time point was considered 100% for 
each experimental condition.  Three biological replicates were quantified for each experimental 
condition. For mass spectrometry analysis of the immunoproteasome peptides, the samples were 
removed following the indicated incubation time and frozen prior to processing. For the 
processing, a modified enhanced filter aided sample preparation (eFASP) was used. Briefly, 10 
kDa cutoff microcon filters (Millipore) were first passivated in a solution of 5% Tween 20 overnight 
to reduce peptide binding, followed by extensive washes with dH2O. The samples were then 
transferred to the filters and centrifuged at 14,000 xg for 10 min, retaining the flow through 
containing the peptides. Sample volume was then reduced to roughly 50 µL by SpeedVac. 
Contaminants in the sample were removed using C18 Stage Tips (Thermo Electron) and the 
samples were transferred to autosampler vials. LC-MS/MS conditions and instrument settings 
proceeded as above with the exception that the samples were not fractionated prior to analysis. 
The raw data was searched against a database constructed with the human sequence of α-
synuclein, proteasome and immunoproteasome subunits using MaxQuant (1.5.1.2) with peptide 
cleavage set to nonspecific and a FDR of 1%. 
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Cell treatments. U-251 cells were grown in high glucose DMEM supplemented with 10% FBS, 
1% penicillin and streptomycin, 1% glutamine and 1% HEPES. Cells were plated at low density 
and allowed to adhere for 24h, after which cells were pretreated with 0.1 µg/mL human interferon 
gamma (Pepro Tech Inc.) alone or in conjunction with the Lmp7 inhibitor ONX 0914 (Cayman 
Chemicals) at a final concentration of 0.2 µM. Following incubation overnight, 5 µg/mL α-
synuclein fibrils were added to the media and incubated for 4d. The cells were washed 3x with 
PBS and lysed in PBS + 1% Trition-X100. 12 µg of protein was loaded into each lane and the 
western proceeded as described above. Primary antibodies to α-synuclein (clone Syn211, 
SigmaAldrich, S5566 RRID:AB_261518), Lmp7 (proteasome subunit beta type-8; Abcam, 
ab3329), and Actin (Sigma Aldrich, A2066 RRID:AB_476693) were incubated with the membrane 
at a concentration of 1:1000 overnight at 4°C (Syn211) or for 1 h at room temp (Lmp7, Actin). IR 
Dye conjugated anti-mouse or anti-rabbit secondary was incubated at 1:5000 for 1 h and the blots 
were visualized using an Odyssey LC scanner (LiCor). 
3.4 Results 
Mouse Model of α-Synuclein Aggregation.   
To identify proteomic and signaling perturbations induced by the aggregation of α-
synuclein, a modified version of the recently developed and independently verified mouse model 
was employed (Luk et al., 2012a; Osterberg et al., 2015; Sacino et al., 2014b).  α-Synuclein 
aggregation in non-transgenic mice was induced by unilateral injection of PFFs into three 
locations, the motor cortex, dorsal and ventral-striatum.  PFFs were generated by aggregating 
purified recombinant mouse monomers of α-synuclein to insoluble amyloid-like fibrils exhibiting 
typical β-sheet secondary structure, then sonicating them to produce smaller, β-sheet PFFs (Fig. 
3.S1).  The changes in the proteome and phosphoproteome were quantified 90 dpi, a time point 
that is characterized by aggregation of α-synuclein, but prior to significant dopaminergic neuron 
loss (Luk et al., 2012a).   
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Although this model has been extensively validated, dopaminergic neurons belonging to 
the substantia nigra pars compacta were stereologically quantified from tyrosine hydroxylase (TH) 
stained coronal sections spanning the entire extent of the midbrain at 90 dpi (Luk et al., 2012a).  
A non-significant 19 ± 6% loss of substantia nigra dopaminergic neurons was quantified in the 
injected side of wild type mice, (n=3, t-test, p-value = 0.0507) as compared to the non-injected 
side (Fig. 3.S2c).  In contrast, no changes in TH staining was observed in the injected side of 
Snca-/- mice (Fig. 3.S2c), consistent with the previous results (Luk et al., 2012a).  An antibody that 
recognizes phosphorylated α-synuclein at Ser-129 (pS129), a marker for α-synuclein inclusions in 
human disorders was used to stain brain tissue obtained at 90 dpi (Anderson et al., 2006; Colom-
Cadena et al., 2017; Fujiwara et al., 2002).  Consistent with the previous report (Luk et al., 
2012a), Lewy body-like inclusions immunoreactive for pS129 were abundant in the substantia 
nigra (Fig. 3.S2a) and striatum (Fig. 3.S2b) ipsilateral to the injection site by 90 dpi.  In contrast, 
no staining was detected in the same areas on the non-injected side at this time point. Total 
levels of mouse α-synuclein are unchanged in the injected and non-injected side (Fig. 3.S2e). 
Moreover, there were no detectable pS129 α-synuclein inclusions in the brains of Snca-/- mice 
injected with PFFs in the same manner (Fig. 3.S2).  Collectively, these data confirmed the 
presence of PFF-triggered α-synuclein aggregation in the ipsilateral injected side of wild type 
mice, which is associated with mild TH-positive neuron loss, consistent with previous findings in 
this model (Luk et al., 2012a).   
Acquisition and overview of the proteome and phosphoproteome.   
A quantitative proteomic workflow depicted in figure 3.1a was implemented to quantify 
changes in the relative abundance of proteins in both wild type and Snca-/- mice.  The method 
incorporated the use of [13C6-lysine]-SILAM mouse brain as an internal “heavy” standard.  
Detailed examination of the [13C6-lysine]-containing internal reference peptides showed excellent 
reproducibility (average Pearson correlation coefficient = 0.87, 80% overlap) (Fig. 3.S3).  
Although the [13C6-lysine] internal standard was derived from the entire brain, whereas the “light” 
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samples were derived from combining the midbrain and striatum regions only, we report high 
correlations and tighter spreads of the corresponding heavy-to-light peptide pairs (average 
Pearson correlation = 0.96) than the heavy-to-heavy peptide pairs (Fig. 3.S3).  This improvement 
likely arises from the coincident sample processing workflow of the SILAM experiment as 
opposed to the parallel sample processing shown by the heavy-to-heavy comparisons.  This 
analysis validated the use of [13C6-lysine]-SILAM mouse brain as an appropriate standard for 
accurate proteome quantification.  
The quantitative proteomic analysis was restricted to brain regions of pathological 
interest, which include the midbrain and the striatum.  These two regions, dissected from two 
mice, were combined to generate sufficient protein for the proteomic analysis.  Using this 
approach the proteomic analysis included four replicates derived from the injected and non-
injected sides of wild type and three replicates obtained from each side of the similarly injected 
Snca-/- mice.  Combined analysis of the replicates in wild type mice applying a false discovery 
rate of 1% and removal of contaminants and reversed sequences resulted in the identification of 
6,508 proteins with a light-to-heavy (L/H) ratio in the injected side, 6,496 in the non-injected side, 
with 6,215 proteins identified in both sides (Fig. 3.1b).  Analysis in the Snca-/- mice resulted in the 
identification of 4,661 proteins with L/H ratio in the injected side, 4,994 in the non-injected side, 
with 4,460 proteins identified in both sides (Fig. 3.S4a).  Immobilized metal affinity 
chromatography (IMAC) enrichment for phosphopeptides resulted in the identification of 10,058 
phosphopeptides in the injected and 10,134 in the non-injected side of the wild type mice; 8,183 
phosphopeptides were common between the two sides.  Similarly, 10,285 and 9,775 
phosphopeptides were identified in the Snca-/- mice; 8,031 were shared between the two sides 
(Data file S1 and Fig. 3.S4b). 
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Figure 3.1.  Workflow for the acquisition and overall description of proteomes.  (a)
Overview of proteomic workflow.  The midbrain and striatum from the brains of two mice were 
dissected and combined to generate one sample replicate.  The ipsilateral injected and the 
contralateral non-injected sides were kept separate and processed throughout the workflow 
independently.  Immobilized metal affinity chromatography (IMAC) was used to enrich for 
phosphorylated peptides.  (b) Venn diagrams depicting the number of proteins and 
phosphopeptides quantified in 4 independent sample replicates in the injected side and non-
injected side in wild type mice.  The acquired proteomes in wild type and Snca-/- showed typical 
distribution in terms of molecular weight, cellular location and major biological processes when 
compared to a whole mouse brain proteome: (c) Distribution of the proteins quantified in wild 
type and Snca-/- mice based on protein molecular weight.  (d) Gene ontology enrichment 
analysis using cellular components (e) Gene enrichment using biological process and KEGG 
pathways.   
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In order to determine the extent by which the proteins quantified in this study are 
reflective of the proteins expressed in the mouse brain, and to protect against potential biases 
during the acquisition of the proteomic data, we constructed a global mouse brain proteome.  For 
the mouse brain proteome we combined our non-injected wild type proteome with proteins 
identified by mass spectrometry in unperturbed mouse brain from several existing studies (Price 
et al., 2010; Sharma et al., 2015; Walther and Mann, 2011; Wang et al., 2006).  The resulting 
proteome comprised of 11,055 unique proteins was curated through UniProt 
(http://www.uniprot.org).  The distribution of the proteins quantified in our study was evaluated 
based on their molecular weight, cellular localization and biological function against the reference 
proteome.  The proteins quantified were representative of the whole mouse brain proteome 
covering the entire range of molecular weights >10 kDa to >400 kDa (Fig. 3.1c) all major cellular 
compartments (Fig. 3.1d) and major biological processes (Fig. 3.1e).  Together, these analyses 
indicated that the number of proteins quantified through this workflow in the midbrain and striatum 
are compatible with recent studies (Jung et al., 2017; Sharma et al., 2015) and are representative 
of the proteins expressed in the mouse brain.   
Analysis of the proteome and phosphoproteome reveals selective disease-related 
changes.   
Changes in the relative abundance of proteins were quantified by a ratiometric method, 
dividing the L/H ratio of the non-injected side by the L/H ratio in the injected side.  The data was 
Log2 transformed, the coefficient of variance for each experiment determined, and the data 
scaled using the standard z-score.  Statistically significant changes in proteins (t-test, p <0.05) 
between the injected and non-injected sides were identified (Data file S2) and typical volcano 
plots integrating the p-value and the magnitude change were generated.  The relative abundance 
of 377 of 6,215 in wild type and 112 of 4,460 proteins in the Snca-/- mice changed significantly in 
the injected side (Fig. 3.2a; Fig. 3.S5).  Similarly, 132 of 8,183 phosphopeptides in wild type and 
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109 of 8,031 in the Snca-/- mice showed significant change (Fig. 3.3a; Fig. 3.S5).  There was a 
minimal overlap between the proteins that showed changes in the injected side of the wild type 
and Snca-/- mice (7 proteins), indicating that the changes in the wild type were driven primarily by 
the aggregation of α-synuclein.  This analysis indicated that aggregation of α-synuclein does not 
induce large remodeling of the proteome or phosphorylation-dependent signaling.  Ontological 
and functional analysis of the 377 proteins is depicted in the circular plot (Fig. 3.2b) in which the 
outer circle is a scatter plot for each biological term of the logFC (fold change) of the enriched 
proteins and the size of the inner trapezoids correspond to the adjusted p-value and the color 
indicates the z-score. Some of these functional protein clusters (extracellular exosome, synaptic 
vesicle) have been previously linked to α-synuclein and may represent adaptive response to 
maintain proteostasis and synaptic function. 
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Figure 3.2. Analysis of Quantified Proteins.  (a) Volcano plot showing the 377 proteins (black 
circles) that changed significantly (p < 0.05) in relative abundance in the injected side as 
compared to the contralateral non-injected side of wild type mice.  The red dots indicate the 
proteins with >2-fold increase and the blue dots the proteins with >2-fold decrease in relative 
abundance.  (b) Ontological analysis of the 377 proteins, which showed significant changes in 
relative abundance between the ipsilateral injected side and the contralateral non-injected side 
in the wild type mice.  The circular plot depicts the enriched functional networks of proteins.  The 
outer circle is a scatter plot for each biological term of the logFC of the enriched proteins.  Within 
each network, a protein is depicted as a dot, red for upregulated and blue for downregulated.  
The size of the inner trapezoids correspond to the adjusted p-value and the color indicates the z-
score as calculated by GOplot algorithm.  (c) Representative immunoblots from two independent 
biological replicates for the significantly changed proteins TH, DAT, and Ddc paired with NSE, 
PKC-β2 and Akt as unchanged protein controls.  The graphs indicate the mean ± sem for protein 
levels quantified by the SILAM-MS based method and the average of two independent western 
blot analysis.  The relative abundance of NSE, PKC-β2 and Akt did not change in the injected 
wild type or Snca-/- mice.  
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 The proteomic analysis identified five proteins selectively expressed in dopaminergic 
neurons among the proteins that decreased in abundance in the injected side of wild type mice.  
The analysis showed a significant decline in the levels of TH 50 ± 3%, aromatic-L-amino-acid 
decarboxylase (Ddc) 26 ± 4%, dopamine transporter (DAT; Slc6a3) 31 ± 9%, synaptic vesicular 
monoamine transporter-2 (VMAT2; Slc18a2) 42 ± 8% and Slc10a4 (specific function is unclear 
but is specifically expressed in dopaminergic neurons) (Larhammar et al., 2015; Patra et al., 
2015) 44 ± 3%.  In contrast, the relative abundance of monoamine oxidase A (MAO-A) and 
catechol-O-methyl transferase (COMT) that metabolize dopamine and are expressed in both glia 
cells and dopaminergic neurons, did not change significantly (increased by 3 ± 4% and 8 ± 4%, 
respectively).  This finding indicates that, despite possible dilution of the proteome by multiple cell 
types, our quantitative proteomic approach was capable of identifying specific changes in 
dopaminergic neurons.  Moreover, the decline in the abundance of proteins critical for dopamine 
synthesis, transport, and recycling exceeded the loss of dopamine neurons (Fig. 3.S2) suggesting 
ongoing dopamine neuron dysfunction consistent with the progressive injury in the setting of α-
synuclein aggregation.  As a reference, the abundance of TH, Ddc and DAT did not change in the 
injected side of Snca-/- mice when compared to the contralateral, non-injected side.   
Finally, the changes in the levels of TH, DAT and Ddc quantified by SILAM-MS-based 
methodology were further confirmed by western blot analysis.  The western blot analysis matched 
closely the MS-based quantification showing similar decline in the levels of TH, DAT and Ddc in 
the injected versus the non-injected side (Fig. 3.2c).  The levels of TH, DAT and Ddc were 
unchanged in the injected side of Snca-/- mice when quantified by western blot (Fig. 3.2c).  As 
controls for the western blots, we probed for unchanged proteins as determined by the MS 
analysis. NSE, PKC-β2 and Akt, showed no change in the levels between injected and non-
injected side in wild type and Snca-/- mice (Fig. 3.2c) by both MS-based quantification and 
western.   
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Although a relatively small number of phosphopeptides showed significant change in the 
injected side of the wild type mice (132 phosphopeptides identified in 125 proteins, Fig. 3.3a), the 
data was mined for kinases and functional pathways impacted by α-synuclein aggregation.  First, 
we performed a motif analysis to identify possible sequences targeted by kinase families.  This 
analysis revealed the enrichment for two motifs (Fig. 3.3b).  The first motif, X(any amino acid)-X-
Serine-Proline is a known minimal sequence motif for phosphorylation by mitogen-activated 
protein kinases (MAPK), which have been implicated in α-synuclein aggregation related disorders 
(Ferrer et al., 2001; Iwata et al., 2001; Wilms et al., 2009; Zhu et al., 2003a).  The second motif, 
Arginine-X-X-Serine-X indicates the minimal motif for phosphorylation by Ca2+/calmodulin-
dependent protein kinase II (CaMK-II), a serine/threonine kinase enriched at synaptic sites (Miller 
and Kennedy, 1986; Moriguchi et al., 2012; Picconi et al., 2004).  To further explore 
phosphorylation signal networks, bubble plots of the enriched cellular components and molecular 
functions were constructed using the z-score and the negative logarithm of the adjusted p-value 
(Fig. 3.3c).  The changes in phosphorylation signaling localize primarily in synapses and axons, 
and functionally relate to proteins that regulate axonal and synaptic cytoskeletal organization and 
structural integrity (Fig. 3.3c; Data file S3).  Moreover, when the changes in synapse associated 
phosphopeptides were combined with changes in synaptic vesicle proteins (Fig. 3.2b), the 
integrated network highlighted numerous physical interactions indicative of functional changes to 
synaptic architecture and secretory processes in response to α-synuclein aggregation occurring 
before significant neuron loss (Fig. 3.3d).   
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Figure 3.3. Analysis of Quantified Phosphopeptides. (a) Volcano plot showing the 132 
phosphorylated proteins (black circles) that changed significantly (p < 0.05) in relative 
abundance in the injected side as compared to the contralateral non-injected side of wild type 
mice.  The red dots indicate the phosphoproteins with >2-fold increase and the blue dots the 
phosphoproteins with >2-fold decrease in relative abundance.  (b) Motif analysis of the 132 
phosphopeptides, which showed a significant change in relative abundance.  Enrichment for two 
motifs was discovered; the XXSP motif, a known target for phosphorylation by MAP kinase and 
RXXS indicating substrates for CaMK-II kinase.  (c) Bubble-plot indicating the cellular 
components (red) and molecular functions (blue) that were significantly enriched among the 132 
phosphopeptides.  The area of the displayed circles is proportional to the number of proteins.  
(d)  Construction of a synaptic network from the 377 proteins and 132 phosphopeptides.  Black 
circles indicate proteins that are functionally assigned to synaptic vesicles and showed 
significant changes in relative abundance. The yellow circles indicate phosphoproteins assigned 
to synapse and showed significant changes in relative abundance.  The gray circles are proteins 
imported based on known interactions.  Physical interactions are depicted as pink edges; 
associations based on co-localization (blue) and shared protein domains (gold).     
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Upregulation of the Immunoproteasome in α-synuclein aggregation disorders.   
Among the significantly changed proteins a prominent increase in the relative levels of 
the proteasome subunit beta type-8 (Psmb8; common name, low molecular mass protein 7; 
Lmp7), was quantified in the injected side of wild type mice (Fig. 3.2a).  The increase in relative 
abundance of Lmp7 by MS in the injected side of wild type mice was validated by western blot 
analysis (Fig. 3.S6 and 3.S7).  Lmp7 is one of the three subunits of the catalytic core of the 
immunoproteasome (Cascio et al., 2001; Driscoll et al., 1993; Gaczynska et al., 1994; Huber et 
al., 2012), an inducible form of the proteasome assembled in response to inflammatory stimuli, 
primarily IFNγ (Ebstein et al., 2013; Nathan et al., 2013; Seifert et al., 2010; Yun et al., 2016).  
The immunoproteasome is defined by the replacement of catalytic subunits β1, β2 and β5 of the 
proteasome with proteasome subunit beta type-9 (low molecular mass protein 2; Lmp2), 
proteasome subunit beta type-10 (multicatalytic endopeptidase complex subunit-1; MECL-1) and 
Lmp7, respectively (Cascio et al., 2001; Driscoll et al., 1993; Gaczynska et al., 1994; Huber et al., 
2012).   
Since there are no previous studies linking α-synuclein aggregation to 
immunoproteasome induction and its potential role in proteostasis, we examined whether a 
similar increase of the immunoproteasome levels and activity occurs in human disease.  We 
compared the levels of Lmp7 in the brains of dementia with Lewy bodies (DLB), which contain 
aggregated α-synuclein (Duda et al., 2002; Giasson et al., 2000; Waxman et al., 2008), and non-
disease control subjects.  The analysis revealed a 3-fold increase in the levels of Lmp7 in DLB as 
compared to controls but no change in the levels of constitutive proteasome catalytic subunit β5 
(Fig. 3.4a and 3.4b).  Chymotrypsin-like activity, which is selectively elevated in the 
immunoproteasome (Gaczynska et al., 1994; Huber et al., 2012), was quantified to evaluate if the 
increase in protein levels correlates with activity.  An 80% increase in the lactacystin-sensitive, 
chymotrypsin-like activity was quantified in the DLB brain homogenates as compared to controls 
(Fig. 3.4c).   
62 
 
Figure 3.4. The Immunoproteasome in Human Disease Driven by α-Synuclein 
Aggregation. (a) Representative western blot analysis in human DLB and non-disease control 
brains for Lmp7 and the proteasome protein β5.  (b) Densitometric analysis of western blots 
normalized to the levels of NSE protein indicate a significant increase (**p<0.01, t test) in Lmp7 
levels in DLB brains (n=5) compared with controls, (n = 3).  (c) Concomitant with the increase in 
Lmp7 protein levels the chymotrypsin-like activity, a proxy for immunoproteasome activity, is 
increased by 189% in DLB brain compared with control brain (**p<0.01, n = 3, t test).  (d) 
Immunohistochemical staining revealed increased immunoreactivity for Lmp7 in PD substantia 
nigra and VTA.  (d1) Representative staining for Lmp7b in control substantia nigra and (d2) VTA.  
Increased Lmp7 staining in both neurons (asterisks) and glia (arrows) in PD substantia nigra (d3) 
and VTA (d4).  Nuclei were counterstained with hematoxylin (blue).  Scale bar = 50 µm.  (e) Co-
localization of Lmp7 with glial markers.  Representative fluorescent staining for the astrocyte 
marker, GFAP; microglial marker, IBA1; and Lmp7.  Overlay of GFAP, IBA1, LMP7 and Hoechst 
nuclear stain is displayed in the right column.  Staining in non-disease control substantia nigra 
(e1-4) and in VTA (e5-8).  Increased staining for Lmp7 in the PD substantia nigra (e9-12) and in the 
VTA (e12-16). Lmp7 co-localized with both astrocytes and microglia.  Staining increased in glial 
processes and soma (arrows) and neurons (asterisks) in PD substantia nigra relative to normal 
controls.  Lmp7 staining increased in astrocytes and microglia (arrows) of PD VTA relative to 
non-disease controls. Scale bar = 20 µm.  
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 Immunohistochemical analysis of PD (n = 5) and non-disease control tissue (n = 5) 
showed increased staining for Lmp7 in both the substantia nigra and ventral tegmental area 
(VTA) in PD tissue (Fig. 3.4d).  Increased staining for Lmp7 was observed in both neurons and 
glia in the substantia nigra of PD cases but not in control cases (Fig. 3.4d and 3.4e).  Neuronal 
staining occurred in pigmented and non-pigmented neurons in PD substantia nigra.  In PD ventral 
tegmental area, Lmp7 staining occurred primarily in glia, while neuronal Lmp7 was not detected 
in PD or control VTA.  In glia and neurons, Lmp7 staining was detected throughout both cell 
bodies and processes.  Lmp7 localization was further characterized by fluorescent triple labeling 
of astrocytes, microglia and Lmp7 (Fig. 3.4e).  In the VTA of PD cases, 47 ± 10% of IBA-1 
positive cells, a marker for microglia, and 40 ± 4 % of GFAP, an astrocytic marker, co-localized 
with Lmp7 (n = 4).  Overall, the biochemical and histological data demonstrate activation of the 
immunoproteasome in human diseases characterized by α-synuclein aggregation.  
To investigate the potential significance of the immunoproteasome we explored its ability 
to degrade α-synuclein fibrils in vitro.  For these experiments, we used the 20S 
immunoproteasome and the 20S proteasome, which degrade proteins without the need for 
ubiquitin tagging or the presence of the 19S regulatory particle (Moscovitz et al., 2015).  First, we 
secured that the purified immunoproteasome degraded myelin basic protein (MBP), a selective 
substrate (Raule et al., 2014).  After 22 hours, 96% of MBP was degraded by the 
immunoproteasome and 69% by the proteasome (Fig. 3.S8).  Next, α-synuclein fibrils generated 
from purified human monomeric α-synuclein with typical β-sheet secondary structure were used 
as substrate.  The immunoproteasome was capable of degrading α-synuclein fibrils in a time 
dependent manner achieving more than 50% degradation by 72 hours and nearly complete 
degradation after 5 days of incubation (Fig. 3.5a and 3.5b).  We further explored the possible 
consequences of immunoproteasome-mediated α-synuclein fibril degradation.  Since one of the 
main functions of the immunoproteasome is to produce peptides for antigen presentation, we 
tested if the degradation products exhibit peptide sequences that have been found to elicit MHC I 
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and MHC II responses (Sulzer et al., 2017).  Mass spectrometry detected 1,111 unique peptide 
sequences covering the entire 140 α-synuclein amino acid residues (Data file S5).  Further 
refinement of the detected peptides indicated that the immunoproteasome produced multiple 
peptides within the antigenic regions of α-synuclein (Sulzer et al., 2017), specifically between 
residues 31-46 and 116-140 (Fig. 3.5c).  Finally, to demonstrate that the immunoproteasome 
degrades α-synuclein fibrils in intact cells, we used U-251 cells, a human glioblastoma cell line 
that does not express endogenous α-synuclein and minimally detectable basal levels of Lmp7.  
The only source of α-synuclein in this cell model is the exogenous α-synuclein PFFs added to the 
culture media.  In these cells, α-synuclein PFF uptake appears to be dependent on inflammatory 
activation as evidence by the lack of uptake of exogenous α-synuclein in PFF only treated cells 
(Fig. 3.5d). The link between inflammatory activation and α-synuclein uptake has been previously 
documented (Lee et al., 2010).  Concurrent treatment with INFγ induces expression of Lmp7 and 
intracellular accumulation of exogenous α-synuclein.  INFγ only treated cells show the expected 
increase in Lmp7, but there is no α-synuclein available to detect in these cells.  Intracellular 
accumulation of the exogenous α-synuclein PFFs was quantified in the absence or presence of 
the Lmp7 specific inhibitor ONX-0914 (Muchamuel et al., 2009).  Inhibition of the 
immunoproteasome results in greater intracellular accumulation of α-synuclein (Fig. 3.5d and 
3.5e) without altering Lmp7 levels.  Taken together, the data suggest a possible neuroprotective 
role for the induction of the immunoproteasome to maintain proteostatic networks in response to 
α-synuclein aggregation. 
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Figure 3.5. Degradation of α-Synuclein preformed fibrils by the immunoprotesome. 
(a) Representative immunoblot for the SDS-soluble fraction of α-synuclein fibrils in the absence 
or presence of purified 20S proteasome or immunoproteasome for the indicated amount of time.  
Incubation of pre-formed α-synuclein fibrils with purified 20S proteasome or immunoproteasome 
resulted in a time-dependent decrease of oligomeric and monomeric α-synuclein.  (b) 
Quantification of the ~14kDa α-synuclein band corresponding to monomeric protein in the SDS-
soluble fraction.  (n = 3).  (c) Analysis by mass spectrometry of the α-synuclein peptides 
generated after the degradation of α-synuclein fibrils by the purified immunoproteasome.  The 
relative intensity of the peptides generated within the presumed antigenic regions, residues 31-
46 and residues 116-140 is shown after 3 and 5 days of incubation. (d) Immunoblot analysis of 
α-synuclein and Lmp7 in U-251 cells.  Cell were treated with 0.1 μg/mL INFγ for 24 hours prior to 
exposure to α-synuclein preformed fibrils.  To ascertain the contribution of immunoproteasome 
in the degradation of internalized α-synuclein fibrils cells were treated with the Lmp7 specific 
inhibitor ONX-0914.  (e) Quantification of the normalized intensity α-synuclein in U-251 cells 
after induction of Lmp7 and α-synuclein preformed fibril uptake in the absence or presence of 
the Lmp7 specific inhibitor ONX-0914, (***p<0.001, n=3, t test). 
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3.5 Discussion 
Here, we quantified changes in the proteome and phosphorylation signaling in a 
validated, non-transgenic mouse model of α-synuclein aggregation.  The proteomic approach 
achieved quantification of more than 6,000 proteins and 8,000 phosphoproteins, with typical 
representation of proteins based on size, localization, and biological function consistent with 
similar MS-based proteomic studies using the entire mouse brain (Walther and Mann, 2011) or 
specific regions of mouse brain (Jung et al., 2017) indicating a reasonable coverage and 
representation of the proteome.  The proteomic workflow enabled the quantification of 46 proteins 
that have been linked to Parkinson’s disease or associated with Lewy body formation and 220 of 
226 proteins that were recently linked to α-synuclein (Chung et al., 2017).  Contrary to 
expectations, the changes in the proteome and phosphorylation signaling pathways induced by 
aggregation of α-synuclein before significant dopaminergic neuron death are minimal and for the 
most part proteostasis is preserved.  Despite the absence of widespread remodeling of the 
proteome, the data provided unique insights for the responses to protein aggregation, revealing 
selective changes in protein clusters that participate in dopamine neurotransmission, 
maintenance of neuronal and synaptic architecture and immune responses.  These selective 
changes were absent in PFF-treated Snca-/- mice.   
Ontological analysis of the changes in the proteome and phosphoproteome revealed both 
expected and novel findings.  Notably, and consistent with the anticipated pathology, the data 
revealed selective and significant decrease in the relative abundance of proteins that regulate 
dopamine biosynthesis (TH, Ddc), transport and storage (VMAT-2) and recycling (DAT).  The 
decline in the levels of TH, Ddc, VMAT-2 and DAT was greater than the magnitude of neuron loss 
supporting previous observations that alteration in synaptic proteins and function precedes 
dopaminergic neuron death (Ara et al., 1998; Chung et al., 2009; Garcia-Reitböck et al., 2010; 
Jackson-Lewis et al., 1995).  This observation is further reinforced by the quantification of 
significant changes in proteins that regulate synaptic vesicles and signaling through 
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phosphorylation for proteins participating in the organization synaptic architecture and function.  
These results support previous reports (Chung et al., 2009; Milber et al., 2012; Rockenstein et al., 
2014) including observations in humans (Milber et al., 2012; Scott et al., 2010) that perturbations 
of synaptic protein function and cytoskeletal integrity precede neurodegeneration in α-synuclein 
aggregation disorders.   
Additional pathways impacted by the aggregation of α-synuclein included changes in 
mRNA processing, binding, protein transport and nucleoplasmic function.  These changes are 
consistent with the alterations in nuclear-cytoplasmic protein and RNA transport observed in 
models of mutant huntingtin and TDP-43 neurotoxicity (Woerner et al., 2016).  Significant 
changes in relative abundance were also quantified for 112 proteins that are annotated as 
extracellular and proteins associated with exosomes.  Augmentation of extracellular protein 
release, including exosomes, in response to α-synuclein has been reported (Danzer et al., 2012; 
Emmanouilidou et al., 2010; Minakaki et al., 2018) and may represent neuronal attempt to 
remove potential toxic species of α-synuclein, which can be engulfed and degraded by 
surrounding glia.  Although this hypothesis implies a neuroprotective strategy to accommodate 
proteostasis, it may also propagate α-synuclein toxicity and activate inflammatory and immune 
glia responses.   
The analysis unearthed an increase in the levels of Lmp7, one of the three cardinal 
subunits of the immunoproteasome, which may represent a response to protein aggregation and 
activation of innate immunity, since the immunoproteasome is primarily induced by inflammatory 
stimuli, namely IFNγ (Aki et al., 1994; Heink et al., 2005).  Increased Lmp7 levels in the mouse 
model of α-synuclein aggregation and, critically, in DLB and PD brains has not been previously 
documented.  However, induction of the immunoproteasome is not specific for α-synuclein 
aggregation.  Levels and activity of the immunoproteasome are elevated in postmortem brains of 
patients with Huntington’s and Alzheimer’s disease (Aso et al., 2012; Díaz-Hernández et al., 
2003; Mishto et al., 2006; Orre et al., 2013).  In Huntington’s disease, Lmp2-positive staining was 
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predominantly within neurons and overlapped with approximately 5% of cortical huntingtin protein 
aggregates (Díaz-Hernández et al., 2003).  In the Alzheimer’s disease brains increased labeling 
for the immunoproteasome was associated with reactive glia that surrounded amyloid-β plaques 
(Mishto et al., 2006; Orre et al., 2013).  Taken in conjunction with our findings that Lmp7 staining 
was increased in both neurons and glia in the substantia nigra and co-localized with microglia in 
the ventral tegmental area in cases with PD, these data indicate that neurons and glia attempt to 
counter protein aggregation by inducing the formation of the immunoproteasome. 
The immunoproteasome serves at least two known biological functions.  The major 
function relates to the generation of peptides presented by MHC class I molecules on the cell 
surface for recognition by CD8+ T cells (Driscoll et al., 1993; Gaczynska et al., 1994; Huber et al., 
2012; Kincaid et al., 2011).  The immunoproteasome also removes ubiquitin-tagged oxidatively-
modified misfolded proteins (Ebstein et al., 2013; Nathan et al., 2013; Seifert et al., 2010; Yun et 
al., 2016).  Both of these functions may be critical for protein aggregation diseases and 
particularly for PD, DLB and related disorders characterized by aggregation of α-synuclein.  Our 
data indicates that the immunoproteasome degrades α-synuclein PFFs in vitro and in cells, 
implicating the induction of the immunoproteasome as a potential pathway for elimination of α-
synuclein aggregates.  Moreover, the degradation of α-synuclein PFFs resulted in the generation 
of potentially antigenic peptides that can induce both MHC I and MHC II responses.  
Expression of MHC I in dopaminergic neurons in control (non-disease) and PD 
postmortem tissues has been reported (Cebrián et al., 2014; Lindå et al., 1999).  Moreover, the 
selective expression of MHC I in dopaminergic neurons renders them susceptible to CD8+ T cell 
mediated injury and death (Cebrián et al., 2014).  A recent study has extended these 
observations to show that peptides derived from α-synuclein elicit both MHC I and MHC II 
responses to drive cytokine secretion from CD4+ T cells and CD8+ cytotoxic T cells  in peripheral 
mononuclear cells from patients with PD (Sulzer et al., 2017).  Therefore, the induction of the 
immunoproteasome in PD may relate to the degradation of α-synuclein and the generation of 
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antigenic peptides for T cell presentation.  This function may be viewed as detrimental for 
dopaminergic neurons as activation of T cells elicits cytotoxic effects in neurons.   
However, the immunoproteasome may play an important protective role. Primates and 
mice with longer lifespans have elevated levels of the immunoproteasome (Pickering et al., 
2015). This may derive from the role of the immunoproteasome in degrading oxidatively modified, 
ubiquitin-tagged, aggregated proteins (Ebstein et al., 2013; Nathan et al., 2013; Seifert et al., 
2010; Yun et al., 2016).  The capacity of the immunoproteasome to degrade proteins modified by 
oxidants may also be a vital response to neurodegeneration since an association between 
oxidized proteins and increased immunoproteasome has been reported (Teoh and Davies, 2004).  
Oxidative stress and oxidized proteins have been long considered in the pathological cascade of 
neurodegenerative diseases including PD and related α-synuclein aggregation disorders 
(Giasson et al., 2000; Ischiropoulos and Beckman, 2003; Souza et al., 2000a).  Although several 
forms of autophagy and the lysosomal pathway may participate in clearing α-synuclein and 
related intermediates such as α-synuclein oligomers (Ebrahimi-Fakhari et al., 2011), the 
immunoproteasome may be a viable strategy to influence neuroinflammation as well as clearance 
of potentially toxic α-synuclein species.  Given these findings, the timely and appropriate 
induction of the immunoproteasome by small molecules or other activators may limit the 
progression of pathology in neurodegenerative disorders.  A recent study provided a proof-of-
concept for this suggestion by identifying small molecules known to inhibit the p38 MAP kinase 
arm of MAPK signaling as potent activators of the proteasome (Leestemaker et al., 2017).  
Interestingly, the activation of the proteasome by the p38 MAPK inhibitors was shown to increase 
removal of overexpressed α-synuclein in cells providing a foundation for future studies that target 
the immunoproteasome (Leestemaker et al., 2017). 
Data uncovered a significant induction of Lmp7, one of the three principal subunits of the 
immunoproteasome.  The induction of immunoproteasome has been associated with removal of 
misfolded proteins and preservation of proteostasis.  Increased Lmp7 levels were also 
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documented in postmortem human brain with Parkinson’s disease and increased levels and 
proteolytic activity were documented in postmortem brains with DLB disease, which is 
characterized by α-synuclein aggregation.   
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3.8 Supplemental Figures 
Figure 3.S1. Characterization of mouse α-synuclein fibrils.  Purified mouse recombinant 
wild-type α-synuclein was aggregated by incubating the protein (5 mg/ml) at 37°C under 
constant shaking at 1,400 rpm for 8 days.  Circular Dichroism (CD) spectra of the aggregated 
proteins revealed the presence of is typical of β-sheet rich structures (red).  PFFs generated by 
sonication of the amyloid-like α-synuclein fibrils retain the β-sheet rich structure (green). The 
purified recombinant soluble mouse α-synuclein monomer showed a typical unstructured 
spectrum (blue).  CD measurements were obtained in 10 mM potassium phosphate.   
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Figure 3.S2. Characterization of wild type and Snca-/- mouse models. (a) Representative 
staining for Ser-129 phosphorylated α-synuclein in the substantia nigra of injected and non-
injected wild type and Snca-/- mice.  Insert is higher magnification of neuronal cytoplasmic 
inclusions in the injected side; no staining for Ser-129 phosphorylated α-synuclein was found in 
the non-injected side.  Scale bar = 100 µm.  (b) Ser-129 phosphorylated α-synuclein in the 
striatum of injected and non-injected wild type and Snca-/- mice.  Scale bar = 100 µm.  (c) 
Staining of midbrain tyrosine hydroxylase (TH) positive neurons in the injected and non-injected 
hemispheres of wild type and Snca-/- mice.  Scale bar = 500 µm.  (d) Immunostaining for TH in 
striatum of injected and non-injected hemispheres of wild type and Snca-/- mice. Scale bar = 
100 µm.  (e) Western blot of total α-synuclein in the injected and non-injected hemispheres of 
wild type mice. 
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Figure 3.S3. Characterization of [13C6]-lysine-containing tryptic peptide component of 
SILAM reference proteome.  Log2 [intensity] of individual heavy peptides for each of 4 
biological replicate experiments (Ah, Bh, Ch, and Dh) are shown plotted each against the others 
below the diagonal.  Area proportional Venn diagrams with accompanying peptide counts for 
each comparison are shown above the diagonal.  Along the diagonal are the corresponding 
heavy vs light pairs for each experiment.  As expected, histograms of peptide intensities unique 
to each experiment in the pairwise comparisons (non-overlap regions of Venn diagrams) were 
very heavily weighted toward the lowest quintile of intensities (not shown).  Pearson correlation 
coefficients for each of the heavy:heavy biological replicate pairwise plots and for the heavy:light 
plots are shown along the diagonal.  High correlations and tighter spreads of the corresponding 
heavy:light peptide pairs (average Pearson correlation = 0.96) than the heavy:heavy peptide 
pairs is observed.  This is likely due to the coincident sample processing workflow of the SILAM 
experiment.  In all, approximately 30,000 heavy peptides were quantified across all four 
biological replicates which corresponds closely to the number of heavy:light ratios for peptides 
determined across the same. 
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Figure 3.S4. Number of proteins and phosphopeptides quantified in of Snca-/- mice.  Venn 
diagrams depict the number of proteins (a) and phosphopeptides (b) quantified in the injected 
side (red), non-injected side (blue), and in both sides (green) of the Snca-/- mouse brains (n=3).  
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Figure 3.S5. Volcano Plot of proteins and phosphopeptides quantified in Snca-/- mice.  (a) 
Volcano plot for proteins and (b) for phosphoproteins depicting the proteins (black circles) that 
changed significantly (P <0.05) in relative abundance in the inject side as compared to the 
contralateral non-injected midbrain.  The red dots indicate the proteins with >2-fold increase and 
the blue dots the proteins with >2-fold decrease in relative abundance.   
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Figure 3.S6. Characterization of the Lmp7 antibody.  Western blot image obtained by 
scanning the PVDF membrane on an Odyssey LC scanner.  U-251 cells were treated with 2 μg 
of interferon gamma (INFγ) or PBS for 24 hours and cell homogenates were analyzed on a 12% 
Bis-Tris gel, transferred to PVDF membrane, and probed with anti-proteasome 20S LMP7 
antibody (ab3329).   
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Figure 3.S7. Western blot detection of lmp7 in the mouse brain. Representative western blot 
image for Lmp7 obtained by scanning the PVDF membrane on an Odyssey LC scanner.  Two 
biological replicates of combined midbrain and striatum homogenates from non-injected (N) and 
PFF-injected (I) wild type mice were separated on a 12% Bis-Tris gel, transferred to PVDF 
membrane and probed with anti-proteasome 20S LMP7 antibody (ab3329).  Quantification of 
Lmp7 by densitometry confirmed the mass spectrometry-based increase in the injected side 
compared to the non-injected side.  Lmp7 was not detected in Snca -/- mice by either western 
blot or mass spectrometry-based proteomics. 
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Figure 3.S8. Degradation of Myelin Basic Protein (MBP) by the 20S constitutive 
proteasome and the 20S immunoproteasome.  (a) Representative immunoblot for BMP after 
incubation with purified 20S constitutive proteasome or 20S immunoproteasome.  The 20S 
proteasome does not require ubiquitin tagging or the presence of the 19S regulatory particle for 
protein degradation.  At the indicated time points, aliquots were removed and analyzed by SDS-
PAGE.  (b) Quantification of the monomeric band of MBP indicated that incubation with the 
immunoproteasome results in 96% degradation compared to 70% with the constitutive 
proteasome after 22 hours of incubation; n=3. 
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4.1 Abstract 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic 
neurons and the presence of Lewy bodies, proteinaceous inclusions containing aggregated α-
synuclein. A growing body of evidence suggests α-synuclein aggregation is a key driver of 
neurodegeneration in PD. Several classes of small molecules, many containing phenolic ring 
structures, have shown promise in altering aggregation of α-synuclein. Herein, novel analogs of 
nordihydroguaiaretic acid (NDGA), a phenolic dibenzenediol lignin, were shown to induce 
modest, progressive compaction of monomeric α-synuclein without preventing the dynamic 
adoption of α-helical conformations. The structural alteration of monomeric α-synuclein prevented 
the primary and secondary nucleation-dependent formation of amyloid-like fibrils. The NDGA 
analog-mediated inhibition of fibril formation persisted for 14 days and NDGA analog-pretreated 
α-synuclein did not aggregate even in the absence of molecules in the aggregation mixture. 
Strikingly, NDGA-preatreated α-synuclein suppressed aggregation of naïve untreated monomeric 
α-synuclein. Further, cyclized NDGA reduced α-synuclein-driven neurodegeneration in 
Caenorhabditis elegans. NDGA analogs that stabilize aggregation-resistant α-synuclein 
monomers, without interfering with their ability to adopt functional conformations, might yield 
therapies to prevent or slow neurodegeneration in PD. 
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4.2 Introduction  
Parkinson’s disease (PD) is an age-related neurodegenerative disorder characterized by 
a progressive motor phenotype including tremors, rigidity, and bradykinesia. These symptoms are 
driven primarily by loss of dopamine-producing neurons in the substantia nigra pars compacta. 
Lewy bodies, intracellular proteinaceous inclusions, are the histopathological hallmark of PD. 
Immunohistochemical analysis of Lewy bodies revealed aggregated forms of α-synuclein, a 140 
amino acid neuronally-expressed protein, as a major component (Baba et al., 1998; Spillantini et 
al., 1997). Mutations, duplications, and triplications of the gene encoding α-synuclein cause 
dominantly-inherited familial forms of PD (Chartier-Harlin et al., 2004; Krüger et al., 1998; 
Polymeropoulos et al., 1997; Singleton et al., 2003). The pathological and genetic evidence 
implicating α-synuclein in PD has sparked numerous studies of the normal function of α-synuclein 
and its role in PD pathogenesis. α-Synuclein has been implicated in synaptic function (Abeliovich 
et al., 2000). It preferentially binds lipid membranes with high curvature (Middleton and Rhoades, 
2010) and may modulate neurotransmitter release and synaptic function by affecting vesicular 
fusion (Greten-Harrison et al., 2010; Larsen et al., 2006; Murphy et al., 2000; Nemani et al., 
2010). 
Repeated studies across various animal models have shown that expression of mutant α-
synuclein with altered aggregation kinetics causes neurodegeneration (Giasson et al., 2002; 
Yang et al., 2015). Likewise, induction of α-synuclein aggregation in wildtype animals by seeding 
with α-synuclein aggregates—isolated from PD Lewy bodies (Recasens et al., 2014) or 
generated in vitro (Luk et al., 2012a; Sacino et al., 2014a; Shimozawa et al., 2017)—produces 
progressive neurodegeneration. α-Synuclein aggregation also occurs in animal models of 
dopamine neuron degeneration induced by oxidative chemical insult (Betarbet et al., 2000; Kowall 
et al., 2000). 
82 
 
The implication of α-synuclein in PD pathogenesis stimulated several screens for small 
molecules that alter its aggregation. Dopamine and related catecholamines were among the first 
molecules found to prevent α-synuclein fibril formation (Conway et al., 2001). Oxidation of vicinal 
hydroxyls in dopamine, and related phenols, induces formation of soluble α-synuclein oligomers 
that do not incorporate into fibrils (Mazzulli et al., 2006; Meng et al., 2009; Norris et al., 2005). 
Recently, dopamine-induced α-synuclein oligomers were shown to contribute to 
neurodegeneration in mice (Mor et al., 2017), but the precise mechanism of oligomer toxicity 
remains a subject of debate (Danzer et al., 2007).  
Ongoing research has identified many other inhibitors of α-synuclein aggregation. Many 
of these inhibitors stabilize multimers or oligomers through direct interaction with α-synuclein (e.g. 
various phenols, catechols, and flavonoids (Ehrnhoefer et al., 2008; Fernandes et al., 2017; Di 
Giovanni et al., 2010; Lorenzen et al., 2014; Masuda et al., 2006; Meng et al., 2009, 2010; Ono 
and Yamada, 2006), Anle138b (Deeg et al., 2015; Wagner et al., 2013), rifampicin (Li et al., 
2004)). One well studied member of this groups is epigallocatechin gallate (EGCG), a polyphenol 
sharing the vicinal hydroxyls implicated in dopamine’s interaction with α-synuclein. Despite their 
chemical similarities, dopamine and EGCG have divergent effects on the structure of α-synuclein 
(Konijnenberg et al., 2016). In fact, while dopamine may induce toxic oligomers, adding EGCG 
during cell-free α-synuclein aggregation produces species less toxic to cells (Ehrnhoefer et al., 
2008). Other aggregation inhibitors alter α-synuclein-protein or -lipid interactions to prevent 
aggregation (e.g. NPT100-18A (Wrasidlo et al., 2016), squalamine (Perni et al., 2017), PcTS 
(Fonseca-Ornelas et al., 2014; Lee et al., 2004), Hsp70 (Danzer et al., 2011)). Recent studies 
have examined small molecules that directly stabilize α-synuclein monomers (e.g. BIOD303 
(Moree et al., 2015), nortriptyline (Collier et al., 2017), CLR01 (Acharya et al., 2014; Prabhudesai 
et al., 2012)). However, it remains unknown whether these small molecules perturb α-synuclein’s 
lipid interactions, which are directly implicated in its role in neurotransmitter release (Burré et al., 
2014; Dettmer et al., 2017; Lou et al., 2017). 
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In this study we employed nordihydroguaiaretic acid (NDGA), a phenolic dibenzenediol 
lignan that inhibits α-synuclein aggregation (Caruana et al., 2011; Ono and Yamada, 2006). 
Recent work has exhaustively characterized the products and kinetics of the oxidation of NDGA 
and several novel analogs (Asiamah et al., 2015). We provide evidence that cyclized NDGA, 
formed during oxidation, interacts with α-synuclein to produce modified monomers. We 
demonstrate that these aggregation-resistant monomers retain their capacity to interact with 
phospholipid membranes and that they inhibit aggregation of untreated α-synuclein. Further, we 
demonstrate for the first time that cyclized NDGA reduces α-synuclein-driven neurodegeneration 
in a relevant animal model. Generating α-synuclein species that undergo native structural 
dynamics while exerting a dominant-negative effect of α-synuclein aggregation and neurotoxicity 
represents a new paradigm for intervening in PD and related disorders. 
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4.3 Results 
NDGA inhibits both primary and secondary nucleation-mediated α-synuclein aggregation 
Two established assays, measurement of insoluble protein and Thioflavin-T binding, 
quantified the effect of NDGA on the aggregation of monomeric α-synuclein. NDGA caused 
concentration-dependent inhibition of insoluble α-synuclein accumulation and amyloid-like 
aggregate formation (Fig. 4.1a and b). Maximal inhibition was achieved at stoichiometric, 
equimolar concentrations of NDGA to monomeric α-synuclein. To confirm the Thioflavin-T 
findings, the secondary structure of aggregates was quantified by circular dichroism (CD). NDGA 
caused a dose-dependent decrease in the β-sheet content of the α-synuclein aggregates, as 
indicated by molar ellipticity decreases at 200nm and increases at 220nm (Fig. 4.1c). Finally, 
transmission electron microscopy was used to image the α-synuclein aggregates produced in the 
presence or absence of NDGA. Typical α-synuclein fibrils were observed in the absence of 
NDGA, but not after aggregation with equimolar NDGA (Fig. 4.1d). These data demonstrate that 
stoichiometric concentrations of NDGA inhibit the formation of amyloid-like α-synuclein fibrils. 
The preceding experiments examined the effect of NDGA on a typical α-synuclein 
aggregation assay, in which primary nucleation is the rate-limiting step for the formation of fibrils. 
Aggregation of α-synuclein can also proceed by a secondary nucleation surface-catalyzed 
formation of fibrils. To test the effect of NDGA on secondary nucleation-dependent aggregation, 
α-synuclein fibrils (representing 5% of total α-synuclein) were added with monomeric α-synuclein. 
Equimolar NDGA (molecule to monomeric α-synuclein) inhibited the formation of insoluble α-
synuclein aggregates in the presence of fibril seeds (Fig. 4.1e). Together, these findings 
demonstrate that stoichiometric NDGA prevents both primary and secondary nucleation 
dependent aggregation of α-synuclein. 
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Figure 4.1: NDGA inhibits recombinant human α-synuclein aggregation. (a) Insoluble α-
synuclein present after 7 days aggregation was reduced by NDGA and EGCG in a dose-
dependent fashion as compared to solvent control. Recombinant human wildtype α-synuclein 
(138 µM) was aggregated for 7 days in the presence of EGCG or NDGA at the indicated molar 
ratios. After aggregation, PBS-insoluble α-synuclein was separated by centrifugation (21k g for 
10 min). Soluble and insoluble fractions were boiled in SDS, run by SDS-PAGE, and colloidal 
stained. α-Synuclein in each fraction was quantified by in-gel densitometry. (n = 3-5). (b) 
Formation of amyloid α-synuclein fibrils quantified by ThioT was reduced by NDGA and EGCG 
in a dose-dependent fashion as compared to control after 7 days aggregation. (n = 3-5). (c) α-
Synuclein beta-sheet secondary structure was reduced by EGCG and NDGA in a dose 
dependent fashion. Recombinant human wildtype α-synuclein (138 µM) was aggregated for 7 
days in the presence of EGCG or NDGA at the indicated molar ratios. Secondary structure was 
quantified by circular dichroism. (d) Transmission electron microscopy images of α-synuclein 
aggregates after 3 days aggregation with small molecules at 1:1 molar ratio. (e) Insoluble α-
synuclein present after 7 days aggregation in the presence of a 5% fibril seed was reduced by 
EGCG and NDGA. EGCG or NDGA were present at a 1:1 molar ratio. After aggregation, PBS-
insoluble α-synuclein was separated by centrifugation (21k g for 10 min). Soluble and insoluble 
fractions were boiled in SDS, run by SDS-PAGE, and colloidal stained. α-Synuclein in each 
fraction was quantified by in-gel densitometry. (n = 3). 
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Interaction with α-synuclein requires oxidation and cyclization of NDGA 
We used N-acetylcysteine (NAC), an electron donor, to inhibit NDGA oxidation in the 
presence of α-synuclein. NAC was included in a typical α-synuclein aggregation mixture at 20:1 
molar excess to NDGA. After aggregation for 3 days, levels of α-synuclein aggregation were 
measured by the established solubility assay. mNDGA, a NDGA analog incapable of oxidation 
and cyclization was included as a negative control (Supplemental Fig. 4.S1). The addition of NAC 
allowed α-synuclein to aggregate in the presence of NDGA, suggesting that oxidation is 
necessary (Fig. 4.2a and b). The inclusion of NAC also reduced levels of quinone-containing 
NDGA oxidation products detected by near-infrared fluorescence (nIRF), a technique developed 
to study the oxidation-dependent interaction between α-synuclein and dopamine (Mazzulli et al., 
2016) (Fig. 4.2c). The correlation of increased aggregation and decreased quinone nIRF 
suggests a relationship between NDGA oxidation and inhibition of α-synuclein aggregation. 
Separately, catalase, which rapidly converts H2O2 to water and hydrogen gas, was included in the 
aggregation assay to determine whether H2O2 that might be produced during NDGA oxidation 
mediated the effects on aggregation. Inclusion of catalase had no effect on α-synuclein 
aggregation in the presence of NDGA nor on quinone nIRF, indicating that the effect is not H2O2-
dependent (Fig. 4.2a, Supplemental Fig. 4.S2). These data indicate that NDGA interaction with α-
synuclein is oxidation-dependent but not mediated by peroxide chemistry. 
Previous work has identified the majority product of NDGA oxidation as a cyclized form 
(Asiamah et al., 2015). During that study, novel NDGA analogs with defined oxidation pathways 
were generated. Here, these analogs were used to examine of the role of cyclization in NDGA’s 
oxidation-dependent inhibition of α-synuclein aggregation. We employed NDGA and two such 
analogs: NDGA-1, which oxidizes with comparable kinetics but does not cyclize due to unilateral 
hydroxyl substitution, and NDGA-5, which cyclizes more readily than NDGA due to reduced steric 
hindrance in the crosslinking region (Supplemental Fig. 4.S1). α-Synuclein was aggregated for 3 
days in the presence of equimolar NDGA analogs, and aggregation was quantified by the 
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solubility assay. Both cyclizing analogs, NDGA and NDGA-5, inhibited α-synuclein aggregation, 
while non-cyclizing NDGA-1 did not (Fig. 4.2d). The products of the above experiment where also 
analyzed by nIRF. NDGA and NDGA-5-treated α-synuclein exhibited quinone nIRF signals, while 
NDGA-1-treated α-synuclein did not (Supplemental Fig. 4.S3). These results indicate that 
cyclized forms of NDGA, or the process of cyclization, are required for interaction with α-
synuclein and inhibition of aggregation. To address this uncertainty, α-synuclein was aggregated 
in the presence of cNDGA and cNDGA-5, the purified cyclized forms of NDGA and NDGA-5, 
respectively (Supplemental Fig. 4.S1). Using the solubility assay, both cNDGA and cNDGA-5 
inhibited α-synuclein aggregation as potently as NDGA (Fig. 4.2e, Supplemental Fig. 4.S4). This 
indicates that NDGA’s inhibition of α-synuclein aggregation is mediated by cyclized oxidation 
products.  
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Figure 4.2: Interaction between NDGA and α-synuclein requires NDGA oxidation and 
cyclization. (a) NDGA treatment did not affect α-synuclein aggregation in the presence of N-
acetylcysteine. α-Synuclein was aggregated for 3 days in the presence of 1:1 small molecules. 
After aggregation, PBS-insoluble α-synuclein was separated by centrifugation (21k g for 10 min). 
Soluble and insoluble fractions were boiled in SDS, run by SDS-PAGE, and colloidal stained. α-
Synuclein in each fraction was quantified by in-gel densitometry. NAC was added at 20x molar 
excess to small molecule and catalase was added equal to 5% of protein, providing excess 
hydrogen peroxide decomposition capacity. (b) Colloidal staining of representative gels showed 
the formation of insoluble α-synuclein aggregates in the presence of NDGA and NAC. (c) Near-
infrared fluorescent imaging of the same gels before colloidal staining showed a reduction of 
quinone-dependent fluorescence in the presence of NAC. (d) α-Synuclein did not aggregate in 
the presence of cyclizable analogs, NDGA and NDGA-5, but did with non-cyclizable NDGA-1. (n 
= 3). (e) α-synuclein did not aggregate in the presence of cyclized cNDGA and cNDGA-5. (n = 
3). α-Synuclein was aggregated for 3 days in the presence of 1:1 small molecules. After 
aggregation, PBS-insoluble α-synuclein was separated by centrifugation (21k g for 10 min). 
Soluble and insoluble fractions were boiled in SDS, run by SDS-PAGE, and colloidal stained. α-
Synuclein in each fraction was quantified by in-gel densitometry. 
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NDGA induces modest, progressive α-synuclein compaction without preventing dynamic 
adoption of α-helical conformation 
During analysis of the interaction between NDGA and α-synuclein, equimolar incubation 
consistently produced nIRF-positive quinone-modified α-synuclein (Supplemental Fig. 4.S5). 
Based on this observation, NDGA-treated α-synuclein was further analyzed to determine any 
structural effects of the interaction. Native nano-ESI mass spectra (ESI-MS), collected following 
10 minute incubations of the protein-ligand mixtures, detected α-synuclein-NDGA complexes with 
masses matching the theoretical values of the unmodified protein and ligand (Natalello et al., 
2017). Masses indicative of α-synuclein modifications such as oxidation or nitrosylation were not 
detected. Complexes were observed with higher relative intensities at low protein charge states, 
suggesting a preferential binding to the more compact α-synuclein conformations as previously 
observed with EGCG. However, levels of α-synuclein binding were much lower for NDGA than 
previously observed with EGCG (Konijnenberg et al., 2016) (Supplemental Fig. 4.S6).  
Ion-mobility mass spectrometry (IM-MS) allows for highly sensitive detection of changes 
in ion compactness, mass, and charge. Of note, this allows ions of identical mass and charge to 
be distinguished by compactness. This attribute of IM-MS has previously been employed to show 
the differential effects of EGCG and dopamine on α-synuclein compaction (Konijnenberg et al., 
2016). IM-MS revealed that incubation with NDGA, but not mNDGA, resulted in α-synuclein 
assuming slightly more compact conformations (Fig. 4.3a). This compaction was more 
pronounced in lower charge states (+5 through +7) in which distinct populations of conformers 
with differing compaction can be observed. These data indirectly indicate complex formation with 
conformational memory, although the complexes are likely lost under these experimental 
conditions. The previous IM-MS study of EGCG-treated α-synuclein found increased pool of 
compact conformations, as well as mass-shifts consistent with EGCG binding (Konijnenberg et 
al., 2016). As with ESI-MS, IM-MS did not detect substantial amounts of α-synuclein with mass-
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shifts indicative of covalent adduction by NDGA. Mass spectrometry indicates that NDGA causes 
subtle structural remodeling of α-synuclein, without forming covalent adducts. 
NMR allowed for localization of NDGA’s structural effects within the sequence of α-
synuclein. After 24 hours incubation with 1:1 NDGA small variations in peak positions were 
observed in the N-terminus – Val 3, Met 4, Phe 5 – as well as His 50 (Fig. 4.3b). cNGDA and 
NDGA-1-treatment caused similar changes in the spectra. Incubation with 3:1 NDGA resulted in 
more pronounced shifts in the same set of peaks.  
These samples were followed for several days through NMR revealing a progressive 
variation of the peak shifts. After several days, additional changes occurred in the signals of 
several peaks. These peaks showed a second set of signals, indicative of a subset of the α-
synuclein population with altered conformation at these residues (Supplemental Fig. 4.S7). 
Förster resonance energy transfer (FRET) analysis of α-synuclein provided further insight 
into the regions altered by NDGA treatment. This examination employed several synthetic α-
synuclein proteins with varying fluorescent label pairs spread throughout the amino acid 
sequence. Based on this methodology, FRET signal from an individual label pair can be 
converted to an intramolecular distance within α-synuclein and, when taken together, the multiple 
label pairs provided eight partially overlapped measurements covering the amino acid sequence 
from residue 9 to 136 (Ferrie et al., 2018). FRET revealed progressive changes in α-synuclein 
conformation when treated with EGCG, while NDGA, cNDGA, and mNDGA did not induce 
changes, even after 24 hours (Fig. 4.3c and d). As with IM-MS and NMR, NDGA-treatment was 
found to induce minimal changes in α-synuclein conformation, while EGCG showed more marked 
effects.  
NDGA-treated α-synuclein secondary structure was examined using circular dichroism 
(CD). CD failed to detect any changes in the secondary structure of pretreated, dialyzed α-
synuclein, further confirming the IM-MS and NMR analyses (Fig. 4.3e). Despite observing limited 
effects of NDGA on α-synuclein structure in aqueous solution, we also examined whether NDGA-
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treatment alters the capacity of α-synuclein to interact with hydrophobic membranes. Membrane 
interaction induces the N-terminus of α-synuclein to assume an α-helical secondary structure 
(Davidson et al., 1998; George et al., 1995; Ulmer and Bax, 2005). Capacity for membrane 
interaction is necessary for α-synuclein’s putative biological functions in the synapse (Abeliovich 
et al., 2000; Murphy et al., 2000; Nemani et al., 2010). Neither NDGA nor mNDGA treatment 
prevented α-synuclein from assuming α-helical conformations in the presence of SDS, just as 
occurred under control conditions (Fig. 4.3f). This indicates that the structural changes induced by 
NDGA do not restrict α-synuclein’s dynamic flexibility.  
The ability of NDGA-treated α-synuclein to interact with membranes was further 
examined by fluorescence correlation spectroscopy (FCS), which has been used extensively to 
study the interaction of α-synuclein with lipid vesicles (Middleton and Rhoades, 2010; Rhoades et 
al., 2006). The binding of fluorescently labelled recombinant human α-synuclein to various 
concentrations of phospholipid vesicles (1:1, POPS:POPC) was compared following α-synuclein 
incubation for 24 hours with equimolar NDGA analogs or solvent alone. NDGA, cNDGA, and 
mNDGA did not alter phospholipid affinity as indicated by similar protein binding affinity at each 
vesicle concentration, regardless of treatment condition (Fig. 4.3g). FCS was also used to 
determine whether the addition of NDGA would displace α-synuclein already bound to 
phospholipid vesicles. The fraction of α-synuclein bound to vesicles was not altered by the 
addition of NDGA as compared to the addition of solvent alone (Fig. 4.3h). These data further 
indicate that NDGA treatment does not perturb α-synuclein interaction with hydrophobic 
membranes. Collectively, these results show that NDGA causes α-synuclein compaction across 
the sequence, without altering secondary structure or preventing structural remodeling involved in 
physiological function. 
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Figure 4.3: NDGA induces compaction of α-synuclein without preventing structural 
remodeling. (a) NDGA treatment induced compaction of monomeric α-synuclein relative to 
mNDGA treatment. Ion-mobility mass spectrometry detected increased abundance of α-
synuclein species with lower collisional cross section after α-synuclein was incubated with 
NDGA at 5:1 excess for 10 minutes. (b) NDGA treatment of α-synuclein did not induce extensive 
shifts in 2D NMR spectra. α-Synuclein was incubated 1:1 with NDGA for 24 hours before spectra 
were collected. NDGA-treated α-synuclein spectra (blue) was overlaid on solvent-treated α-
synuclein (red). FRET measurement of (c) 0 hour and (d) 24 hour small molecule treatments 
showed progressive alteration of α-synuclein intramolecular distances by EGCG, but not NDGA, 
cNDGA, or mNDGA. The dashed line depicts 1 µM α-synuclein treated with buffer (1x PBS). 
Treatments were 5 µM NDGA (green square), EGCG (red triangle), cNDGA (purple inverted 
triangle), and mNDGA (blue diamond). (n = 3). (e) α-Synuclein secondary structure was not 
altered by pretreatment with NDGA. (f) NDGA pretreatment did not prevent α-synuclein 
assuming α-helical secondary structure in the presence of SDS micelles. α-Synuclein was 
incubated 1:1 with NDGA, mNDGA, or solvent alone for 24 hours and then dialyzed against PBS 
for 24 hours. 40 mM SDS micelles were added 5 minutes before analysis. Secondary structure 
was quantified by circular dichroism. (g) NDGA treatment did not alter α-synuclein phospholipid 
binding. α-Synuclein was incubated 1:1 with NDGA analogs or solvent alone for 24 hours before 
fluorescence correlation spectroscopy in the presence of POPS:POPC vesicles at the indicated 
concentrations. (n = 3). (h) Addition of NDGA did not displace fluorescently labeled α-synuclein 
from POPS:POPC vesicles. (n = 3).  
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NGDA pretreated α-synuclein stably resists seeded aggregation 
Based on the progressive remodeling of α-synuclein treated with NDGA, we analyzed the 
capacity of NDGA-pretreated α-synuclein to aggregate into fibrils. α-Synuclein was incubated with 
equimolar NDGA (as well as mNDGA and EGCG controls) for 24 hours before dialysis against 
excess PBS for 24 hours. This pretreated, dialyzed α-synuclein was then aggregated for 3 days 
before undergoing the solubility assay (as depicted in Supplemental Fig. 4.S8). NDGA, but not 
mNDGA, pretreatment prevented α-synuclein aggregation (Fig. 4.4a). Further, pretreated, 
dialyzed α-synuclein was aggregated for 14 days to test the duration of the effect. Again, NDGA 
but not mNDGA pretreatment prevented α-synuclein aggregation (Supplemental Fig. 4.S9). 
Consistent with previous data, we found that pretreatment with cyclizing (NDGA and NDGA-5) 
and cyclized (cNDGA and cNDGA-5) analogs prevented α-synuclein aggregation, while non-
cyclizing analogs (NDGA-1 and SECO-1) did not (Supplemental Fig. 4.S10 and 4.S11). We also 
examined the soluble species that remained following aggregation of pretreated, dialyzed α-
synuclein using native state SEC and found that monomeric species are the majority product 
(Supplemental Fig. 4.S12). Collectively, these findings demonstrate the NDGA pretreatment 
renders α-synuclein monomers resistant to aggregation. This effect was not observed with non-
oxidizable and non-cyclizing analogs of NDGA.  
Native-state SEC fractionation found that pretreatment with either NDGA or EGCG 
produces both monomeric and oligomeric α-synuclein species (Supplemental Fig. 4.S5). We 
compared the aggregation of these two pools of α-synuclein species. α-Synuclein was incubated 
with equimolar small molecules for 24 hours before oligomeric (≥51Å) and monomeric (<51Å) 
species were separated using native state SEC. The resulting fractions were then aggregated for 
3 days before analysis by the solubility assay. Both monomers and oligomers produced upon 
NDGA and EGCG pretreatment resisted aggregation, while the majority of mNDGA treatment 
products formed insoluble aggregates (Fig. 4.4b). This indicates that while aggregation-resistant 
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α-synuclein oligomers do form after NDGA treatment, resulting monomers are also aggregation-
resistant, even in the absence of oligomers.  
Next, we explored whether NDGA can prevent surface-catalyzed, secondary nucleation-
dependent, aggregation of α-synuclein. Pretreated, dialyzed α-synuclein was aggregated for 3 
days in the presence of α-synuclein fibril seeds (equal to 5% of total α-synuclein in solution) 
before aggregation was quantified by the solubility assay. Again, NDGA but not mNDGA 
pretreatment reduced α-synuclein aggregation (Fig. 4.4c). This demonstrates that NDGA-
pretreated, dialyzed α-synuclein does not readily undergo secondary nucleation to form species 
capable of incorporating into existing fibrils.  
Based on the observation that NDGA treatment prevents α-synuclein aggregation, we 
conducted a novel analysis to determine whether aggregation of untreated α-synuclein is altered 
by the presence of NDGA-pretreated α-synuclein. Pretreated, dialyzed α-synuclein was 
generated as before, then mixed with untreated α-synuclein at varying ratios and the resulting 
mixtures were aggregated for 3 days before undergoing the solubility assay (as depicted in 
Supplemental Fig. 4.S12). The addition of pretreated, dialyzed α-synuclein caused a super-
stoichiometric reduction in insoluble α-synuclein, demonstrating that aggregation of untreated α-
synuclein was reduced (Fig. 4.4d). This effect is demonstrated in the 20% condition wherein 
NDGA pretreated, dialyzed α-synuclein represents only 20% of total α-synuclein, but insoluble α-
synuclein is reduced from 88% in control conditions to 37%. These data, taken in totality, indicate 
that pretreatment with NDGA produces α-synuclein monomers that are not only resistant to 
aggregation, but reduce aggregation of α-synuclein never exposed to NDGA.  
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Figure 4.4: NDGA pretreatment prevents α-synuclein aggregation. (a) α-Synuclein did not 
aggregate after pretreatment with NDGA. α-Synuclein was incubated 1:1 with small molecules 
for 24 hours then dialyzed against PBS for 24 hours. After aggregation for 3 days, PBS-insoluble 
α-synuclein was separated by centrifugation (21k g for 10 min). Soluble and insoluble fractions 
were boiled in SDS, run by SDS-PAGE, and colloidal stained. α-Synuclein in each fraction was 
quantified by in-gel densitometry. (n = 3). (b) Both oligomeric and monomeric α-synuclein 
species induced by NDGA treatment resist aggregation. α-Synuclein was incubated 1:1 with 
small molecules for 24 hours then subjected to native state size exclusion chromatography. 
Oligomeric (≥51Å) and Monomeric (<51Å) α-synuclein fractions were collected and aggregated 
separately for 3 days. Soluble and insoluble species were separated and quantified as above. (n 
= 3). (c) NDGA-treated α-synuclein resisted fibrillization in the presence of 5% fibril seed. α-
Synuclein was incubated 1:1 with small molecules for 24 hours then dialyzed against excess 
PBS for 24 hours. Untreated α-synuclein fibrils equal to 5% total protein was added immediately 
before mixtures were aggregated for 3 days. Soluble and insoluble species were separated and 
quantified as above. (n = 3). (d) NDGA pretreated, dialyzed α-synuclein inhibited aggregation of 
untreated α-synuclein. α-Synuclein was incubated 1:1 with small molecules for 24 hours then 
dialyzed against excess PBS for 24 hours. Pretreated, dialyzed α-synuclein was then mixed with 
untreated monomeric α-synuclein at the indicated ratios. Mixtures were aggregated for 3 days. 
Soluble and insoluble species were separated and quantified as above. (n = 3).  
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cNDGA reduces α-synuclein-driven dopamine neurodegeneration in animals 
We examined the effect of NDGA and cNDGA treatment on α-synuclein-driven 
neurodegeneration. We employed a widely used C. elegans model in which expression of human 
wildtype α-synuclein in dopaminergic neurons leads to progressive neurodegeneration. Animals 
were treated with varying doses of NDGA or cNDGA from hatching until the day before scoring on 
either day 6 or day 8. NDGA did not have a statistically significant effect on the number of 
animals undergoing neurodegeneration. However, cNGDA caused a significant reduction in the 
number of animals with degenerating dopamine neurons across all doses at day 8 (Fig. 4.5a). 
Representative images of animals scored during this experiment show the loss of fluorescent 
dopamine neuron processes and bodies in solvent and NDGA-treated animals (Fig. 4.5b). This 
demonstrates, for the first time, that cNDGA can reduce neurodegeneration caused by α-
synuclein. 
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Figure 4.5: cNDGA reduces α-synuclein-driven neurodegeneration. (a) cNDGA, but not 
NDGA reduces dopaminergic neurodegeneration in C. elegans expressing wildtype α-synuclein. 
Animals were exposed to each concentration of the drugs on days 0-3, 5, and 7 post-hatching. 
Animals were scored on days 6 and 8 post-hatching for dopaminergic neurodegeneration. The 
data are represented as mean ± SEM; one-way ANOVA with Tukey’s post hoc test for multiple 
comparisons. (n = 3; 30 animals per replicate; * p < 0.05; ns, not significant). (b) Representative 
images from day 8 post-hatching. Arrowheads indicate intact neurons while arrows indicate 
degenerating or missing neurons. Scale bar represents 10 µm.  
 
100 
 
4.4 Discussion 
α-Synuclein aggregation remains a promising target for therapeutic development. Using 
NDGA and novel analogs, we uncovered that NDGA oxidation and cyclization was required for 
interaction with monomeric α-synuclein. This interaction caused slight compaction throughout the 
α-synuclein sequence and prevented α-synuclein aggregation into fibrils. Indeed, NDGA-treated 
monomers not only resisted aggregation, but prevented aggregation of naïve untreated α-
synuclein. Treatment with cNDGA reduced neurodegeneration in an animal model of α-synuclein 
neurotoxicity. Taken together, these findings suggest that NDGA and related molecules that 
prevent α-synuclein aggregation without perturbing native structure and associations may be 
promising targets for PD and related disorders characterized by α-synuclein aggregation.  
Attempts to develop therapeutic strategies targeting α-synuclein have included 
decreasing levels by altering expression (Zharikov et al., 2015b) and clearance (Dehay et al., 
2010; Lee, 2004), immunological targeting (Masliah et al., 2005, 2011), and altering aggregation. 
Many aggregation inhibitors were identified through chemical library screens before being 
subjected to mechanistic analysis (Conway et al., 2001; Masuda et al., 2006; Ono and Yamada, 
2006). The neurotransmitter dopamine, and molecules that share structural and chemical 
similarities, were the first inhibitors identified and are among the most potent inhibitors of α-
synuclein aggregation (Conway et al., 2001).  
Identification of dopamine and related phenols as inhibitors of α-synuclein aggregation 
has led to many studies of phenolic compounds as potentially neuroprotective inhibitors. The 
most studied of these is EGCG, which is currently undergoing clinical trials in multiple system 
atrophy, a synucleinopathy characterized by microglial inclusions (Levin et al., 2016). EGCG was 
found to be neuroprotective in animals treated with MPTP, which induces α-synuclein-dependent 
dopaminergic neurodegeneration (Chen et al., 2015; Reznichenko et al., 2010). Adding EGCG 
during in vitro α-synuclein aggregation results in less toxic products (Ehrnhoefer et al., 2008). 
Given the structural differences between EGCG and NDGA, as well as the existing knowledge 
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about NDGA oxidation and the availability of analogs, we hope that studying NDGA as an α-
synuclein aggregation inhibitor will provide new insight into the neuroprotective potential of 
inhibiting α-synuclein aggregation.  
Our analysis revealed some substantial departures between the effects of NDGA and 
EGCG on α-synuclein. Konijnenberg et al. found, using IM-MS, that EGCG induces α-synuclein 
compaction (Konijnenberg et al., 2016), while analysis conducted by the same group for this 
study showed that NDGA and cNDGA cause a more subtle effect (Fig. 4.3a). Likewise, FRET 
found that EGCG causes substantial α-synuclein remodeling, while NDGA and cNDGA have no 
measurable effect on intramolecular distances (Fig. 4.3b). We also observed consistent 
differences in the patterns of SDS-stable multimers present after α-synuclein was treated with 
EGCG and NDGA (Fig. 4.2b and Supplemental Fig. 4.S2, 4.S5, and 4.S12). This trend of subtle, 
but measurable, differences between the effect of the two molecules leaves open the possibility 
of different mechanisms of interaction with α-synuclein and differing biophysical properties of the 
resulting species.  
Previous studies of EGCG have focused on the oligomers formed when α-synuclein is 
aggregated in the presence of EGCG (Bieschke et al., 2010; Ehrnhoefer et al., 2008; Yang et al., 
2017). In this study, we found that α-synuclein aggregation in the presence of EGCG and NDGA 
does produce oligomers, but that monomers are the predominant product, representing more 
than 75% of soluble protein (Supplemental Fig. 4.S12). Further, we found that α-synuclein 
monomers and oligomers induced by pretreatment with EGCG and NDGA both resisted 
aggregation (Fig. 4.4b). This aggregation was conducted after separation by size-exclusion 
chromatography, which removed from solution any EGCG or NDGA not interacting with α-
synuclein, suggesting a stable interaction or modification of α-synuclein itself. Most strikingly, 
pretreated species inhibited aggregation of untreated α-synuclein, suggesting a dominant-
negative effect on aggregation. This effect, not previously described for EGCG or any other 
exogenous phenolic inhibitors, may contribute to their neuroprotective effects. The combination of 
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a durable modification of α-synuclein and a dominant negative effect on aggregation are very 
desirable given concerns over polyphenol bioavailability in the brain (Pogačnik et al., 2016) and 
the hepatotoxic side effects seen with EGCG (Lambert et al., 2010; Levin et al., 2016). 
Lipid-bound α-synuclein is resistant to aggregation (Zhu and Fink, 2003), and appropriate 
membrane interactions are implicated in its physiological function (Burré et al., 2014; Dettmer et 
al., 2017). As such, an ideal therapeutic targeting α-synuclein aggregation would allow normal 
lipid interaction. Interestingly, both CD and FCS showed that the membrane interactions of α-
synuclein were not perturbed by NDGA-treatment (Fig. 4.3f, g, and h). Preservation of α-
synuclein membrane interaction may help explain the divergent effects of NDGA and dopamine 
on neuron viability. Indeed, α-synuclein oligomers induce membrane destabilization and 
dopamine-induced oligomers may contribute to neurodegeneration in synucleinopathies (Danzer 
et al., 2007; Mor et al., 2017). Future studies aimed at identifying neuroprotective α-synuclein 
aggregation inhibitors would be well served by incorporating methods to determine whether 
membrane interactions are maintained, as is the case with NDGA.  
NDGA pretreatment induced an NMR peak shift at His 50 (Fig. 4.3b). His 50 falls within 
the second α-helical region during α-synuclein interaction with curved lipid membranes, falling in 
sequence just after the fourth lysine-rich repeat (George et al., 1995; Ulmer and Bax, 2005). His 
50 also mediates oligomer-stabilizing interaction between α-synuclein and divalent metal ions, 
particularly Cu(II) (Binolfi et al., 2006; Rasia et al., 2005). Additionally, His 50 to Gln mutation 
causes autosomal dominant familial PD and accelerates α-synuclein aggregation in vitro (Appel-
Cresswell et al., 2013; Ghosh et al., 2013; Proukakis et al., 2013). This suggests that interaction 
with His 50 could alter α-synuclein aggregation kinetics. Further investigation of the interaction 
between NDGA and His 50 might provide insight into NDGA’s inhibition of α-synuclein 
aggregation.  
The chemistry underpinning dopamine and related small molecule modulators of α-
synuclein aggregation includes the capacity for auto-oxidation and the presence of vicinal 
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hydroxyl (catechol) moieties (Meng et al., 2009; Norris et al., 2005). In this study, we have 
expanded the previous observations and documented many new mechanistic insights for the 
biochemistry of catechol structures to inhibit the aggregation of α-synuclein. We found that 
NDGA-analogs require two pairs of vicinal hydroxyls to interact with α-synuclein. NDGA-1, which 
contains only one pair of vicinal hydroxyl groups, did not modify α-synuclein or inhibit 
aggregation. This indicates that NDGA cyclization, which is enabled by its two pairs of vicinal 
hydroxyls, is required for inhibition of α-synuclein aggregation (Asiamah et al., 2015). Indeed, 
cNDGA and cNDGA-5, two cyclized analogs of NDGA, were found to inhibit α-synuclein 
aggregation. The finding that NDGA’s cyclized oxidation products are responsible for its effects 
on α-synuclein aggregation presents the dual opportunities to study NDGA as a prodrug, 
converted by oxidation-dependent cyclization to active cNDGA, and to examine novel molecules 
based on the cNDGA structure in hopes of identifying inhibitors of α-synuclein aggregation. 
The importance of NDGA cyclization is reinforced by the finding that cNDGA, but not 
NDGA, treatment reduces neurodegeneration caused by expression of human α-synuclein in 
dopamine neurons in C. elegans (Fig. 4.5). There are many potential explanations for the 
divergent effects of the two molecules, including differences in stability, uptake, metabolism, and 
excretion. One possibility is that NDGA does not form cNDGA under these conditions. Oxidation 
of NDGA likely occurs less frequently in the reducing environment of the cell (Back et al., 2012), 
and yield of cNDGA may be lower than previously observed. While the cyclization of NDGA has 
been precisely described under controlled conditions in buffer (Asiamah et al., 2015), it has never 
been examined in a complex milieu or within a living cell, where other chemistry may occur.  
Collectively, these findings change our understanding of the mechanisms of phenolic α-
synuclein aggregation inhibitors. We demonstrate, for the first time, that NDGA’s interaction with 
α-synuclein requires oxidation-dependent cyclization, reframing NDGA as a prodrug. Additionally, 
we show that both NDGA and EGCG stably modify α-synuclein monomers, rendering them 
aggregation incompetent. In the case of NDGA, this is achieved without altering the structure of 
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α-synuclein in solution, nor perturbing membrane interactions. This combination of attributes has 
not been previously observed in other inhibitors of α-synuclein aggregation. Further examination 
is certainly warranted to determine whether NDGA analogs might provide the basis for novel 
neuroprotective therapies for PD and related synucleinopathies.  
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4.5 Methods 
In vitro α-synuclein aggregation analyses 
Recombinant human wildtype α-synuclein was expressed and purified from E. coli as previously 
described (Winner et al., 2011). Purified α-synuclein was used at at 2 mg/ml (138 µM) with or 
without small molecules at various molar ratios in PBS with 1% DMSO. Mixtures were aggregated 
for 3 or 7 days at 37°C shaking at 1400 rpm. Alternatively, purified α-synuclein was incubated for 
24 hours with or with equimolar small molecules in PBS with 1% DMSO. Resulting mixtures were 
then dialyzed against excess PBS for 24 hours at 4°C (using mini-dialysis tubes, Thermo Fisher 
69572). Mixtures were aggregated for 3 or 14 days shaking at 1400 rpm. 
α-Synuclein solubility analysis and densitometric quantification 
Sedimentation was performed by centrifugation at 21,000 g for 15 minutes. Supernatants were 
removed, and pellets were resuspended in an equal volume. Pellets and supernatants were 
boiled in SDS sample buffer for 3 minutes at 95°C. α-Synuclein species were resolved by SDS-
PAGE in 12% Bis/Tris gels and stained in-gel with colloidal blue (Invitrogen LC6025). Stained 
gels were imaged at 700 nm using LI-COR Odyssey Infrared Imaging System and densitometric 
quantification was conducted using LI-COR Odyssey software suite 3.0.  
Near infrared fluorescence 
SDS-PAGE gels were imaged as previously described (Mazzulli et al., 2016). Briefly, gels were 
imaged immediately after electrophoresis at 700 nm with intensity 10 on LI-COR Odyssey 
Infrared Imaging System. 
Size-exclusion chromatography 
For size exclusion chromatography 200µL recombinant α-synuclein (2mg/ml) was injected onto a 
Superdex 200 10/300 GL (GE Healthcare) connected to an Agilent 1100 series HPLC system and 
fraction collector controlled by ChemStation software version 1.04 (Agilent). Mobile phase 
consisted of 25mM HEPES and 150 mM NaCl, pH 7.25 with a 0.3 ml/min flow rate. Fractions 
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corresponding to 140-100, 100-85, 85-75, 75-68, 68-61.5, 61.5-56, 56-51, 51-47, 47-43, 43-39, 
39, 39-36, 36-32, 32-29, 29-26 Å were combined and concentrated using 3kDa NMWL ultracel 
microcon filters (Millipore UFC5003). SEC column elution time was calibrated to Å size using 
globular protein standards (GE Healthcare). 
Circular dichroism 
Circular dichroism spectra were obtained on a Jasco-810 spectropolarimeter maintained in the 
Children's Hospital of Philadelphia Protein Core facility. Protein in PBS was diluted to 20 μM in 
0.05 M KH2PO4 pH 7.8. Spectra were corrected for baseline measurement of an equivalent 
volume of PBS diluted in KH2PO4 buffer. Spectra were collected with a scanning width of 1 nm, at 
5 nm/min with 2 accumulations per run.  
Transmission electron microscopy 
Transmission electron microscopy was conducted on a JEOL1010 maintained in the University of 
Pennsylvania Electron Microscopy Resource Laboratory. Protein solutions were diluted to 0.5 
mg/ml (34.5 µM) before mounting to carbon-coated 300 grids and negative staining with 2% 
uranium acetate. Images were collected with at HV = 80.0 kV, Magnification 50,000x. Contrast 
was automatically adjusted during capture for each image, and not altered after capture. 1 µm 
scale bars were included for each image presented. 
Nuclear magnetic resonance spectroscopy  
To provide atomic resolution information on α-synuclein, 2D 1H-15N NMR spectra were acquired 
through a series of BEST-TROSY HSQC (Favier and Brutscher, 2011), a fast and common 
experiment used to evaluate if there is an effect of the different molecules on some amino acids, 
each of them represented by a HN-N correlation (a cross-peak in the 2D spectrum). 
All the NMR experiments were recorded on a Bruker Avance III spectrometer operating at 900 
MHz 1H frequency (21.14 T) equipped with a cryogenically cooled probehead for triple resonance 
experiments (TCI). The pulses involved in this pulse sequence were the standard ones used to 
investigate bio-molecules(Brutscher et al., 2015). The 15N hard pulses were applied at the center 
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of the region (117.02 ppm) and the 1H band selective pulses were applied at the center of the 
amide proton region at 8.70 ppm. A spectral width of 10822.511 Hz in the direct 1H dimension 
and 3647.991 Hz in the indirect 15N dimension was used. All the spectra were recorded with 8 
scans per increment, 4096 and 2048 points in the direct dimension and in the indirect dimension 
respectively and a recycle delay of 500 ms.  
The experiments were recorded at 288.0 K on a 165 μM uniformly 15N labeled α-synuclein 
sample, prepared as previously described (Huang et al., 2005), in buffer (10 mM KPi, 140 mM 
NaCl, 0.25 mM EDTA + Roche protease inhibitors, pH 7.5). 5% D2O was added for the lock 
signal. The different drugs (described above) were added as DMSO solutions at 1:1 
stoichiometric ratio and left at room temperature 24 hours to incubate before NMR 
measurements. The same experiments were acquired on a sample containing 3 equivalents of 
NDGA. Care was taken to minimize the volume of the DMSO solution added and to keep it 
constant for all the samples investigated. All the samples were analyzed again in the following 
days (outlined in Supplementary Table 1) to evaluate thermodynamic and kinetic effects. 
Native nano-electrospray ionization mass spectrometry 
ESI-MS experiments were conducted as previously described (Konijnenberg et al., 2016). The 
only methodological departure was the inclusion of DMSO to solubilize the ligands. Briefly, MS 
spectra were collected after 10 minute incubation of protein-ligand mixtures in 7.4 pH 10 mM 
ammonium acetate. Spectra were collected using a hybrid quadrupole-time-of-flight mass 
spectrometer (QSTAR-Elite, Biosystems, Foster City, CA) equipped with a nano-ESI sample 
source. 
Ion mobility mass spectrometry 
IM-MS experiments were conducted as previously described (Konijnenberg et al., 2016). The only 
methodological departure was the inclusion of DMSO to solubilize the ligands. Briefly, MS spectra 
were collected after 10 minute incubation of protein-ligand mixtures in 7.4 pH 10 mM ammonium 
acetate. α-Synuclein was present in the mixtures at 20 µM, ligand at 100 µM. Ion mobility-mass 
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spectrometry (IM-MS) was performed on a Synapt G2 HDMS (Waters, Manchester, U.K.) using 
nano-ESI with homemade gold-coated borosilicate capillaries. 
Fluorescence correlation spectroscopy 
Expression of fluorescently-labeled α-synuclein 
α-Synuclein protein labeled at residue S9C with Alexa Fluor 488 was produced via recombinant 
protein production. Plasmid containing α-synuclein S9C fused to a polyhistidine-tagged GyrA 
intein from Mycobacterium xenopi (Mxe) was transformed into BL21 DE3 competent cells by heat 
shocking at 42°C. Single colonies grown on Ampicillin (Amp) plates were picked to inoculate 
primary cultures in LB supplemented with 1μg/mL Amp. Primary cultures were combined into 
secondary cultures, which were grown at 37°C in a shaker-incubator until optical density (OD) 
reached ~0.6. Expression of the gene of interest was induced with Isopropyl β-D-1-
thiogalactopyranoside (IPTG). Cells were then grown in the shaker-incubator at 18°C overnight. 
After centrifugation (5000 rpm, 20 min, 4°C), cell pellets were re-suspended in re-suspension 
buffer (20 mM Tris, 1 mM PMSF, 1 Roche protease inhibitor tablet, pH 8.3) and sonicated in a 
cup in an ice bath (5 min, 1 s ON, 1 s OFF). The resulting lysate was centrifuged (14,000 rpm, 25 
min, 4°C), and supernatant containing the protein of interest (POI) was purified over Ni-NTA 
affinity column. Intein cleavage was carried out by incubation with 200 mM β-mercaptoethanol 
(βME) on a rotisserie over night at room temperature. Cleaved POI was dialyzed into 20 mM Tris 
pH 8 before purification over a second Ni-NTA column to remove the free intein from the sample. 
Flow-through containing the POI was kept, dialyzed into 20 mM Tris pH 8, and spin concentrated. 
Labeling with Alexa Fluor 488 (AF488) maleimide was done by adding 4 equivalents (eq.) of 
fluorophore dissolved in DMSO. The reaction tube was wrapped in aluminum foil and incubated 
at 37°C for ~6 hrs. Formation of the product α-synuclein C9-AF488 was checked by matrix-
assisted laser desorption ionization mass spectrometry (MALDI-MS) and polyacrylamide gel 
electrophoresis (SDS-PAGE). Labeled protein was purified by fast-protein liquid chromatography 
(FPLC) using a Hi-Trap Q 5 mL column and by reverse-phase high-performance liquid 
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chromatography (RP-HPLC) using a C18 preparatory column. Purified protein was spin 
concentrated into buffer (20 mM Tris, 100 mM NaCl), and aliquots were stored at -80°C. 
Treating α-synuclein with drug molecules 
The concentration of α-synuclein aliquots was determined by UV-Vis at 488 nm. The drug 
molecules NDGA, mNDGA, and cNDGA were dissolved in DMSO and diluted 10-fold into buffer 
(20 mM Tris, 100 mM NaCl). A control of 10% DMSO in buffer was also made. Each aliquot of α-
synuclein was respectively treated with 1eq. of NDGA, mNDGA, and cNDGA, and DMSO-buffer. 
Treatment samples were incubated at room temperature for 8 hours, then dialyzed against 10 
mM Tris, 100 mM NaCl overnight. 
Preparation of lipid vesicles 
Synthetic lipid vesicles were prepared for use in binding experiments. A mixture in 50:50 molar 
ratio of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS) and 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) were drawn from chloroform stock and dried under nitrogen 
gas to form a film inside a glass vial. Films were desiccated under vacuum and re-hydrated in 3-
(N-morpholino)propanesulfonic acid (MOPS) buffer. 10 Freeze-thaw cycles consisting of cooling 
in liquid nitrogen for 40 s and warming in a 60°C water bath for 2 min were performed to aid the 
formation of uniformly sized vesicles. Using syringes fitted onto an extruder, vesicles were 
pushed 31 times through 50 nm pore membranes. Vesicles were determined by Dynamic Light 
Scattering (DLS) to be monodisperse and distributed uniformly around 80 nm in diameter, 
consistent across different concentrations of all samples. All lipid vesicles were prepared fresh 
and used within 48 hours of extrusion.  
Fluorescence correlation spectroscopy 
Eight-well chambered coverglasses (Nunc, Rochester, NY) were prepared by plasma cleaning 
followed by incubation over night with polylysine-conjugated polyethylene glycol (PEG-PLL), 
prepared using a modified Pierce PEGylation protocol (Pierce, Rockford, IL). PEG-PLL coated 
Chambers were rinsed with and stored in Milli-Q water until use. FCS measurements were done 
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on a lab-built instrument based on an Olympus IX71 microscope with a continuous emission 488 
nm DPSS 50 mW laser (Spectra-Physics, Santa Clara, CA). All measurements were done at 
20°C. The laser power entering the microscope was adjusted to 4.5 μW. Fluorescence emission 
collected through the objective was separated from the excitation signal through a Z488rdc long 
pass dichroic and an HQ600/200m bandpass filter (Chroma, Bellows Falls, VT). Emission signal 
was focused through a 50 μm optical fiber. Signal was amplified by an avalanche photodiode 
(Perkin Elmer, Waltham, MA) coupled to the fiber. A digital autocorrelator (Flex03Q-12, 
correlator.com, Bridgewater, NJ) was used to collect 30 autocorrelation curves of 30 seconds for 
each measurement. Fitting was done using MATLAB (The MathWorks, Natick, MA). 
Binding assay of drug-treated α-synuclein to lipid vesicles 
FCS was used to examine the binding affinity of drug-treated α-synuclein to lipid vesicles. Each 
drug-treated α-synuclein labeled with AF488 was examined in the presence of varying 
concentrations of lipid vesicles, and each autocorrelation curve was fit to a 2-component equation 
to extract the fraction of bound α-syn at each concentration. From these data, a binding curve 
was generated and fit to an exponential to determine the dissociation constant Kd, i.e. the 
concentration at which half of the protein is bound. In fitting the autocorrelation curves for α-syn in 
the presence of lipid vesicles, the diffusion time (τ) of bound and unbound α-syn were 
respectively fixed to experimentally determined values. The diffusion time of unbound protein, 
ταS, was determined by measurements of the protein in buffer without lipids. Since bound protein 
diffuses with the vesicles to which they are bound, the diffusion time of the vesicles, τvesicle, was 
determined by measurements of BODIPY-labeled 50:50 POPS/POPC. The diffusion time of our 
unlabeled vesicles were also deduced from a calibration curve generated from the diffusion times 
of commercial fluorescent bead standards of 50 nm and 100 nm in diameter. 
To generate a vesicle-binding curve, FCS was performed on α-syn C9-AF488 in the presence of 
varying concentrations (0.005 mM to 1 mM lipid) of 50:50 POPS/POPC. The accessible surface 
lipid concentration was calculated based on the characteristic bilayer thickness of POPS and 
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POPC. The fraction of bound protein was extracted from the fit to each autocorrelation curve by 
fixing ταS and globally fitting τvesicle to the same value across all concentrations. 
 
The fraction bound was plotted against accessible lipid concentration and fit to an exponential, 
from which the Kd was determined. 
 
Assay for effect of NDGA on lipid-bound α-synuclein 
Untreated α-synuclein C9-AF488 (final concentration 20 μM) was added to 250 μL of 0.05 mM 
POPS/PC in a microscope chamber well. The sample was incubated for 15 minutes to ensure 
maximum binding interactions. NDGA stock was made by dissolving the drug in ethanol and 
diluting 10-fold into buffer (20 mM Tris, 100 mM NaCl). NDGA was added at 20 μM final 
concentration to the vesicle-bound α-synuclein sample, and fraction of protein bound was 
determined using the fitting described above. A control treatment was made of 10% ethanol in 
buffer, and fraction of protein bound was determined in the same manner. 
Förster resonance energy transfer anaylsis 
Small molecule stock solutions containing either NDGA, EGCG, cNDGA or mNDGA were 
prepared in DMSO. Labeled proteins constructs, including new constructs not previously 
described, were prepared using methods previously described (Ferrie et al., 2018). Labeled 
positions not previously reported were confirmed by mass spectrometry of both the full-length 
protein and fragments from trypsin digestion using MALDI. The concentration of each protein 
stock was assessed by UV-Vis absorbance of the attached fluorescein-maleimide [Fam] (ε494 = 
68,000 M-1cm-1) and/or tetramethylrhodamide azide [Raz] (ε555 = 87,000 M-1cm-1) dyes. 
Fluorescence assays were performed in a black, clear bottom half-diameter Greiner 96-well plate 
and measurements were taken on a Tecan M1000 plate reader. Each well of the plate contained 
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a single protein sample, containing either one or both fluorescent labels, and one of the small 
molecules of interest. Protein samples were also measured in the absence of small molecules as 
a control. Each sample was prepared in 1X PBS with a final concentration of 1 μM protein. 
Samples containing NDGA, EGCG, cNDGA and mNDGA were prepared with a 5-fold excess of 
small molecules relative to the protein concentration. Small molecule stocks were prepared just 
prior to performing the assay. Each assay was performed by diluting the protein in buffer in each 
well and adding the small molecule solution, using a multichannel pipette, just prior to measuring 
the fluorescence. Each sample was excited at 494 nm and the emission spectrum was measured 
from 502 - 700 nm with a 1 nm step size. Each step consisted of 50 flashes at a frequency of 400 
Hz with a 20 μs integration time and the gain was set to 135. The Z-position of the plate was 
optimized prior to the first measurement and was maintained at 21728 μm for all measurements. 
All measurements were performed at room temperature. After measuring the emission spectrum 
from each well immediately after the introduction of small molecule, the plates were sealed with 
parafilm and covered in aluminum foil and left at room temperature for 24 hrs. After 24 hrs the 
fluorescence of each sample was measured again as detailed above. The FRET between Fam 
and Raz probes attached to a single protein was assessed by computing the fluorescence 
quenching of the donor Fam fluorophore induced by the presence of the Raz acceptor as 
previously described (Ferrie et al., 2018). FRET efficiencies were converted to average 
interresidue distances using the Förster equation and a gaussian chain polymer model. 
Analysis of dopaminergic neurodegeneration in C. elegans 
Generation of transgenic nematodes  
Transgenic C. elegans lines were generated by microinjection using previously described 
methods (Berkowitz et al., 2008). The strain UA294 (baEx175 a,b,c [Pdat-1::WT a-syn, Punc-
54::tdTomato]; vtIs7[Pdat-1::GFP]) was generated by injecting with a solution of 50 ng/μl plasmid 
with either Pdat-1::WT a-syn with a phenotypic marker (Punc-54::tdTomato, 50 ng/μl, for body wall 
muscle expression). Three distinct stable lines (a, b, c) were generated. 
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Analysis of dopaminergic neurodegeneration and NDGA analog treatments in C. 
elegans  
NDGA and cNDGA were used at final concentrations of 10µM, 50µM, or 100µM in ethyl acetate 
(EtAc). Three resulting independent transgenic lines (a, b, c) were synchronized, and exposed to 
corresponding concentration of NDGA, cNDGA, or solvent (EtAc) from hatching to day 3, then 
were transferred and maintained on NGM plates until the day of analysis. Animals on NGM plates 
were treated with additional NDGA, cNDGA, or solvent on days 5 and 7. For dopaminergic 
neurodegeneration analyses, the transgenic animals were scored as described previously 
(Hamamichi et al., 2008). Briefly, on the day of analysis, the six anterior dopaminergic neurons 
(four CEP (cephalic) and two ADE (anterior deirid)) were examined in 30 randomly selected 
nematodes with the marker transgene (tdTomato) in the body wall muscle cells. Worms were 
considered normal when all six anterior neurons were present without any signs of degeneration, 
such as broken dendritic process, cell body loss, dendritic blebbing, or a missing neuron. In total, 
at least 90 adult worms were analyzed for each treatment condition, at least 30 for each 
independent transgenic line. An average of total percentage of worms with normal neurons was 
reported in the study.  
Reagents 
Nordihydroguaiaretic acid, NDGA 74540 Aldrich; (−)- Epigallocatechin gallate, EGCG E4143 
Sigma; Terameprocol/mNDGA, T3455 Sigma; Catalase, C9322 Sigma; NDGA analogs NDGA-1, 
SECO-1, NDGA-5, cNDGA, and cNDGA-5 were generated, purified, and validated by Krol et al. 
at the University of Saskatchewan as previously described (Asiamah et al., 2015). 
Statistical analysis 
Statistical analysis was conducted using Prism 5 software (GraphPad). Unpaired students t test 
was used for comparisons between two groups. Comparisons between multiple independent 
groups used one-way ANOVA with Tukey’s post hoc test for multiple comparisons. Comparisons 
involving multiple groups, such as molecule and dose comparisons, used two-way ANOVA with 
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Tukey’s post hoc test for multiple comparisons. In all cases p < 0.05 was considered statically 
significant.  
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4.6 Supplemental Figures 
 
Figure 4.S1. Structures of EGCG, NDGA, and NDGA analogs employed in this study. 
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Figure 4.S2: Colloidal and nIRF images of α-synuclein aggregation in the presence of 5% 
catalase. (a) Colloidal stained gel (b) nIRF image of the same gel before colloidal staining 
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Figure 4.S3: Colloidal and nIRF images of α-synuclein aggregation in the presence of 
NDGA analogs. (a) Colloidal images of gels after separation by centrifugation. (b) Near-infrared 
images of the same gels before colloidal staining. 
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Figure 4.S4: Colloidal and nIRF images of α-synuclein aggregation in the presence of 
cyclized NDGA analogs. (a) Colloidal images of gels after separation by centrifugation. (b) 
Near-infrared images of the same gels before colloidal staining. 
 
Colloidal 
nIRF 
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Figure 4.S5: NDGA pretreatment produces nIRF positive α-synuclein monomers. (a) 
Workflow for CD analysis and aggregation. (b) Near-infrared fluorescence images of NDGA and 
EGCG pretreated, dialyzed α-synuclein separated by native-state size-exclusion 
chromatography. (c) Colloidal staining of the same gels shown in panel b. 
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Figure 4.S6: Electrospray mass spectrometry characterization of α-synuclein-NDGA 
interaction. (a) Nano-ESI-MS spectra in positive-ion mode of 30 μM α-synuclein in the absence 
and presence of NDGA at 90 μM and 140 μM. (b) Magnification of the spectra in the Upper 
panel. The number of NDGA molecules bound to α-synuclein monomers is indicated by red 
numbers. Dimer-specific peaks of α-synuclein are labeled as “D”. Charge states are indicated by 
black numbers. 
Nano-ESI-MS spectra were collected as described in Konijnenberg et al., 2016. 
 
121 
 
Figure 4.S7: 2D NMR spectra comparing α-synuclein treated with 1:1 NDGA for 24 hours 
(red), with (a) α-synuclein treated with 3:1 NDGA for 24 hours (blue), and (b) α-synuclein treated 
with 1:1 NDGA for 10 days (blue).  
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Figure 4.S8: Workflow for analysis of pretreated, dialyzed α-synuclein  
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Figure 4.S9: NDGA pretreatment inhibits α-synuclein aggregation despite 14 days under 
aggregation conditions. 
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Figure 4.S10: Colloidal and nIRF images of NDGA analog pretreated, dialyzed α-synuclein 
aggregation (a) Colloidal images of gels after separation by centrifugation. (b) Near-infrared 
images of the same gels before colloidal staining. 
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Figure 4.S11: Colloidal and nIRF images of cyclized NDGA analog pretreated, dialyzed α-
synuclein aggregation (a) Colloidal images of gels after separation by centrifugation. (b) Near-
infrared images of the same gels before colloidal staining. 
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Figure 4.S12: nIRF positive monomers are the predominant product of α-synuclein 
aggregation in the presence of EGCG and NDGA. (a) Workflow (b) Colloidal (c) Densitometry 
(d) nIRF 
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CHAPTER 5: SUMMARY AND CONCLUSION 
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Lewy bodies serve as the histopathological hallmark of sporadic PD. Their presence 
correlates with disease progression and, more roughly, with dysfunction in the regions containing 
pathology (Braak et al., 2003; Emre, 2003). However, this correlation is imperfect, as highlighted 
by the presence of Lewy bodies in some non-parkinsonian patients and the lack of Lewy 
pathology in certain forms of PD (Ding et al., 2006; Gaig et al., 2007). Despite the uncertainty 
surrounding the relationship between Lewy pathology and neurodegeneration in sporadic PD, 
results from familial forms of PD and animal models strongly imply that α-synuclein aggregation 
drives neuron dysfunction and eventual death. All of the SNCA gene mutations that drive familial 
forms of PD cause alterations in α-synuclein aggregation kinetics (Appel-Cresswell et al., 2013; 
Krüger et al., 1998; Lesage et al., 2013; Pasanen et al., 2014; Polymeropoulos et al., 1997; 
Proukakis et al., 2013; Zarranz et al., 2004). Likewise, transgenic animals expressing these 
mutants show both pathology and neurodegeneration, though none perfectly recapitulates human 
disease caused by the same mutation (Emmer et al., 2011; Giasson et al., 2002; Gomez-Isla et 
al., 2003; Lee et al., 2002; van der Putten et al., 2000). 
Compelling evidence for the neurotoxicity of α-synuclein aggregation can been found in 
animal models driven by PFF injection. In these models, injection of α-synuclein aggregates into 
wildtype mice gives rise to progressive α-synuclein aggregation and concomitant 
neurodegeneration (Luk et al., 2012b, 2012a). Notably, this phenotype is dependent on the 
aggregation of endogenous α-synuclein and does not occur in SNCA knockout mice. α-Synuclein 
aggregate injection has been shown to induce pathology and neurodegeneration in several 
mammals (Manfredsson et al., 2018; Shimozawa et al., 2017) and similar results are induced by 
injection of Lewy body extracts from PD patients (Holmqvist et al., 2014; Recasens et al., 2014). 
Considered alongside the evidence from sporadic and familial PD, these data further strengthen 
the arguments that some unknown form or forms (Peng et al., 2018) of aggregated α-synuclein 
act as pathogenic seeds, leading to the propagation of pathology throughout the brain (a feature 
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that may be shared by other neurodegenerative diseases (Guo and Lee, 2014)), and that the 
aggregation of α-synuclein drives neurodegeneration.  
The later conclusion begs the question of which processes during α-synuclein 
aggregation, or products thereof, cause neurotoxicity. This study aimed to provide tools and 
understanding to address this deficit. We reviewed how the dynamic structure of α-synuclein 
affects its physiological functions and roles in pathology. We endeavored to untangle the cellular 
processes involved by examining the changes in the mouse brain proteome and 
phosphoproteome during α-synuclein aggregation. We deepened understanding of the products 
of aggregation by evaluating the chemistry and products of the interaction between α-synuclein 
and NDGA, a putatively neuroprotective α-synuclein aggregation inhibitor.  
Chapter 2 underscores how much of α-synuclein function and pathology can be traced to 
its remarkable structural dynamism. α-Synuclein’s role in the synapse is made possible by 
interactions with lipids, other α-synuclein monomers, and lipid-bound V-SNAREs (Burré et al., 
2010, 2014; Davidson et al., 1998; Wang et al., 2014; Zhu et al., 2003b). Identifying the native 
state of α-synuclein remains difficult, and it seems increasingly unlikely that there is one single 
cytosolic conformation of α-synuclein. Native states may include lipid-containing conformations, 
multimers, and monomeric conformers (Bartels et al., 2011; Gould et al., 2014; Wang et al., 
2011). Despite this complexity, many studies have found that disturbance of native α-synuclein 
structure increases its propensity to aggregate. In fact, all SNCA mutations linked to early onset 
PD fall in the α-synuclein N-terminal domain involved in lipid and protein interaction. Indeed, 
these mutations perturb native multimers/conformers (Dettmer et al., 2015a). Further, mutations 
designed to interrupt native structure also alter vesicular trafficking (Dettmer et al., 2017). Taken 
together, existing research shows that complex dynamics link α-synuclein’s native state, its 
interactions with vesicular function, and its propensity for pathological aggregation. When 
considered through the lens of therapeutic development, this demonstrates the importance of 
examining the effect of any intervention on the native structure of α-synuclein. 
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The findings presented in Chapter 3 represent the first proteomic analysis of the mouse 
brain undergoing neurodegeneration due to endogenous α-synuclein aggregation. Our analysis 
was able to quantify relative abundance (between healthy and diseased hemispheres) of more 
than 6,000 proteins and 8,000 phosphopeptides. Among these, only 6% of proteins and 1.6% of 
phosphopeptides changed in relative abundance during α-synuclein aggregation. This 
demonstrates that proteomic changes were limited to a small subset of proteins. This result does 
not support the hypothesis that widespread proteostatic disruption mediates α-synuclein 
neurotoxicity (Balch et al., 2008; Douglas and Dillin, 2010). Significant changes were observed in 
the relative abundance of several proteins involved in dopamine biosynthesis and 
neurotransmission, consistent with localized dysfunction of dopamine neuron synapses. 
Ontological analysis of proteins with significant changes in relative abundance showed marked 
changes in the areas of mRNA processing, mRNA binding, protein translation, and protein 
folding, suggesting adaptive proteostatic responses to α-synuclein aggregation and 
neurodegeneration. 
Of particular interest, Lmp7―a component of the immunoproteasome―increased in 
hemispheres undergoing α-synuclein aggregation. Strikingly, this result was observed in each of 
the varying statistical workflows evaluated during the preparation of the manuscript. The 
immunoproteasome is induced in other neurodegenerative diseases, but had never been studied 
in synucleinopathies (Aso et al., 2012; Díaz-Hernández et al., 2003; Mishto et al., 2006; Orre et 
al., 2013). We found increases in Lmp7 levels and immunoproteasome function in brain tissue 
from patients with PD and DLB. In vitro, the immunoproteasome degraded α-synuclein 
aggregates, producing potentially antigenic peptide fragments (Sulzer et al., 2017). In totality, 
these data demonstrate that the immunoproteasome is induced in response to α-synuclein 
aggregation and directly digests α-synuclein fibrils. The data further suggest that Lmp7 may 
modulate inclusion formation, propagation, and neuroinflammation.   
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Functional immunoproteasome knockout mice exist (Kincaid et al., 2011) and PFF 
injection of these mice could provide an excellent model in which to test whether induction of the 
immunoproteasome during α-synuclein aggregation is protective or deleterious. Activity of the 
immunoproteasome can also be manipulated pharmacologically (Muchamuel et al., 2009), raising 
the possibility of the immunoproteasome as a druggable target in human disease. However, it is 
difficult to predict the downstream effects of genetic or pharmacological reduction of 
immunoproteasome activity during α-synuclein aggregation. If immunoproteasome induction in 
the brain produces α-synuclein peptide fragments that cause T-cell activation, the induction may 
contribute to the neuroinflammation that occurs prior to neurodegeneration driven by α-synuclein 
aggregation (Duffy et al., 2018; Sulzer et al., 2017). Indeed, dopaminergic neurons in the SNpc 
express MHC-I and MHC-I-induced T-cell activation leads to neuron death (Cebrián et al., 2014). 
Additionally, partial degradation of α-synuclein fibrils might increase the number of seeding-
competent α-synuclein species in the brain, accelerating the spread of pathology (Luk et al., 
2012b; Tran et al., 2014). This uncertainty underscores the value of investigating the effect of 
Lmp7 induction on α-synuclein aggregation pathology and neurodegeneration.  
The study of NGDA, presented in Chapter 4, first sought to elucidate the chemistry of the 
interaction between NDGA and α-synuclein. NDGA shares the vicinal hydroxyl substitution 
responsible for the interaction between α-synuclein and dopamine (Conway et al., 2001). As with 
dopamine, and related catecholamines (Mazzulli et al., 2007; Norris et al., 2005), NDGA must 
undergo oxidation to interact with α-synuclein. NDGA analogs allowed for further insight into the 
interaction between NDGA and α-synuclein. Oxidation-dependent cyclization of NDGA was 
required for interaction with α-synuclein and inhibition of aggregation. As mentioned in Section 
4.4, this recasts NDGA as a prodrug that can be oxidized to form α-synuclein-interaction 
competent cNDGA. As such, if future studies employ NDGA and related analogs, careful 
consideration should be given how rates of oxidation and cyclization might impact bioavailability 
and side-effects. Particular attention should be given to hepatotoxic side-effects which are 
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common in studies evaluating aggregation-inhibiting polyphenols, such as EGCG and exifone 
(Lambert et al., 2010; Levin et al., 2016; Ouzan et al., 1990). Promisingly, rates of NDGA 
cyclization have already been manipulated though rational chemical modification of the 
crosslinker connecting the two aromatic rings. Reducing steric hindrance in the region increases 
kinetics and yield of NDGA cyclization (Asiamah et al., 2015).  
 Given the importance of α-synuclein conformation―reviewed in Chapter 2―we also 
analyzed the conformational effects of NDGA. Independent analysis by IM-MS, NMR, and FRET 
found that NDGA and cNDGA induced only subtle conformational changes. Both compounds 
caused slight compaction of monomeric α-synuclein, which progressed with incubation time. 
These effects were much less profound than those caused by EGCG in previous studies 
employing IM-MS and NMR (Ehrnhoefer et al., 2008; Konijnenberg et al., 2016). Likewise, FRET 
analysis showed that EGCG induced significant changes in α-synuclein conformation after 24 
hours, while NDGA was indistinguishable from negative controls. As α-synuclein physiological 
function requires membrane interaction (Burré et al., 2010; Lou et al., 2017), we also measured 
the effect of NDGA treatment on phospholipid binding affinity using FCS. FCS found that 
treatment with NDGA and cNDGA did not alter phospholipid binding affinity, nor did NDGA 
displace lipid-bound α-synuclein. This result demonstrates that while interaction with cNDGA 
prevents α-synuclein aggregation, it does not alter native α-synuclein conformational dynamics 
essential for physiological function.  
Maintaining the dynamic structure of monomeric α-synuclein suggests two potential 
advantages when considering NDGA analogs as potential neuroprotective anti-aggregation 
therapies. First, this attribute might preserve α-synuclein’s function in the presynapse. 
Membrane-bound α-synuclein mediates SNARE function and vesicular fusion (Burré et al., 2010; 
Lou et al., 2017). α-Synuclein multimerization has also been implicated during this process (Burré 
et al., 2014; Wang et al., 2014), highlighting the importance of complex interactions. Disruption of 
α-synuclein function in the synapse does not cause profound neurological dysfunction (Abeliovich 
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et al., 2000; Dettmer et al., 2017; Vargas et al., 2014), but prolonging typical neurotransmission 
should be paramount during neurodegeneration. Second, membrane binding may enhance 
aggregation resistance of NDGA-treated α-synuclein. During in vitro aggregation of α-synuclein, 
levels of lipid binding directly correlate with lag time to fibril formation (Zhu and Fink, 2003). 
Likewise, native multimers/conformers are more resistant to aggregation (Bartels et al., 2011) and 
mutation of the lysine-rich repeats implicated in lipid binding and multimerization leads to 
inclusion formation (Dettmer et al., 2015b). Indeed, using small molecules to stabilize α-
synuclein-lipid interactions both reduces inclusion formation and cytotoxicity (Fonseca-Ornelas et 
al., 2014).  
It is important to note that there is some controversy around the role of lipids in α-
synuclein aggregation. Lipids may enhance fibril nucleation (Galvagnion et al., 2015) and one 
small molecule has been shown to displace α-synuclein from lipids while reducing aggregation 
(Perni et al., 2017). However, given the physiological role of lipid-bound α-synuclein and the 
importance of native multimerization in reducing aggregation, the preponderance of evidence 
supports the conclusion that disrupting native conformations increases the likelihood that α-
synuclein will form pathological aggregates.  
Ultimately, our study of NDGA was motivated by its potential to reduce α-synuclein 
aggregation. As expected, its presence during aggregation prevented α-synuclein fibril formation 
(Ono and Yamada, 2006). Remarkably, however, pretreatment with either NDGA or EGCG 
rendered α-synuclein resistant to aggregation, even after dialysis or native-state SEC was used 
to remove unbound NDGA or EGCG from the aggregation mixture. This effect persisted during a 
two week aggregation of pretreated α-synuclein, suggesting the modification is highly stable. 
Adding fibril seeds to the aggregation mixture did not induce aggregation of pretreated α-
synuclein, demonstrating that the effect does not simply prevent fibril nucleation, but that 
pretreated α-synuclein is resistant to incorporation into existing fibrils. One potential explanation 
of these effects is that the slight conformational changes induced by NDGA treatment might 
134 
 
prevent α-synuclein aggregation. Another is that the SDS-stable, dialysis-resistant interaction that 
occurs between NDGA oxidation products and α-synuclein (observed by near-infrared 
fluorescence) results in a chemical change, or direct steric hindrance, that prevents incorporation 
into α-synuclein fibrils. 
Most strikingly, the presence of pretreated α-synuclein inhibited aggregation of naïve, 
untreated α-synuclein. To the best of our knowledge, this dominant-negative effect has not 
previously been documented with EGCG nor any other neuroprotective inhibitor of α-synuclein 
aggregation. Our study does not explore the mechanism by which this effect occurs. It is possible 
that pretreated α-synuclein interacts with and transforms untreated α-synuclein monomers, or 
recruits untreated α-synuclein into aggregation-resistant multimers. This seems unlikely given the 
random coil structure exhibited by pretreated recombinant α-synuclein in solution, which is 
inconsistent with the α-helical structure exhibited by aggregation-resistant α-synuclein multimers 
extracted from cells (Bartels et al., 2011; Wang et al., 2011). Likewise, given the slight 
conformational changes observed, there is no ready explanation for why untreated α-synuclein 
would adopt the same conformation in solution. Instead, it seems more likely that incorporation of 
pretreated α-synuclein into fibrils or oligomers composed of untreated α-synuclein renders them 
aggregation incompetent. This hypothesis provides an explanation for the dominant-negative 
effect without having to propose that structural changes propagate between pretreated and 
untreated monomers. It is also consistent with our observation of α-synuclein oligomers after α-
synuclein aggregation in the presence of both EGCG and NDGA (Fig 4.S12), as well as previous 
reports of EGCG-stabilized oligomers (Ehrnhoefer et al., 2008).  
Results from C. elegans reinforced the potential for neuroprotective therapies based on 
NDGA analogs and the importance of cyclization in NDGA’s interaction with α-synuclein. 
Expression of α-synuclein in C. elegans dopamine neurons leads to age-related progressive 
degeneration that can be altered by direct interaction between α-synuclein and small molecules 
(Mor et al., 2017). NDGA treatment of these animals failed to alter the neurodegenerative 
135 
 
phenotype. However, treatment with cNDGA reduced the number of animals experiencing 
neurodegeneration. This divergence is striking given the similarity of the effects of NDGA and 
cNDGA on α-synuclein conformation and aggregation in vitro. Potential explanations for this 
difference are discussed in Section 4.4, though no conclusion can be reached based on the 
current study. Regardless, the finding that cNDGA, but not NDGA, affords protection against α-
synuclein-driven neurodegeneration powerfully underscores the importance of considering NDGA 
cyclization in subsequent studies of its interaction with α-synuclein. Pending further study, our 
findings suggest that cNDGA should be considered the active form of NDGA with regard to 
inhibiting α-synuclein aggregation and reducing neurotoxicity caused by α-synuclein.    
Overall, this thesis provides three novel findings. First, inhibition of α-synuclein 
aggregation by NDGA requires oxidation-dependent cyclization. Second, phenolic molecules 
inhibit α-synuclein aggregation by remodeling α-synuclein monomers, rendering them stably 
resistant to aggregation. Third, modified α-synuclein monomers exhibit a dominant-negative 
effect on α-synuclein aggregation. Consequently, small molecule induction of dominant-negative, 
aggregation-preventing α-synuclein monomers may represent a new paradigm for therapeutic 
development in PD and related synucleinopathies.   
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